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Abstract
Safety Pharmacology is becoming an increasingly important field to pharmaceutical companies in order to determine if medical treatments (drugs) are safe for use in human subjects.
In the pre-clinical phase, test models, most commonly small rodents, undergo various gene
alterations to affect, for example, their cardiovascular system in order to emulate human diseases. Pharmaceutical companies rely on these models to determine the drug efficacy and
to ensure minimal side effects and safety for human subjects. Currently, no fully implantable
left-ventricle pressure–volume (PV) telemetry systems have been implemented for Safety Pharmacology assessment applications. A fully implantable PV telemetry system would not only
allow safety pharmacologists to better determine a drugs effect on the heart over traditional
assessment methods (heart rate, blood pressure, ECG) but would also improve drug efficacy
with the additional physiological parameters that PV loops provide.
The research in this thesis focuses on the design, implementation, and testing phases of
a wireless telemetry system for pressure–volume cardiac monitoring in a live animal subject. A commercial MEMS PV sensor is implanted into the subject’s left-ventricle (LV), while
the telemetry system is implanted outside of the heart and connected to the sensor with a 7microwires tether. The RF telemetry system is suitable for commercial application in medium
sized subjects, its total volume of 2.475 cm3 and a weight of 4.0 g. The designed system is
58% smaller in volume, 44% in weight and has a 55% reduction in sampling power over the
last reported research in PV telemetry. In–vivo data was captured in both an acute and a freely
moving setting over a 24 hour period.
This real–time implantable telemetry system allows researchers to continuously monitor
cardiac health by collecting real-time chronic PV data from freely moving conscious animals.
Thus, enabling safety pharmacologists to utilize the gold standard of PV loops in their drug
studies by using PV implants, facilitating safer and more effective drugs for human use.
Keywords: mixed–signal, implantable, bio–medical applications, radio frequency, sensors, pressure–volume, low–power, admittance, lock–in amplifier, conductance based catheter,
i
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Chapter 1
Introduction
This chapter introduces the motivation behind this thesis. The research problem is outlined and
solutions are explored. This is followed by research objectives and organization of the thesis.

1.1

Motivation

Safety Pharmacology is becoming an increasingly important field to pharmaceutical companies
in order to determine if medical treatments are safe for use in human subjects [34, 35]. More
specifically, in the cardiac field, Safety Pharmacology refers to the drug’s (medical treatment)
effects on the cardiovascular system [35]. It is extremely important for all parties involved
(drug developer, clinical trial patient, end user, etc) for medical drugs to be safe and effective. Unsafe drugs that get released to the general population can cause adverse side-effects
to patients and worse can cause death [36]. Pharmaceutical companies have a vested financial
and ethical interest in the safety of the designed drug, as they have the possibility of gaining
a high return on investment and novelty if found safe and effective, on the contrary they face
consequential financial loss or company closure if unsafe. In the pre-clinical phase, the test
models, most commonly small rodents, undergo various gene alterations to affect, for example,
their cardiovascular system in order to emulate human cardiovascular diseases. Pharmaceutical companies rely on these models to determine the drug efficacy and to ensure minimal side
1
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Figure 1.1: Diagram of a human heart, displaying the right and left atriums and ventricles.
Licensed by CC BY-SA 3.0.

effects and safety for human subjects. Furthermore, the insights gained in Safety Pharmacology during clinical trials can greatly impact medical treatments for human diseases including
cardiovascular disease and heart failure [37, 38].
The main organ in the cardiovascular system is the heart, as it regulates and pumps blood
throughout the living body. The heart contains four chambers, two atria and two ventricles (left
and right), Fig. 1.1. The left ventricle (LV) is generally studied over the right ventricle because
it supplies blood to the whole body rather than just the lungs, as the right ventricle does, therefore accomplishes the majority of work in the heart [39]. In addition, the left ventricle pumps
blood at a much higher pressures than the right ventricle. Two measurements, blood pressure
and volume, of the LV provide insight into the efficiency of the living heart. Combining the
measurement of the LV volume with measured LV pressure, pressure–volume (PV) loops can
be created, Fig. 1.2, allowing for the extraction of various medical parameters.
A pressure–volume loop can be described as the PV relationship during a cardiac cycle.
Here, the four stages of the cardiac cycle: diastolic filling, contraction, ejection (systolic phase),
relaxation are represented by various blood pressure and volume values [40] [41], Fig. 1.2. A
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Figure 1.2: Pressure vs Volume (PV) Loop. Stroke Volume (SV) is calculated by subtracting
ES volume from ED volume. This is used to calculate the Cardiac Output (CO) in conjunction
with the heart rate. A larger SV indicates healthier heart.
brief overview of these four stages is given below:
• Stage 1: Diastolic Filling (between point D and A in Fig. 1.2): During this stage the LV
muscles relax to allow for the increase in blood volume . The blood pressure during this
stage is relatively low and constant and the blood volume increases to its highest level.
• Stage 2: Contraction (between point A and B in Fig. 1.2): This stage begins when the LV
blood filling is complete. The mitral valve closes and the cardiac muscle starts to contract
to increase blood pressure inside the LV. The blood volume during this stage is constant
at its highest value (as both valves mitral and aortic are closed) and the blood pressure
is constantly increasing. At the beginning of this stage, two important parameters are
measured, A in Fig. 1.2, end–diastolic volume (EDV) and end–diastolic pressure (EDP).
EDV and EPV represent the value of blood volume and pressure in the heart at the time
filling is complete [40].
• Stage 3: Ejection (Systolic Phase): This stage begins at B and ends at C in Fig. 1.2, where
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the aortic valve opens up and the blood is ejected into the Aorta. This occurs as the left
ventricular pressure is greater than the aortic pressure, thus causing the aortic valve to
open. The heart muscles continue to contract to get the maximum blood ejection. The
blood volume reduces to its minimum value during this stage
• Stage 4: Relaxation: The start of stage four ends the Systolic phase and the heart muscles
begin to relax (i.e., reduce blood pressure) to allow the LV to refill and repeat the cycle
(between point C and D in Fig. 1.2). At point C, the aortic valve closes as aortic pressure
is greater than LV pressure. This in conjunction with the heart relaxing causes the LV
pressure to drop quickly. Note from C to D, the mitral valve is still closed (i.e, no filling)
just pressure reduction. At the beginning of this stage, two important parameters are
measured, C in Fig. 1.2, end–systolic volume (ESV) and end–systolic pressure (ESP).
ESV and ESP represent the value of blood volume and pressure in the heart at the time
ejection is complete or at end of systole [40]. During this stage the blood volume is at
its lowest and the pressure is reduced to its minimum. At the end of this stage, Point D,
the LV pressure is below left atrium pressure which causes the mitral valve to open, thus
causing diastolic filling and repeating the heart cycle.
The relationship between aortic pressure, LV pressure, LV blood volume, and the Electrocardiogram (ECG) is commonly described in the traditional Wiggers diagram, Fig. 1.3. This
describes each major physiological signal in the time domain as it relates to the heart cycle.
A valuable feature of PV loops is that various cardiac parameters can be calculated from just
two measurements, LV pressure and volume. Some of these include: stroke volume (SV),
stroke work (SW), cardiac output (CO), ejection fraction (EF), max and min

dP
,
dt

etc, outlined

in Table 1.1 [40].
In addition, by plotting a series of loops, one can obtain valuable measurements of heart
contractility and elastance. These are found by plotting the End Diastolic Pressure–Volume
Relationship (EDPVR) line, End Systolic Pressure–Volume Relationship (ESPVR) line, and
the Ea (Arterial Elastance) line. EDPVR describes the passive properties of the myocardium
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Figure 1.3: Traditional Wiggers diagram that shows the relationships between Aortic pressures,
left ventricle pressures, left ventricle volume, and ECG. [1, 2] Licensed by CC BY-NC-SA 2.0

Table 1.1: Various cardiac parameters
Cardiac Parameter
SV – Stroke Volume
SW – Stroke Work
CO – Cardiac Output
EF – Ejection Fraction

Description
Volume of blood being pumped
with each beat
Mechanical work done by the heart
muscle
Volume of blood being pumped by
the heart in 1 min
Volumetric fraction of blood
pumped out of the LV with each heart beat

Formula
S V = EDV − ES V
S W = Area inside PV loop
CO = S V x Heart Rate
SV
End Diastolic Volume

× 100%
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and the slope of the EDPVR line represents the reciprocal of ventricular compliance [42]. If
the ventricle is less compliant (stiffer), higher EDP will result at a given EDV. If compliance
increases, EDV may become high but EDP may not increase substantially [42,43]. ESPVR describes the maximum pressure that can be developed by the left ventricle at any given volume,
i.e, PV relationship at end of systole [42]. The slope of this line represents the end systolic elastance, which is used to provide a measure of contractility. Its volume intercept point is fixed
as the left ventricle always has set amount of blood left after ejection. As the ESPVR shifts
leftward, contractility increases, this results in increased SV, SW and ESP. If shifted rightward,
contractility decreases, causing a decrease in SV, SW and ESP. The ESPVR is insensitive to
changes in heart rate (HR), preload, and afterload, providing a highly accurate measure of contractility [44–47]. Preload is defined as the LV wall stress at end diastole and can be calculated
directly from the PV loop. Another important paramater is Afterload which refers to the LV
wall stress during ejection. The descriptions of these paramaters are just brief introductions into
the topic of cardiovascular research and provide the reader with a basic understanding for this
thesis. For additional reading, see [42, 48]. The arterial elastance (Ea) line is a measure of the
arterial load and can be pivoted (ie moved left or right at same volume intercept point) and/or
can move volume intercept point [42]. By pivoting the Ea line up, there will be a decrease in
SV but an increase in ESP, and if pivoted down, SV will increase but ESP will decrease. Additionally, by moving the volume intercept point left or right, there will be a decrease or increase
in Preload, respectively. When Preload increases, ESP, SV and SW will increase and the opposite will occur when Preload is decreased. The analysis of in–vivo measured LV PV loops as an
indicator of the cardiac functionality is remarkably useful, as it allows researchers to determine
load independent indexes of contractility and chamber stiffness [37, 49]. In addition, accurate
real–time PV loops allow researchers to quantify cardiac pathology, e.g., congestive heart failure, by extracting stroke volume, cardiac output and various other parameters with just two
physiological measurements, pressure and volume [37,38,50–55]. Currently, PV loop analysis
is the gold standard for investigation of cardiac function with respect to clinical disease [56].
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Cardiac contractility is an inherent property of the heart muscle that enables and affects
the heart’s ability to generate force [56, 57]. Contractility can be altered by the nervous system, hormones, drugs or diseases and it is critical to understand the affects on the heart that
changes in contractility can create. If contractility increases, the hearts energy consumption
will increase causing increased oxygen consumption and increased blood flow [57]. If the patient has heart disease or other cardiovascular conditions, increases in blood flow and oxygen
consumption can cause significant health issues. On the other hand, if contractility decreases,
blood pressure will be decreased as well as blood flow. This can cause significant issues for
patients with pre-existing heart conditions and can cause clinical heart failure. It is essential in
drug studies to determine the affect on contractility that a drug has and to ensure that changes
in contractility are discovered and accounted for, failure to do so could result in adverse heart
effects or death. Currently, the FDA and the ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) provide
guidelines to pharmaceutical companies for safety pharmacology studies, these guidelines are
known as “The S7A: Safety Pharmacology Studies for Human Pharmaceuticals” [58, 59] and
“The S7B: The Non-Clinical Evaluation of The Potential for Delayed Ventricular Repolarization (qt interval prolongation) by Human Pharmaceuticals ” [60, 61]. These two documents
provide guidelines for which measurements should be done to assess the potential risks of
novel pharmaceuticals for human use [57–61]. These guidelines only require the assessment
of blood pressure (central arterial pressure), heart rate (HR), and electrocardiogram (ECG) in
nonclinical in–vivo safety pharmacology studies. Contractility effects are not required by the
guidelines and only are a suggestion for additional studies, thus may be missed if traditional
measurements are used. Nevertheless, by measuring contractility during drug safety testing,
will reduce the human risk during clinical trials and the possible failure of the drug to market.
Traditionally, two main methods are used to assess contractility in pre-clinical safety pharmacology using the suggested measurement techniques from the S7A guidlines: 1) ECG with
blood pressure and 2) HR with blood pressure. The majority of researchers [62–64] use ECG
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with a LV blood pressure sensor to study the changes in the QA interval (measured from the
Q wave point on the ECG to when the Aortic valve opens) and LV

dP
dtmax

(peak positive rate

of pressure change inside the left ventricle) as an index of contractility change. Both, QA interval and LV

dP
dtmax

should change when contractility changes, however, some drugs can delay

the ECG signal and not effect LV

dP
,
dtmax

thus, extend the QA interval and not actually change

contractility [62–64]. This would provide a false assessment of contractility change and may
effect other functions of the heart. In addition, LV

dP
dtmax

and heart rate (HR) [65]. Consequently, changes in LV

is also affected by preload, afterload,
dP
dtmax

may not directly indicate a drug’s

affect on contractility, rather its affects on preload, afterload, or HR. Furthermore, this method
is known to capture reduced contractility more accurately than increased contractility due to
the accuracy of the QA interval. Many drugs will directly or indirectly affect the HR, thus impacting LV

dP
.
dtmax

As a result, HR must be taken into account when using LV

dP
dtmax

to accurately

determine changes in contractility. The second method, presented in [65], introduces a HR
correction factor for LV

dP
,
dtmax

producing a more accurate contractility assessment. This method

does not account for loading conditions (preload and afterload), thereby possibly providing a
incorrect assessment of changes in contractility.
As mentioned above, PV loops are used to measure many hemodynamic parameters and
are considered the gold standard for assessing contractility in the heart due to ESPVR’s insensitivity to preload, afterload, and HR [66]. PV loops are typically limited to clinical disease
testing environments [67], however not until recently have they been used in safety pharmacology studies [67, 68]. The main reason why the traditional methods for contractility assessment
(LV

dP
,
dtmax

QA interval) are used over PV loops in safety pharmacology studies is the lack of

a fully implantable PV loop measurement solution [65, 67]. These traditional methods can
be implemented in small implantable telemetry systems allowing many animals to be monitored remotely and in free moving environments. Currently, no fully implantable PV telemetry system has been implemented for Safety Pharmacology assessment applications. A fully
implantable PV telemetry system would not only allow safety pharmacologists to better deter-
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mine a drugs effect on the heart over traditional assessment methods (heart rate, blood pressure,
ECG) but would also improve drug efficacy with the additional physiological parameters that
PV loops provide. Therefore, it is critical to obtain real–time PV telemetry data to allow for
the calculation of these parameters instantaneously.

1.2

Research Problem

Left ventricle volume measurements in small laboratory animals is a difficult task to achieve
due to the size restrictions and heart rate of these animals. For example, a small mouse heart’s
LV volume can be as small as 40 µl and have a heart rate of 500-600 beats per min (bpm)
with heart rates reaching as low as 300 bpm for an anesthetized mouse [69]. In addition, the
weight of these animals is quite small (mice: 20 g – 40 g, rats: 150 g – 400 g). This requires
measurement systems to be quite small, impacting the effectiveness and overall functionality
of the measurements. Methods to obtain PV data can be categorized into either non–invasive or
invasive measurement techniques. Multiple non–invasive approaches on the measurement of
instantaneous blood volume from small laboratory animals have been accomplished, these include echocardiogram [70,71], X–Ray computed tomography (CT), [72], Magnetic Resonance
Imaging (MRI) [71, 73–75], and piezoelectric crystals [76].
With each of these techniques, detailed images of the heart are created indicating the volume of the heart as well as many other physical features including possible tissue tears and
the surrounding heart muscle. However providing very accurate LV volumes, these techniques
require large–scale costly physical measurement equipment (CT scanner, MRI, etc.) along
with imaging technicians to operate the equipment. Furthermore, extensive post–processing
imaging methods are required to generate a detailed cardiac image. These factors prevent economical large–scale, long–term cardiac data collection. Currently, the predominate invasive
measurement technique is the conductance catheter measurement method [70, 77, 78]. This
technique provides a method for the accurate measurement of LV blood volume from small lab
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animals in a cost effective and accurate fashion.
To obtain cardiac PV data with the conductance method, a small catheter is inserted into
the LV of the heart where measurements are taken. Pressure and volume measurements are
captured separately by different electronic systems. A pressure measurement is acquired by
a solid state pressure sensor located at the tip of the catheter where the pressure from the
blood will react with the sensor to cause a potential difference representing the pressure signal
[79]. A volume measurement is obtained using a four electrode catheter system inserted into
the subject’s LV to generate an electric field and to continuously measure the conductance
or admittance from the animal which is converted to volume [80]. These PV catheters are
connected to measurement systems to fully capture and process the cardiac data for physicians
and researchers to use.
Commercial PV measurement systems employ a tethered approach to measure cardiac signals from small animals. A moderate sized PCB (60 mm x 35 mm) is used as an interface
from a conductance catheter to a larger external base station where main processing occurs,
Fig. 1.4 [3]. Although accurate, this method does not allow for long–term and large scale
realistic cardiac data collection from animal subjects as they are generally under anesthesia
during the procedure, thus not allowing the animal subject to move naturally in their normal
environment.
To solve this critical problem, implantable telemetry systems are used. Telemetry systems
are able to capture, process and transmit specific information to an end device, wired or wirelessly. These systems contain sensors to measure the biomedical data from inside the living
body and can be external, for example in ECG, EEG monitoring or implantable in the case of
most cardiac monitoring, Fig. 1.5. Implantable telemetry systems are found in many different areas of medicine including diagnostics and monitoring [81], drug delivery systems [82],
neurology [83], audiology [84], and cardiology [85].
Implantable wireless telemetry systems have many advantages over traditional wired solutions especially in safety pharmacology applications including: freely moving conscious ani-
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Figure 1.4: Commercial Pressure–Volume Tethered Measurement System from Transonic
Scisense Inc. Interface Module, 1.2F Catheter, External Processing Unit [3].
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Figure 1.5: RF telemetry system shown inside a rabbit model. Note: implant location not to
scale. [4, 5].

mal data collection, chronic data collection, fewer measurement site infections, decreases costs
as less personal are required, enhancement of safety of lab personal as fewer animals have to
be physically handled to collect data, etc. Many issues exist with the current implementations
of such systems including size restrictions, power consumption, reliability, number of sensors
used etc. These issues are significantly more important for cardiac research due to the size of
the animals involved.
A cardiac PV implantable telemetry system would contain all sensor electronics as well as
power and data transmission electronics. However, realistic design constraints are driven by
the subject’s body size and the implant’s power consumption. Larger subjects (e.g. bovine or
human) can accept an implant whose volume is in the order of a few tens of cubic centimetres,
while a tiny mouse body (20 g – 40 g weight) can only tolerate a fully implanted object with
the volume in the order of a few tens of cubic millimetres. Existing discrete components
are not suitable for small subjects due to the package size. Thus, micro–sized implantable
telemetry systems are an active area of research [79, 86, 87]. Power consumption is also of
great importance to the implantable system design as decreased power consumption can lead
to smaller battery sizes, further reducing the systems volume. A low–power telemetry system
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Figure 1.6: Wireless implantable system active cage measurement environment, [4]

is capable of being implanted for longer periods of time while operating off of smaller capacity
batteries. Active measurement cages have been used to provide wireless power to the implants
enabling long–term data collection without the need for batteries [21, 88], Fig. 1.6.
Current state–of–the–art wireless cardiac telemetry systems typically employ blood pressure (aortic), ECG, and temperature sensors [21, 22, 89]. Although small and advanced, these
systems currently do not measure left ventricular blood volume, thus cannot be used to measure PV loops. In order to generate accurate PV loops it is essential to measure both pressure
and volume data at the same time, thus a dual sensor approach is required. Limited research
has been completed on implantable PV telemetry systems in literature, where only four systems have been developed [23–25, 90], a detailed review of these systems along with other
relevant works is provided in the following chapter. These devices are all limited by their size,
weight, power consumption, and battery life to be implanted for long periods of time. It is
extremely important to develop a fully implantable cardiac pressure–volume telemetry system
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that is small enough to fit into mice and rats. This would enable researchers to continuously
monitor cardiac health by collecting real-time chronic PV data from freely moving conscious
animals. Thus, enabling safety pharmacologists to utilize the gold standard of PV loops in
their drug studies. By using PV implants along with other diagnostic tools, pharmaceutical
companies can create safer and more effective drugs for human use.

1.3

Research Objectives

The aim of this thesis is to develop a miniature, low–power wireless implantable telemetry
system that is designed to measure left ventricular pressure and volume physiological data.
This device should be suitable for small to medium sized animals (e.g., rats, rabbits). The
objectives of this thesis are:
• Existing commercial PV telemetry systems rely on tethered data from large external
processing units, preventing natural environment data collection, hence an implantable
telemetry system is required. This system should contain all lower level blocks to allow
for data collection, processing, and transmission to an end device for post processing. To
acquire pressure–volume measurements, a sensor interface must be developed to deliver
excitation signals to the test subject and convert the measure voltages to valid application
data.
• The implantable system must be very small and light weight to ensure no impact on
the animal subject. Therefore, external components should be minimized and state–
of–the–art printed circuit board (PCB) manufacturing techniques should be employed.
Furthermore, different packaging technologies should be explored to create an optimum
implant enclosure for the telemetry system.
• A realistic phantom tissue is required to evaluate and characterize the system prior to
implantation. This phantom should have similar electrical properties to animal tissue,
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allowing RF transmission to be evaluated. In addition, the system must be calibrated to
ensure valid measurement data.
• Design a measurement application to receive physiological signals and log data. An
external base station is required along with a software interface to view, collect, and
analyze the data.
• Evaluate the implantable PV telemetry system in–vivo in a non–anaesthetized test subject. Live physiological signals should recorded and compared with existing recording
techniques.
• This research should advance the knowledge of implantable medical devices by providing a detailed literature review and insights on the trends in this research field.

1.4

Organization of the Thesis

In this thesis an implantable telemetry system is developed and manufactured that measures
both left ventricle pressure–volume. The telemetry system is tested and evaluated in–vitro and
in–vivo in a free moving swine.
In Chapter 2, background info on implantable medical devices is presented, discussing application areas, challenges, and other important concerns in the design of implantable medical
devices. Furthermore, background on blood pressure and blood volume measurement techniques in small laboratory animals is presented. State-of-the art in pressure–volume systems is
discussed in this chapter.
In Chapter 3, a comparison study of all three conductance–to–volume equations along with
the accuracy of the analytical model of the conductance catheter is presented. In addition, the
overall accuracy of the admittance catheter volume measurements is studied.
In Chapter 4, the wireless telemetry system design is discussed in detail. The system captures, processes PV data and transmits this data wirelessly to an end base station for further
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processing.
In Chapter 5, the in-vitro (non-implanted, external of body) characterization of the implantable telemetry system is presented. A phantom tissue study to model the effects of implant
conditions, followed by details of the enclosure design and study. Calibration of the system is
also presented.
In Chapter 6, details of the in-vivo study are presented. The study was designed to evaluate
the PV system in a non–anaesthetized test subject, i.e., freely moving animal. In addition, the
study was completed to determine initial catheter-heart interaction. Furthermore, a comparison
of previous works is discussed in this chapter.
The research work is summarized in Chapter 7. Main achievements and milestones are
listed, and suggestions for future work are presented.

Chapter 2
Implantable Medical Devices
In the previous chapter a brief overview of the main research problems, motivation, and objectives for this thesis were stated. In this chapter, implantable medical devices are introduced
providing the reader with a general knowledge of the typical applications, challenges, and research problems that exist in this field. Pressure and volume measurement techniques in small
laboratory animals are discussed in Section 2.2 and 2.3. In addition, a discussion of state-ofthe-art in both implantable pressure telemetry systems as well as those that incorporate both
pressure and volume sensors. This background knowledge provides a basic understanding of
the application subject and the required theoretical knowledge for the remaining chapters in
this thesis.

2.1

Overview of Implantable Medical Devices

An implantable system is generally referred to as any device/system that is intended to function
inside a living body for either short or long term use [91]. Implantable systems provide a
method to improve the quality of life of living beings as well as provide monitoring solutions
for various medical applications. The specific advantages of implantable devices in comparison
to other monitoring methods such as magnetic resonance imaging (MRI), and CT scans are
their small size [92], low weight [93], low power [94], and increased functionality [92]. As
17
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these micro–systems are dealing with living bodies, they require additional research into areas
such as packaging [95], reliability [96], and bio–compatibility [97]. To achieve these various
measurements, different types sensors are utilized to convert the bio–signals to electrical data
for processing. One of the most common sensors used is a pressure based sensor. These
different sensors are utilized in many application areas such as retinal [87,98], neurological [83,
86, 99], and cardiac [85]. In addition, the focus on power consumption, small size and wireless
power are common themes found throughout the different application areas that implantable
telemetry systems are utilized.
For example, one of the more recent advancements in retinal implantable systems has been
achieved by Shih [94]. Here, Shih presents a 2.3µW wireless intraocular pressure/temperature
implant. This implant is used to monitor intraocular pressures that are used in the diagnosis
and treatment of glaucoma. In addition, Yang [98] has studied inductor modelling to wirelessly
power such retinal implants. These retinal implantable systems have the potential to greatly
improve the monitoring of such diseases as well as the possibility of early detection before
current diagnostic methods can.
Another major application area for implantable systems is in neurological research. For
instance, Neihart [86] presents a low–power bi-directional telemetry system that is designed to
be fully implanted inside a human body for neural recording applications. Additional research
was achieved by Ghovanloo [99] who developed an implantable system which contained a
multichannel mircostimulating system–on–a–chip (SOC). This system was designed to work
as a neural protheses. These systems are able to emulate natural neurological functions that
are damaged and provide rehabilitation to the patient. Auditory and visual prostheses are examples that this device strives to emulate. Furthermore, Lee [83] presented an inductively
powered wireless neural recording system, that contained a 14.19 mm2 integrated circuit (IC)
that consumes 5.85 mW. This publication focused on the wireless power transfer of the custom
IC and system.
More recent research has been completed by Greenwald et al. [6] who developed a low–
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(b)

Figure 2.1: Implantable Neural Monitoring System by [6] where a) the block diagram and
PCB implementation; b) system on mounted on rat’s head. Images from [6]. Copyright c 2011
IEEE.

power neural monitoring system for small animals that contains three PCBs configured in a
headstage with a weight of 24 g, Fig. 2.1. This device was evaluated in–vivo in awake rats.
Zhang et al. [100] improved upon this research by creating a smaller, lighter backpack device
for neuro recording at 10 g and sub 1 cm3 , however, battery life was greatly reduced to achieve
the smaller sized device. The most recent advancements in neuro recording have come from
Gagnon-Turcotte et al. [7] and Liu et al. [8]. In [7], they present a wireless headstage for combined optogenetics and multichannel electrophysiological recording. The headstage is able to
perform readings and stimulation simultaneously. The headstage itself is 3.06 cm3 in volume
and weighs 2.8 g, both volume and weight are measured without battery. It is designed with a
foldable semi-ridged structure and is placed on the mouse’s head while in use, Fig. 2.2. In [8]
an optimized wireless sensing neural recording system is presented. Their system includes a
custom SOC with integrated ADC, filters, and sensing module. The implant is placed under the
skin on the head where wireless power and data is transfered from an external device placed
on the exterior of the skin, Fig. 2.3. Although only tested in-vitro, this system has the capability to become a fully integrated neural measurement solution for monkeys. Another area
of research in neurological implants is microstimulation. Two of the more recent publicatons
in this area are from Azin et al. [9] and Khalifa et al. [101]. In [9] a miniaturized system for
spike-triggered intracortical microstimulation in rats is presented. Azin’s system operates on
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Figure 2.2: Wireless headstage for combined optogenetics and multichannel electrophysiological recording by [7] where a) is the two-sided view of the rigid-flex system, b) top system
view folded with battery, c) side view attached to the implantable electrode module. Images
from [7]. Copyright c 2016 IEEE.

Figure 2.3: Implantable neural recording system proposed by [8] where the SOC is located
under the skin with a larger external device located on the head of the subject. Images from [8].
Copyright c 2016 IEEE.
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Figure 2.4: Implantable system by [9] for spike-triggered microstimulation in rats. Images
from [9]. Copyright c 2011 IEEE.

battery power with a volume and weight of 2.8 cm3 and 1.7 g, respectively, Fig. 2.4. Most
recently, Khalifa presented initial results in a novel microstimulator IC that consumes 16 µW,
however, this system has yet to be tested in–vivo. Neurological implantable systems represent
one of the most active areas of research [102–105], however, significant challenges still exist
including miniaturization and power consumption. Implantable systems for neurological research provide methods to monitor and stimulate brain functions to improved diagnosis and
long term health care of patients with neurological disorders.
Implantable systems are actively researched in other application areas as well such as blood
glucose monitoring [106], drug delivery systems [107], and blood flow measurements [108].
A wireless implantable microsystem for blood glucose monitoring is presented in 2009 by Ahmadi [106]. Furthermore, Georgiou’s group from Imperial College London is working on an
artificial pancreas for treatment of diabetes, Fig. 2.5, [10, 109]. This is a closed-loop system
that incorporates a glucose sensor, controller and insulin pump. These types of implants allow
diabetic patients to monitor their glucose levels in real time and can help reduce symptoms
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Figure 2.5: Artificial pancreas for treatment of diabetes from [10]. Images from [10]. Copyright c 2014 IEEE.
associated with diabetes [110]. Biosensors are also a heavily researched area for implantable
medical devices [11,111–115]. One such example was developed by Baj-Rossi [11] et al. Here
she presented a fully implantable system for remote monitoring of glucose and acetaminophen
that was tested in-vivo in mice, Fig. 2.6. The implant itself contained custom ICs for measuring
and processing the molecule concentrations as well as wireless data and power. In addition,
a detailed examination into implant bio-compatibility was also provided in this paper. A full
litrature review on biosensor development is found in [115]. Related to the development of
biosensors are drug delivery systems. Smith [107] proposed a miniaturized drug delivery system for delivering medications to the eye. These types of systems allow doctors to control the
exact dosage and delivery areas for maximum effectiveness.
In 2010, Khannur [108] presented an implantable IC for blood flow measurements within
prosthetic grafts. Additionally, Lee et al. [12] developed a programmable implantable telemetry system for cardiac pacemaker applications. This device features a fully wireless recharging
system and a custom IC to perform measurement and stimulus actions, Fig. 2.7. The device
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Figure 2.6: Three versions of Baj-Rossi’s fully implantable remote monitoring system [11].
Implant contains custom IC measuring and processing the molecule concentrations as well as
wireless data and power circuits. Images from [11]. Copyright c 2016 IEEE.

Figure 2.7: Implantable telemetry system for cardiac pacemaker applications designed in [12].
Images from [12]. Copyright c 2011 IEEE.
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Figure 2.8: Smart hip implant proposed by [13]. Images from [13]. Copyright c 2016 IEEE.
was tested in-vivo in large rats, with reported power consumption of 48 µW. These systems
allow doctors to monitor and create better treatments for vascular based diseases. A full review of blood pressure and blood volume systems is provided in Section 2.2 and 2.3. Implantable systems have also been developed for other application areas including smart pills
for the gastrointestinal tract [116] and artificial bladder applications [117, 118]. More recently,
implantable systems are beginning to be developed for hip and bone applications [13], Fig. 2.8.
In addition to the major application areas above, much research is being conducted on specific
features of implantable telemetry systems such as antenna design [102, 119, 120], analog front
end circuits [121, 122], wireless powering [113, 123, 124], and RF transmitters [81, 125].

2.1.1

Implant Design Challenges and Concerns

Implantable medical device designers are presented with numerous design challenges and concerns when developing an implantable solution for their specific medical application. This
section will introduce a few of the main challenges including power management, data transfer, security, and packaging.
Power management and implant powering are of great concern to medical device manufac-
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tures as implants are required to remain functional for long periods of time while collecting
data. Traditionally, medical devices are powered off of small batteries which offer limited
power, high toxicity, and must replaced in chronic long term patients, i.e., cardiac pacemakers.
These batteries are typically replaced via a surgical procedure that can cause complications
with patients. Research into different battery technologies has yielded smaller, higher density
batteries, however, these are still only available in research applications [126–129]. Higher
power applications including pacemakers, neurostimulators, etc, will often utilize rechargeable
batteries to extend the life of the implant. These can be recharged using wired or wireless
methods.
An alternative to battery power is to use wireless energy transfer and energy harvesting
techniques. Wireless energy transfer typically refers to an inductive link involving small coils,
power amplifiers, an external power source, and AC to DC circuits [129, 130]. The link must
be optimized for power efficiency to ensure maximum power transfer. This process is not
trivial as all factors of the design must be accounted for including the tissue medium [113,131–
133]. Additional power transfer technologies exist including Ultrasound [134,135], Resonance
based coupling where coils are resonant at a specific frequency allowing transfer range to
increase versus traditional inductive coupling [131,136], RF [133,137], etc, each with their own
advantages and drawbacks. A more recent field of research is in direct energy harvesting from
within the body. Energy harvesting refers to harvesting ambient energy from another source
that is not actively delivering power to the implant [138–141]. Examples of power harvesting
solutions published in literature are optical harvesting [138], bio–fuel (glucose) [139], thermal
[140], and kinetic [141]. The main drawback of power harvesting solutions is the limited power
density achieved, typically in the sub 20 µW/cm2 range. This power density is not practical
for todays high power implants, thus these solutions are typically part of a rechargeable battery
solution or powering the sensor interface only [142]. The implant’s size, function, expected
lifetime, distance from base station, and reliability all determine the power source (battery,
power transfer, energy harvesting) used [143]. This is significantly important for small animal
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implant design as the size is severely limited, thus the applicable power sources are limited
[4]. Nevertheless, small animal power transfer is an active area of research focusing on coil
misalignment [136] and full power cage solutions [21, 126, 127, 144–146].
Another design consideration is wireless data transfer from the implant to the external base
station. In order to determine the operation frequency for data transfer, implant designers
must first evaluate the final implant location to determine the tissue properties for which the
wireless signal must pass through. Lower frequencies pass through tissue better than higher
frequencies, however, the structure of the medium (muscle, fat, bone) will also dictate the
frequency choice [147–149]. The application will determine the data-rate required for data
transfer which will impact frequency choice. Finally, the size of the implant must be considered
as higher frequencies (2.4 GHz) allow for much smaller antennas than lower frequencies (915
MHz, 13.56 MHz). In addition, frequency choice will impact power consumption. Although,
one may be able to find an optimal frequency of use, only specific frequencies mandated by
the FCC are for use in medical applications [150, 151], known as the Industrial, Scientific, and
Medical (ISM) band [152]. The most common ISM frequencies used in implantable medical
devices are 13.56 MHz, 433 MHz, 915 MHz, and 2.5 GHz [150]. Another frequency band
designed specifically for small low-power, low-bandwidth implants is the MedRadio band at
various points in the 400 MHz frequency range [151]. Most of the research in this band is on
custom MedRadio antennas for implant applications [153, 154]. Therefore, a trade off must be
made between the required data rate, antenna size, tissue absorption, allowed frequency and
power consumption when deciding operational frequency.
Although much consideration goes into the operational frequency and power supply choices,
data security is often overlooked. Implantable medical devices commonly use existing wireless
protocols for data transfer, bluetooth, MSK, FSK, OOK, etc, which are unencrypted and can be
viewed with standard electrical equipment [155]. This may not be a large concern for animal
testing, not withstanding safety pharmacology studies, however, this poses a large security and
privacy issue for human implantable devices. Furthermore, it is not only the data collection se-
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curity issue, but the base station to implant data can also be intercepted and compromised. It is
common for pacemakers, drug delivery devices, insulin pumps, and other implantable devices
to receive external commands, thus the possibility of an external attack, for example cause a
electric shock from a pacemaker [155]. Currently, the limited power and range of implantable
devices removes much of the the data threat, however, newer longer range devices are prone
to attack. Encryption is not commonly used on implantable devices due its complexity, power
consumption, and slower data rate [155], however, recently memristors have shown promise to
be used in implantable encryption schemes [156, 157]. Implant designers must be aware of all
data security and privacy concerns when designing medical devices.
Implant designers are also faced with the challenge of medical device package design. The
package of an implantable system must protect the internal electronics from being damaged
and must also protect the living body from tissue damage and other undesirable effects caused
from mechanical, thermal or biological stresses, [11,158]. The harsh environment puts extreme
requirements on the overall system design, including electronic and package design. For example, the design of an intraocular implant is bound by the specific shape of the eye impacting
the electronics and antenna design [85]. However, the volume of the eye cavity is still suitable
for implanting a high frequency antenna [94]. Furthermore, research into custom antenna solutions, e.g., flexible electronics, remains a heavy area of research [159, 160]. Custom solutions
allow for the system design to be minimized for the specific implant application, that is, to
reduce the size and weight of the overall implant. Thus, biomedical implant package design is
a very important stage in the design process. Every implant designer is faced with these issues
and must determine which is the most critical to their particular application.

2.2

Blood Pressure

Blood Pressure is one of the most important vital signals [161] in the study of the living body.
Blood pressure refers to the force exerted by circulating blood on the walls of blood vessels
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[162]. Pressure can be measured in various parts of the body including the aorta, known as
arterial blood pressure [42], the left ventricle [163], the femoral artery [42, 164], intracranial
[165], etc. Recall from Chapter 1 that the relationship between aortic pressure, LV pressure,
LV blood volume, and ECG is described using the traditional Wiggers diagram, Fig. 1.3.
Typically, when referring to blood pressure, without the measurement location known, arterial pressure is assumed. This is generally the case when referring to human blood pressure
measurements, where a pressure cuff located on the upper arm and is used to measure systolic and diastolic (max and min) pressures. This measurement represents the pressure exerted
within the brachial artery [42], and is slightly different if measured directly in the Aorta. More
specifically, the brachial pressure typically has higher systolic and lower diastolic pressures
compared to a direct aortic pressure measurement [42]. A brachial artery or aortic pressure
measurement provides doctors with valuable health information and can determine if the patient has hypotension (low blood pressure) or hypertension (high blood pressure) further determining their risk for cardiovascular desease. Similar to brachial pressure, the pressure in the
femoral can be measured with a pressure cuff and can indicate the onset of various diseases
including peripheral vascular disease [166, 167]. Femoral pressures exhibit slightly higher
magnitudes of pressures compared to brachial pressures.
More importantly, the measurement of left ventricle (LV) pressure can provide insight into
cardiac contractility. As mentioned in Chapter 1, cardiac contractility is very important when
determining the safety of a new drug in the field of pharmacology safety. Furthermore, measuring LV pressures provides researchers with the most accurate real–time measurements of
the heart filling cycle. Various important cardiovascular parameters are extracted from LV
pressure measurements including End Diastolic Pressure (EDP), End Systolic Pressure (ESP),
etc. One important LV pressure parameter is

dP
,
dtmax

known as the peak positive rate of pressure

change inside the left ventricle [34, 168]. As mentioned in Chapter 1
tional methods to measure contractility. To measure

dP
dtmax

dP
dtmax

is one of the tradi-

accurately, the sampling rate of the

pressure measurement circuit must be much higher than the signal of interest. The remaining
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subsections will focus on measurement techniques for left ventricle pressure in animals

2.2.1

Blood Pressure Measurement Techniques in Animals

Blood pressure monitoring has been around since 1733 [48, 169] and has advanced from invasive wired techniques [170] [171] to fully wireless solutions [79]. In 2005, the American
Heart Association (AHA) published recommendations for measuring blood pressure in animals [168, 172]. The AHA compared both indirect and direct measurement methods. Direct
LV pressure measurement methods include fluid-filled catheters [173], MEMS based catheters
[174], and full implantable systems [79]. Indirect pressure measurement methods for animals
typically use a tail cuff device [175–177]. Direct methods allow for continuous real–time measurements whereas indirect methods typically will only provide major changes throughout the
measurement cycle.

Indirect Measurement Methods
Traditional indirect measurement techniques for blood pressure monitoring include Doppler
sphygmomanometry [178,179] and oscillometry [180–184]. In both approaches, a small cuff is
placed around the animal’s tail to measure the arterial blood pressure, similar to a human blood
pressure cuff. Unlike when humans use blood pressure cuffs, animals require confinement
and restraint that can create stress on the animal, further impacting measurement results [34,
184]. Furthermore, the blood pressure cuff must be located along the same plane (height)
as the bottom of the heart to achieve accurate pressure readings which is difficult to achieve
in laboratory animals compared to a human [34]. As opposed to pressure sensors inside of
catheters, tail cuffs cannot obtain continuous blood pressure measurements, only systolic blood
pressure data [79] and mean arterial pressures [183], thus non-LV pressures. Moreover, due
to the infrequent measurement cycles of pressure cuffs, minor changes in blood pressure will
not be detected. These methods are typically much less expensive and non-invasive than the
direct based methods. A full comparison between Doppler and Oscillometry indirect pressure
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measurement methods is found in [179, 185, 186].
For larger animals, a newer measurement method known as high definition oscillometry
(HDO) can be used [34, 187]. This technique still relies on a tail or leg cuff to perform the
measurement, however, it is able to more accurately detect systolic, diastolic and mean arterial pressures over Doppler sphygmomanometry and oscillometry [34, 188]. In addition, this
method provides a quicker measurement rate and allows for measurement data to be viewed
on a computer screen, allowing measurements to be rejected if required [34, 168, 188]. Various
studies [176, 177, 187, 189] have been completed comparing HDO to direct methods for measuring arterial pressures. These studies indicate good correlations in arterial pressures when
movement is kept to a minimum. As with traditional tail cuff methods, if the animal moves
while measurements are taken, artifacts will be created on the measurements [34, 190]. Additional stress on the animal can occur if extra restraints are involved, further impacting blood
pressure results [34, 190].
All three of these indirect methods will only provide systolic, diastolic and mean arterial
pressures and will not provide LV pressures. Thus, indirect methods cannot be used when
creating a LV pressure–volume loop, only direct methods can provide real–time LV pressures.

Direct Measurement Methods
Direct methods refer to measuring blood pressure at the specific internal location, i.e., arterial
pressure [177, 191], femoral pressure [192], LV pressure [41], etc. In addition, the blood itself
is in direct contact with the measurement device. The direct pressure measurement methods
can be separated into two distinct categories: 1) catheters with external signal processing and
conditioning; and 2) fully implantable telemetry solutions. Direct measurement methods allow
for real–time monitoring of blood pressure such that minute changes in pressure can be detected
[172]. This method allows researchers to obtain more comprehensive measurements for their
studies.
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Catheters with external signal processing and conditioning: One of the first recorded direct pressure measurements was performed by Stephan Hales in 1733 [48, 169] where he measured arterial pressure in a horse. This was an extremely crude measurement where a glass tube
was directly inserted into the femoral artery and the height of the blood in the tube above the
LV of the blood was recorded. He measured both systolic and diastolic arterial pressures with
this procedure [34]. The next major improvement in direct pressure monitoring was in 1828
when Poiseuille invented the U-Tube mercury manometer [48] where pressure measurement
units (mmHg) were first used. The U-Tube was replaced by a strain gauge pressure transducer
that was connected to a fluid filled catheter by Statham in 1943 [15, 34]. The system used by
Statham and solutions similar to this had various limitations including low frequency response,
pressure delay through the catheter tip to the transducer, etc [34].
To solve these issues, researchers moved the pressure sensor directly to the tip of the
catheter to make pressure measurements. This was first completed by Van Citters and Franklin
in large animals in 1965 [193]. Here, the sensor was placed at the tip of the catheter with
additional external wires to complete the measurement. These fluid filled catheter tip sensors
have improved and miniaturized greatly over the years and have been used in numerous animal
studies [173, 191, 193–195].
With the arrival of MEMS (Microelectromechanical Systems) based pressure sensors, traditional fluid-filled catheter pressure solutions have been replaced. These systems utilize either
solid-state resistive [196] or capacitive [197] sensors to measure blood pressure. The sensors
are assembled on the tip of the catheter and create an electrical voltage when the blood pressure changes. As with the fluid-filled catheters, these require a surgical procedure to guide the
sensor to the measurement location, an invasive procedure. The first solid state based pressure
sensor solution was invented in 1989 by Brockway et al. [14], Fig. 2.9. It was connected to a
short fluid-filled catheter to complete the measurement [14, 15].
Solid state pressure sensors have rapidly advanced to their current form of using MEMS
based sensors and are now the gold standard when measuring blood pressure in animals. These
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Figure 2.9: First solid state based implantable pressure system in 1989 [14, 15].
solutions still require external measurement equipment to provide stimulus to the MEMs sensor (note: capacitive based solutions can be read without any direct voltage or current stimulus [142]). MEMS catheter based pressure systems are very accurate however they allow
for minimal overall movement of the test subject due to its direct connection with a larger
measurement source. Similar to other direct methods, the surgical procedure can also cause
possible complications such infection or trauma to the heart [198–202]. Several commercial
catheter options are available for large and small animal from Transonic Scisense [196] and
Millar Instruments [203] that are available down to the 1.2F size to fit in a mouse left ventricle,
Fig. 2.10. These catheters are used in acute hemodynamic studies today [175, 191, 200]. The
catheter used in this thesis utilizes a MEMS based pressure sensor. More info on the specific
catheter used is provided in Section 4.4.2

Implantable Pressure Measurement: From Citters and Franklin’s first implantable transducer in 1965 [193], implantable pressure telemetry has advanced a long way. The first fully
implantable system for animal research, mentioned above, was completed by Brockway et
al. [14], Fig. 2.9, however, various aspects of implantable telemetry system research have existed for human and animal research prior to this [204–207]. When referring to implantable
blood pressure telemetry, a pressure sensor, typically MEMS based, is attached to a processing
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Figure 2.10: MEMS based pressure catheters for small animals from two manufactures: a)
Millar Inc. and b) Transonic Scisense.

and control system where the data is transmitted external from the body, [197, 208]. Currently, implantable telemetry is considered the gold standard for large animal blood pressure
measurement [168]. Various toxicology and pharmacology studies have been completed using
implantable pressure telemetry [209–211].
Commercial pressure telemetry solutions exist for small and large animal research. Three
main companies provide these systems: Millar Inc., Transonic Inc., and Data Science International (DSI).
Millar Instruments: Millar offers a single implant for the mice range [212] and 7 implants
over its rat range [213]. In the mice range, the implant can only measure biopotential signals
(ECG, EMG, EEG) and weighs 2.5 g with a volume of 1.4 cm3 . These implants can only be
used in animals larger than 22 g. In the larger rat range, four types of signals can be measured
with the available implants: pressure (arterial, venous, ventricular, intracranial), biopotential,
tissue oxygen, and sympathetic nerve activity [213]. As the work in this thesis focuses on LV
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Figure 2.11: Millar TRM54P implantable pressure telemetry system [16]. Copyright c Millar
Instruments Inc.

blood pressure and volume monitoring, only single LV pressure implant, TRM54p [16], will
be discussed for comparison. The TRM54p has a weight of 12 g, a volume of 7 cm3 , and a
battery life of 4 to 7 h, Fig. 2.11. All Millar implants can be recharged via an external power
station and are single use implants, i.e., cannot be interchanged with different sensors. Millar
does not offer telemetry volume monitoring.
Transonic Inc.: Transonic Inc. offers two implants: EndoGear1 [17], Fig. 2.12a and EndoGear3 [18] Fig. 2.12b, large and small animal respectively. Unlike Millar’s offerings, the
EndoGear is interchangeable and configurable with various senors including doppler flow velocity, LV blood pressure, ECG, and temperature. Both the EndoGear 1 and 3 offer the same
sensor options, however, for measuring LV pressure EndoGear3 can utilize a 1F catheter size.
Each system can be used with different batteries ranging from 2400 mAh to 7200 mAh, providing 200 to 600 hours of use. The main difference between the EndoGear 1 and 3 are the size of
the main implant and the ability to use wireless power. The EndoGear 1 is 6.35 cm x 3.175 cm
x 1.27 cm (25.60 cm3 ) compared to the smaller EndoGear 3 at 2.8 cm x 3.0 cm x 0.9 cm (7.5
cm3 ). The EndoGear 3 can be powered wirelessly via an attached coil. Although, much larger
than the Millar TRM54P, the EndoGear 3 is much more versatile in its measurement options.
There is no implantable volume telemetry offered by Transonic Inc.
Data Science International: Data Science International (DSI) offers the most commercially
available implantable telemetry systems for a variety of measurement signals (pressure, biopotential, glucose, temperature, heart rate, respiration) and across small, medium, and large an-
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Figure 2.12: Transonic EndoGear for a) large animal EndoGear1 [17] and b) small animal
EndoGear 3 [18]. Copyright c Transonic Inc.
imal ranges [214]. DSI’s implants are also offered in different shapes and battery sizes to
suite the researchers requirements. Only two systems offered measure LV pressure, DSI HDS21 [19] and L11 [20], for medium (rat) and large animal, respectively. The DSI HD-S21 is
able to measure LV pressure, ECG, temperature and heart rate. It weighs 8 g with a volume of
5.9 cm3 and has a 2 month battery life, Fig. 2.13. The large animal implant, L11, measures the
same signals however, is much larger in size at 5.9 cm x 3.8 cm x 1.5 cm (33.63 cm3 ) and has
a weight of 56 g, Fig. 2.14. The L11 has a battery life of 105 days. There is no implantable
volume telemetry offered by DSI.

Academic Research Devices: More recently, researchers have focused on creating fully custom wireless implantable system with integrated blood pressure sensors [89,127,137,192,208–
210, 215, 216]. These systems range from creating a fully implantable cardiovascular pressure
monitor with a medical stent [85] to a fully implantable blood pressure sensor for hypertonic
patients [217]. Furthermore, much research has been placed on miniaturizing and improving
the pressure sensor itself [197, 215, 218, 219].
The most recent research in this application area is in long term cardiac monitoring of small
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Figure 2.13: DSI HD-S21 small animal left ventricle pressure measurement system [19]. Copyright c DSI.

Figure 2.14: DSI L11 large animal left ventricle pressure measurement system [20]. Copyright
c DSI.
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Figure 2.15: Implantable wireless telemetry system featuring a cuff blood pressure sensor: a)
before packaging, b) after encapsulation, Cong [21]. Copyright c 2010 IEEE.

animals. New research challenges occur such as reduced implantable area when dealing with
smaller sized subjects over larger ones (e.g., non-human primates, humans, etc), as well as sensor drift and frequency resolution. This prevents larger external components from being used
along with larger power sources. In [197], a pressure monitoring system is proposed that uses
a passive telemetry link to send and receive power and data. Further advancement in miniaturization and packaging techniques has lead to the implantable system developed in [217].
In [89, 192], a fully implantable wireless pressure monitoring system was developed for hypertension patients. Here, both a custom pressure sensor and telemetry system were developed,
however, it was designed to monitor femoral pressures and not the higher LV pressure. Others [127, 137] have focused on creating wireless power systems for these pressure implants to
be used long term. Full implantable blood vessel cuff monitoring systems have also advanced
throughout the years to current state–of–the–art methods such as the systems mentioned in [79]
and [220].
In 2010, Cong [21] proposed a wireless batteryless implantable blood pressure monitoring
microsystem for small laboratory animals, Fig. 2.15. Cong’s implantable system employes a
blood pressure cuff to measure the blood pressure around the blood vessel it is attached to. The
pressure cuff is made from bio–compatible materials and contains an internal MEMS pressure
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Figure 2.16: Implantable cardiac monitoring system developed by Volk [22] incorporating
ECG, arterial pressure, and temperature sensors. Copyright c 2015 IEEE.

sensor. The fully implantable system dissipates 300 µW and was experimentally tested. The
complete size of the wireless system is 6.4 mm diameter with a length of 4 mm and was also
powered wirelessly via RF. However, Cong’s implantable system is only focused on arterial
blood pressure monitoring not LV blood pressure and does not combine any additional sensors
to provide increased functionality.
A more recent implantable telemetry system was developed by Volk et al. [22] that measured ECG, arterial pressure, and temperature, Fig. 2.16, in mice using custom flexible ECG
and pressure sensors. The system was powered wirelessly via Radio Frequency Identification
(RFID) protocol, where a RFID reader is placed under the mouse cage to provide power and
data transfer. This system was initially tested in–vivo in rats with successful results [22]. This
system is much larger than the one presented in [21] at 29 mm x 21.5 mm. However, ECG
and temperature monitoring are present. The increase in size is also attributed to the lower
frequency RFID protocol used.
All telemetry systems mentioned in this section all measure blood pressure in one way
or another, nevertheless, only a few (fully commercial solutions) measure the higher pressure
higher bandwidth left ventricle signal. Furthermore, none of these existing systems measure
blood volume. Implantable pressure–volume systems are discussed in the following section.
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Figure 2.17: Example of the physical size of a implantable catheter, along with the electrode
spacing for volume measurements and pressure sensor location.

2.3

Blood Volume Measurement in Animals

As described in Section 1.2, non-invasive left ventricle volume measurement methods were
discussed indicating major issues including large equipment, highly trained personal, and large
laboratories. In this section, direct volume measurement methods will be discussed in detail.
Direct catheter based methods have been developed [77] [70] that provide a low cost, yet
accurate measurement solution for finding LV volume in small test subjects. Two techniques
exist to measure LV blood volume using a catheter based system: conductance and admittance.
These techniques provide methods for the accurate measurement of LV blood volume from
small lab animals in a cost effective and accurate fashion.

2.3.1

Conductance

The classical method of measuring blood volume in a catheter based system is the conductance
technique, first introduced by Baan et al. in the early 1980s [77]. This method utilizes a tetra–
polar catheter, Fig. 2.17, with two sets of rings located at the top and bottom of the catheter
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is placed inside the LV. The two outer electrodes inject a constant AC current into the blood
to create an electric field within the LV and the two inner electrodes measure instantaneously
the voltage created as the heart goes through its pump cycle. Conductance is calculated from
the known excitation current and measured voltage. It should be noted that the myocardium
conductance varies over the cardiac cycle.
The classical equation to convert the measured conductance to a LV volume is directly
found by using Baan’s linear conductance to volume equation (2.1):
1 2
ρL (Gmeas − Gm )
α
1
= ρL2Gb
α

Volume =

(2.1)

where ρ is the blood resistivity (Ωm), L is the length between the voltage sensing electrodes
1
(m), is the stroke volume (SV) calibration factor (originally assumed to be 1), Gmeas is the
α
instantaneous measured conductance, Gm is the surrounding myocardial conductance, and Gb
is the blood conductance [37].
Baan’s equation makes the following assumptions: a) the electric field distribution is uniform throughout the cardiac cycle; b) the ventricular wall is insulated from the blood, i.e., the
total measured conductance is due to the blood and not the heart muscle; c) the heart cavity
has a cylindrical shape; and d) the catheter is stationary and always perfectly centred along the
cylinder’s axis.
The electrical model of the heart used in the conductance measurement method, Fig. 2.18
(Gb and Gm ), models the blood and muscle as single resistive components. A single conductance measurement, Gmeas , includes information about both blood, Gb and myocardium muscle,
Gm , leading to an over estimation of the LV blood volume. However, they are a combined value
and cannot be separated without calibration [77]. Additionally, the model assumed that conductance Gm remains constant throughout the cardiac cycle, this has since been addressed [221].
Based on these assumptions Baan suggested the use of a hypertonic saline bolus to be injected
into the bloodstream in order to help estimate Gm [37, 222]. Although this method is still used
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Figure 2.18: Conductance (Gb and Gm ) and Admittance (Gb , Gm , and Cm ) electrical heart
model, where Iin represents the injected current, Gb blood conductance, Gm muscle conductance, and Cm as the capacitive component of the muscle.

it has several significant drawbacks: it only provides one constant value for Gm over the cardiac cycle, the saline bolus may temporarily change value of Gm , and the increased volume
can cause harmful effects to the murine cardiovascular system [223, 224]. In addition, this
technique is predominantly used in larger animals because the saline solution will significantly
alter the blood resistivity and blood volume of smaller animals [70] causing Baan’s equation to
become invalid [77]. An alternative method to estimate parallel conductance based on the use
of dual frequency stimulation was suggested in [225–227], which also does not account for the
variation in Gm during the cardiac cycle. However, these calibration techniques are not time
dependent, therefore not creating instantaneous calibration to the conductance measurement.
The conductance value requires a time dependent calibration factor to take care of the change
in LV volumes (i.e., changing the electric field based on heart cycle) during the cardiac cycle
from end–diastolic to end–systolic.
To correct for the effects from the non-uniform electric field on the conductance measurement, Wei et al. proposed a new improved equation denoted as Wei’s equation (2.2) [228,229].

Volume =

γ

γ − Gmeas − Gm
γ
=
ρL2 (Gb )
γ − Gb

ρL2 (Gmeas − Gm )
(2.2)

Where ρ is the blood resistivity (Ωm), L is the length between the voltage sensing electrodes

Chapter 2. Implantable Medical Devices

42

(m), γ is the field form factor, Gmeas is the instantaneous measured conductance (S), Gm is the
surrounding myocardial conductance (S), and Gb is the blood conductance (S) [228]. The field
form factor γ is calculated by (2.3).
√
γ=

−b ±

b2 − 4ac
2a

where a = S V − ρL2 (Gb−ED − Gb−ES )
b = −S V(Gb−ED + Gb−ES )
c = S V × Gb−ED × Gb−ES

(2.3)

S V = strokeVolume (L)
ρ = blood resistivity (Ωm)
L = distance between sensing electrodes (m)
The main benefit of Wei’s equation compared to Baan’s is the compensation for the non–
linear electric field throughout the LV. This is corrected using the field form factor or γ. Wei’s
equation does however, require an independent stroke volume (SV) measurement for the calculation of γ. For larger subjects, Wei’s equation can reduce the overestimation error to 10%
compared to using the original Baan’s equation [228]. In addition, this equation still requires
parallel conductance removal through Hypertonic saline techniques. Therefore, a new technique, admittance, was created to separate blood volume from the surrounding muscle (myocardium) to calculate a more accurate LV volume measurement using Wei’s equation. A full
detailed analysis comparing the various conductance–to–volume equations is described in the
following chapter.

2.3.2

Admittance

Porterfield et al. [230] proposed a new admittance based technique in the late 2000s, where the
electrical and permittivity properties of the murine myocardium [231] are exploited to remove
the myocardium conductance (Gm ) component from the overall measured signal. In addition,
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this technique includes the effects of the parallel myocardium capacitance (Cm ), where the
original conductance method did not. This is described in the admittance equation (2.4), where
the myocardium conductance and capacitance vary over the cardiac cycle.
Ymeas = Yblood + Ymuscle

(2.4)

= Gb + Gm + jωCm
The known excitation current iAC , whose frequency is set to 20 kHz, flows mostly through
the blood and partially through myocardium volume. At that frequency, the blood exhibits
purely resistive behaviour, while myocardium shows both resistive and capacitive properties [147–149, 229, 231, 232]. Therefore, an updated electrical model of the heart is realized,
Fig. 2.18 (Gb , Gm , and Cm ). Using an excitation frequency of ∼20 kHz, allows for the separation of the admittance of the myocardium from the combined measured admittance using
electric field theory [230]. For this reason, in order to derive accurate blood volumetric results
the measured conductance must be corrected for the parasitic effects of the myocardium.
The measured conductance and capacitance of the electric field are related by (2.5), where
σm
(muscle conductivity and permittivity) is found using a surface probe measurethe ratio of
εm
ment before the main experimental procedure. The derivation and process on measuring and
calculating these parameters is detailed elsewhere [231].

Gm = Cm

σm
εm

(2.5)

During an experimental procedure, only the magnitude and phase of the admittance signal
will be measured (i.e., Ymeas = |Ymeas |∠θY ). This is conducted using the same catheter, Fig 2.17,
as the conductance method. Therefore, using these two parameters, the values of Gb , Gm ,
and Cm can be calculated. Recall, that Ymeas is given in eq. (2.4) and that blood is purely
resistive and the myocardium has both resistive and capacitive electrical properties when using
an excitation frequency of 20 kHz. With this knowledge, one can calculate the instantaneous
values of Cm , Gm , and finally Gb using equations (2.5), (2.6), and (2.7), respectively.
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|Ymeas | sin(θY )
2π f

Gb = |Ymeas | cos(θY ) − Gm

(2.6)

(2.7)

These three equations allow the parallel conductance (myocardium conductance) to be dynamically calculated based on the frequency dependent value of Cm , (2.8).
Gb = |Ymeas | cos(θY ) − Gm
σm
∗ Cm
εm
σm |Ymeas | sin(θY )
Gb = |Ymeas | cos(θY ) −
∗
εm
2π f
Gb = |Ymeas | cos(θY ) −

(2.8)

This eliminates the need for hypertonic saline injection to calculate Gm , which is extremely
beneficial for testing in small laboratory animals. Finally, with the complex admittance calculated (2.8), Wei’s equation (2.2) can be used to calculate accurate volumes of the LV [231] [80].
State–of–the–art LV volume systems use this technique to calculate absolute volumes.

2.3.3

Pressure–Volume Systems

Implantable systems incorporating blood volume sensors for small animals have been an area
that has yet to be exploited to its full potential. Currently, the majority of blood volume monitoring systems are what is known as tethered systems (i.e., attached to an end unit). These
are generally commercially available from manufactures such as Transonic Scisense Inc. [3]
and Millar Instruments Inc. [233]. These systems obtain their power and communication from
attached end units, Fig. 1.4. The reason that these telemetry systems still remain wired is
the increased complexity and external component count required when dealing with accurate
blood volume measurements in comparison to simpler blood pressure measurements. By being
tethered to an end unit the test subject is not allowed to move freely in their own natural envi-
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Figure 2.19: Implantable PV system developed by Raghavan [23] that is 17.67cm2 and 27g.

ronment and may affect the measurement results [23]. The solution to this would be to create a
wireless implantable system similar to implantable pressure systems described in the previous
section but incorporate blood volume sensors as well.
One of the first developments of wireless implantable systems incorporating both LV blood
pressure and volume sensors for small animal subjects reported by Uemura et al. [90] in 2004
was based on Bluetooth wireless technology. However, this telemetry system had a few drawbacks. First, the telemetry system was quite large as it used a programmable digital logic device
and other large components to preform the processing. This increased the overall weight to 26
g. The second drawback of this initial telemetry system is that the conductance technique was
used to measure volume rather than admittance and it also used a dual frequency approach
to remove parallel capacitance from the measured volume. This reduced the accuracy of the
volume measurements as is documented above.
Raghavan [23] improved this initial research by designing an admittance based telemetry system using analog circuit techniques, and a printed circuit board (PCB) whose size and
weight are 17.67 cm2 and 27 g, respectively, Fig. 2.19. This system improved over the previous
system by using admittance based measurements rather than conductance methods, providing
more accurate volume measurements. Although, improved over [90], there are still drawbacks
and areas of improvement. This device was tested in large rats [23] and the size and weight of
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Figure 2.20: Implantable PV system developed by Schuhatovich [24] that weighs 4 g and has
a volume of10 cm3 .
this telemetry system are still quite large for small animals, with the weight at 27 g.
Schuhatovich [24] furthered Raghavan’s research by reducing the size and weight to 4 g
and 10 cm3 , Fig. 2.20. Schuhatovich’s work mainly focused on the firmware development
and built upon Raghavan’s implant design by using a two board approach where each board
measured 1.27 cm x 1.9 cm. The implant operated off of battery power and transmitted data on
the 915 MHz band. This work was only evaluated in–vitro without the use of phantoms or in
animal models. It also had high operating currents of 7.6 mA in active mode and up to 38 mA
in transmission.
More recently, Loeffler et al. [25, 26] designed an admittance based telemetry system with
a volume of 5.92 cm3 and a weight of 7.2 g, Fig. 2.21. This implementation is an extension of
Raghavan’s research and a second iteration of Schuhatovich’s work [24,26]. In Loeffler’s work,
she decreased the transmission power and increased the weight compared to [24], however, her
implementation was tested in large rats. As with [24] and unlike Raghavan [23], Loeffler’s
device operated in the 915 MHz band.
Loeffler’s work represents the most recent published work [25,26] in implantable pressure–
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(a)

(b)

(c)
Figure 2.21: Implantable PV system developed by Loeffler [25,26] where a) shows the implant
assembled with the battery; b) implant PCBs; and c) fully encapsulated implants. Implant is
5.92 cm3 in volume and has a weight of 7.2 g.
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Figure 2.22: System designed by Holt [27] to measure volume in the right ventricle. Volume
is 96.7 cm3 .

volume telemetry systems for small animal cardiac research, however, more recent work has
been completed by Holt [27] and Le [234] that focused on the development of much larger
higher power devices for heart failure patients. In [27], Holt created a device that measured
right ventricle blood volume only with future intentions for it to be used in conjunction with
pacemakers. This device was 5 cm x 7.6 cm x 2.5 cm (96.7 cm3 ) and used a 1000 mAh battery,
Fig. 2.22. This system did not contain any pressure monitoring and was not tested in–vivo.
Following the device in [27], Le developed a right ventricle volume measurement system [234]. This system measured volume, pressure (non-LV, surface pressure only), ECG, and
temperature. It did not use a catheter to measure hemodynamic data, rather it uses a novel
spring loaded device to perform measurements. Size and weight of this system was not reported, however, [234] focused on the development of the firmware rather than minimize size
and power. The system operated on large 7.4 V 2200 mAh batteries. This device was not tested
in–vivo and did not include measurement of LV pressure or volume.
A full comparison of the relevant published works and the system designed in this thesis
is shown in Table 6.7. If the telemetry system is to be implemented in a small animal subject,
e.g., a rat and mouse, for an extended period of time without harm, further reduction in size,
weight, and power consumption are required.
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Conclusion

In this chapter, a introduction into the field of implantable medical devices along with their
various application areas and challenges is presented. A detailed discussion of blood pressure
measurement technologies and techniques are presented with a focus on animal measurements.
Relevant research and commercial blood pressure implants are discussed in detail outlining the
few LV pressure systems available and the lack of commercial systems that measure LV blood
volume. Moreover, an extensive background is provided for LV blood volume measurement
techniques. Critical pressure-volume telemetry systems are discussed and compared, with the
conclusion that further miniaturization is required for long term chronic use.

Chapter 3
Numerical Comparison and Calibration of
Conductance Catheter Models∗
In the previous chapter, the focus was on implantable medical devices where we looked at
different applications, sensors, and challenges involved in creating a implantable medical device. Furthermore, details of pressure–volume (PV) telemetry systems were discussed, with
emphasis on the specific pressure and volume measurement approaches. More specifically,
conductance and admittance measurement techniques were introduced followed by a brief introduction to the conductance–to–volume equations (Baan’s, Wei’s, and Dubois). These three
conductance–to–volume equations are currently being used in industry yet there are no published works on their comparative analysis. In this chapter, a comparison study of all three
conductance–to–volume equations along with the accuracy of the analytical model of the conductance catheter is presented. In addition, the overall accuracy of the admittance catheter
volume measurements is studied and an empirical calibration factor to improve the volume
measurement accuracy with the existing conductance–to–volume equations is presented. Although catheter design is not the direct focus of this thesis, it is important to study its effects
on volume measurement in order to fully understand its application within a implantable envi∗

Portions of this chapter are published in IEEE Transactions on Biomedical Engineering [235].
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ronment.
The rest of this chapter is organized as follows. In Section 3.1 the basic principle behind
conductance based PV measurements with a detailed look at each conductance–to–volume
equation is introduced, numerical verification of the models is presented in Section 3.2, which
is followed by in–vitro experimental data in Section 3.3. Sensitivity due to physical variations
of the catheters and correction factor is in Section 3.4. Concluding remarks for this chapter are
in Section 3.5.

3.1

Conductance Based PV Measurements

In this section, the ideal conductance–to–volume conversion technique is reviewed followed
by a detailed look at Baan, Wei, and Dubois’ conductance–to–volume equations. Calibration
techniques are also discussed.

3.1.1

Review of Ideal Conductance–to–Volume Technique

The principle of idealized volumetric measurements of a cylindrical cavity made of perfectly
conductive material (σm → ∞) and filled in with non–perfect conductive fluid (σb , εr ) is illustrated in Fig. 3.1 and Table 3.1.

The volume is calculated from measured conductance

values of a tetra polar catheter centred inside the cylinder, where the four ring electrodes
( in, V+ , V− , gnd ) serve as the input and output terminals. Thus, the conductance of the blood
and myocardium volume is calculated from the known excitation current iAM (which is injected between ( in, gnd ) terminals), and the measured potential difference (which is measured
between ( V+ , V− ) terminals) by using Ohm’s law. In the idealized case of cylindrical volume,
~ θ), it is trivial to calculate that real
and perfectly symmetrical homogeneous electric filed E(r,
cylindrical volume as Vreal = πR2 H and measured reference volume as exactly Vref = πR2 L,
where R is the cavity radius, H is the cavity height, and L is known distance between the two
output electrodes. Therefore, real volume Vreal is effectively measured between the centres of
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Table 3.1: Physical dimensions of used catheters.
Catheter

a [mm]

b [mm]

L [mm]

a0 [mm]

1.2F Nominal

0.5000

0.5000

4.5000

0.2500

#190

0.4768

0.4914

4.4966

0.2000

#315

0.5146

0.4648

4.5436

0.2000

#507

0.5243

0.5166

4.5648

0.2000

#587

0.5301

0.4718

4.5529

0.2000

#590

0.4848

0.4852

4.5046

0.2000

#12-870

0.4815

0.5110

4.4787

0.2000

#12-1146

0.5150

0.5110

4.4663

0.2000

#12-1147

0.4969

0.5277

4.5501

0.2000

σm

Vreal = π r2 H

∞

σm

∞

h
in
d
2

a

V+

θ r1
E(r,θ)

r

L
H

d
2

r2
Vb

gnd

c

σb
ε0 εr

Vref = π r2 L

a0

R

x

Figure 3.1: Geometry of a general conductance based measurement environment, where specific material properties can be modelled by σm , σb , r , m and overall shape by R. Summary
for eight catheter sizes used along with nominal 1.2F is in Table 3.1.
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V+ and V− electrodes, which actually defines the smaller reference volume Vref . Obviously, the
reference volume measurement is function of the catheter geometry; and the measured voltage
between the two inner electrodes (V+ , V− ) is due to not only the conductance of the blood (Gb )
but also the parallel admittance of the myocardium (Gm , Cm ), Fig. 2.18.

3.1.2

Conductance–to–Volume Equations

Recall from the previous chapter, Baan’s linear model [37] that connects measured conductance
and volume VolB , (3.1). Note equation (3.1) and (2.1) are identical and only repeated for clarity
purposes.
1
ρ L2 (Gmeas − Gm )
α
1
= ρ L2 G b
α
Gb−ED − Gb−ES
α = ρL2
SV

VolB =

(3.1)
(3.2)
(3.3)

where, ρ is blood resistivity, Gmeas is the measured conductance, Gm is parallel conductance,
Gb−ED and Gb−ES are the calculated blood conductance at diastole and systole respectively. This
technique assumes a uniform electric field and a linear conductance–to–volume relationship,
which results in the overestimated LV volume in mice. This overestimation is even greater
in relative magnitude in larger animals due to the increased non–linearity of the conductance
volume relationship for larger volumes [228].
In order to improve accuracy of (3.1), starting from Maxwell’s equations in [228] Wei
derived equation (3.4) from a cylinder model.



 4a20


πG2inf L d2  d2 + 1
1


VolW =
−
 (Ginf − Gb )2 G2 
4
inf 


(3.4)
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where, Ginf is conductance of infinitely large volume of blood, assuming cylindrical blood
volume; spherical electrodes; non–conducting inner electrodes (V+ ,V− ); and uniform electric
~ θ). However, the shape of the ventricular is not cylindrical and (3.4) does not include
field E(r,
an empirical factor to force volume differences created from Gb ES and Gb ED . Wei introduced
an empirical correction factor β to include the experimentally measured SV in the analytic
equation (3.6) [228]. The improved analytic approximation becomes (3.5).
β
β
−
(Ginf − Gb ED )2 Ginf 2
1
1
where β = S V[
−
(Ginf − Gb ED )2 (Ginf − Gb ED )2
VolW =

(3.5)

From the analytic approximation equation (3.5), Wei’s non–linear conductance to volume
equation (3.6) is empirically developed for non cylindrical volumes which includes an empirical correction factor γ to force the measured Stroke Volume(SV) to the known SV, measured
from an independent SV probe.
γ

VolW =

γ − Gmeas − Gm
γ
=
ρL2 (Gb )
γ − Gb

ρL2 (Gmeas − Gm )
(3.6)

where, ρ is the blood resistivity (Ωm), L is the length between the voltage sensing electrodes
(m), γ is the field form factor, Gmeas is the instantaneous measured conductance (S), Gm is the
surrounding myocardial conductance (S), and Gb is the blood conductance (S) [228]. The field
form factor γ is calculated by (3.7). Note (3.6) is identical to (2.2) and (3.7) is identical to (2.3)
from chapter 2, it is repeated here for readability purposes only.

γ=

−b ±

√
b2 − 4ac
2a

where a = S V − ρL2 (Gb−ED − Gb−ES )
b = −S V(Gb−ED + Gb−ES )
c = S V × Gb−ED × Gb−ES

(3.7)
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In [228] it is indicated that (3.6) reduces volume calculation error by an order of magnitude
relative to the error of Baan’s equation (3.1).

VolD = πa20 L −

S V (Y − Ya0 )(YED − Yinf )2 (YES − Yinf )2 (Y + Ya0 − 2Yinf )
(Y − Yinf )2 (Ya0 − Yinf )2 (YED − YES )(2Yinf − YED − YES )

(3.8)

As a further extension to (3.4) Dubois et al. recently developed a non–linear admittance–to–
volume (3.8) that is computationally simpler than Wei’s equation (3.6) (3.7) [80]. The equation
is derived for the case of finite cylindrical volume and takes into account the small complex
component of blood’s admittance by including both blood conductivity (σb ) and blood permittivity (εb ). The equation uses the raw measured admittance Y and eliminates the parallel
contribution of the inherent myocardium (σm + iωεm ). The asymptotic admittance, Yinf , is calculated purely analytically based on catheter geometry L, d and the catheter radius a0 , Fig. 3.1.
Admittances YED and YES are measured at diastole and systole respectively, while admittance
Ya0 is calculated at the boundary condition where the radius of the cylinder is equal to the radius
of the catheter. The equation is derived from the analytical derivation (3.4), while the authors
imply it is self–calibrating for any effects of either the electrodes or catheter system overall.
The mean error of VolD compared to ultrasound measurements was reported to be within the
industry acceptable range of 15% [80]. In–vivo studies have also been completed, [33, 236]
that compare measured volumes calculated using Wei’s equation along with the admittance
technique to MRI and 3D echo cardiography. Additional details on these studies is provided in
Section 6.2.4.

3.1.3

Calibration Techniques

All three equations (3.1) (3.6) and (3.8) require some form of empirical correction factor to
compensate for the irregularity of the non-uniform myocardium, which must be determined
in–vivo by using an independent stroke volume measurement, for instance a flow meter. The
main purpose of in–vivo calibration is to estimate the parallel contribution of the myocardium,
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Gm [237], while in–vitro calibration is required to correct the magnitude and phase angle of the
measured admittance [229]. Magnitude calibration focuses the electrical instrumentation that
the catheter is connected to, for example, known resistor and capacitor (RC) loads are used to
calibrate the conversion from voltage to conductance. Phase calibration is performed by obtaining admittance measurements in Plexiglas cuvettes filled with saline of known conductivities
that span the range of typical conductivity values for murine blood and myocardium [229].
The purpose of this calibration is to determine the phase shift attributed to the catheter itself
(since saline has a negligible complex component in its admittance) so that the parasitic error is
subtracted from the measured results. The specific calibration techniques used for the designed
PV telemetry system in this thesis are found in Chapter 5 Section 5.3.

3.2

Numerical Comparison of Equations

Using COMSOL Finite Element Method (FEM) simulation setup [238] as the reference, the
accuracy of the three conductance–to–volume conversion equations were evaluated.

3.2.1

FEM Numerical Conductance Model Setup

To numerically evaluate the analytical conductance–to–volume model equation (3.4), the geometry of the catheter in the FEM simulation is modified to match that of the one used in the
derivations in [228]. The catheter used in the derivation of (3.4) neglects the effects of the
catheter body, and assumes that the input electrodes are perfect spheres of radius a0 while the
voltage electrodes are assumed point size in order to eliminate the averaging of voltage values
of the entire electrode. This is the ideal case, in a realistic catheter the electrodes are platinum
cylindrical rings rather than spheres and the measurement electrodes measure the average voltage induced from the electric field produced via an instrumentation amplifier circuit.
The geometry of the catheter model created follows that of Fig. 3.1 and the nominal 1.2F
catheter dimensions outlined in Table 3.1. The catheter is centred in a cylindrical cuvette and
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modelled as a cylinder of radius a0 and total length 8 mm. The top of the source electrode (top)
is located 2 mm below the surface of the cuvette with the remaining dimensions of the 1.2F
(Table 3.1) measured centre to centre. Distortions of the electric field due to proximity effects
from the surface of the cuvette should not be present since the catheter is inserted deeper than
0.5 mm into the cuvette [238]. The cuvette radius is parameterized along with its 20 mm length
to vary the volume of the cuvette cylinder between 8 µL and 60 µL which corresponds to the
typical range of murine LV volumes. For example, the shape and distribution of the resulting
electric field for a single volume is shown in Fig. 3.2. This simulated geometry is referred to
as the standard geometry.
The cuvette material is set to have a conductivity of 1.26 S/m and a relative permittivity of
86 to replicate the electric properties of 0.1 mol Potassium Chloride (KCL) solution in 1 litre
of water [228]. The KCL solution is used as a non–perfect conductive solution to measure
conductances corresponding to known volumes. The material of all four electrodes is set to a
conductivity of 9, 661, 000 S/m (Platinum). The boundary AC current source at the cylindrical
surface of the source electrode is set to a current density of 9.5 A/m2 , equivalent to a peak current
of 30 µA at 10 kHz (the equivalent electrical diagram is in Fig 2.18). It should be noted that
in a realistic catheter, electrode edge effects result in higher current densities at the top and
bottom of the electrode edges.
In order to represent the realistic case of current flow between the sensor itself and the
instrumentation amplifier, the sensing electrodes are modelled as high impedance. In the ideal
derivation of (3.4) no current flows into the sensing electrodes.

3.2.2

Analytical Conductance–to–Volume Model Accuracy

Three additional simulations are preformed to investigate the effects of the physical simplification of the analytical model (3.4) specifically with the sensing electrodes [228]; a) cylindrical
sensing electrodes are changed to spherical electrodes to match the physical model used in
the derivation of (3.4), b) spherical sensing electrodes are set to 10µS/m to approximate a non–
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Figure 3.2: COMSOL FEM simulation of a standard geometry catheter in the standard environment.
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conductive material, and c) spherical electrodes are replaced by point probes to determine the
effect of the shape and size of the electrode itself.
For each simulation, the measured voltage sensed from the inner electrodes is used to calculate the conductance values and the corresponding volume is calculated by (3.4). It can be
shown that intermediate result for equation (3.4) includes an analytical expression for blood
conductance Gb , which is found to be (3.9).

Gb =

π d (d2 − L2 )
× (σ + j ωε)×
 4L



1
1

− s
×  s
!2
!2

d
d

2
2
R +
 a0 +
2
2










(3.9)

This value of Gb is used to calculate an ideal conductance value from the known cuvette
geometry, denoted as analytically calculated reference data. Four simulations are preformed
with volumes ranging from 13.56 µl to 435 µl along with the analytically calculated reference
conductances: a) analytically calculated reference Gb from known volumes (3.9), b) original
cylindrical environment described in Section 3.2.1, c) spherical electrodes low conductance,
d) spherical electrodes modelled as in derivation of (3.4), and e) point probes, Fig 3.3, that are
based on known cuvette volumes yielding five conductance–to–volume relationships. The full
list of measured conductance values used to generate Fig. 3.3 and shown in Table 3.2.
It becomes clear that the analytical equation greatly underestimates conductance values by
an average of 135% when spherical electrodes are used to calculate conductance (i.e., comparing spherical electrodes, Fig. 3.3b, to analytically calculated conductance values Fig. 3.3a.
This is the moel used in (3.4) and Furthermore, the analytically derived conductance values
from (3.9) are not linearly correlated with either the cylindrical electrode simulated data or any
set of the spherical electrode simulated data. It is shown, Fig. 3.3, that when using the standard
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Figure 3.3: Conductance–volume data sets: a) Analytically calculated Gb from known volumes (3.9), b) Simulated cylindrical electrodes, c) Spherical low conductance electrodes, d)
Simulated spherical electrodes, e) Spherical low conductance point probes; are compared to
analytical data for (3.9).

Table 3.2: Data sets used to generate Fig. 3.3 Conductance–volume data sets: a) Analytically
calculated Gb from known volumes (3.9), b) Simulated cylindrical electrodes, c) Spherical low
conductance electrodes, d) Simulated spherical electrodes, e) Spherical low conductance point
probes; are compared to analytical data for (3.9).
Known Volume

Analytically

Cylinder

Spherical

Spherical

Spherical

[µL]

Calculated Gb [µS]

Electrodes [µS]

Low Conductance [µS]

Electrodes [µS]

Point Probes [µS]

13.56

243.30

775.20

686.00

768.53

733.86

20.64

360.03

1151.74

963.05

1092.76

1096.02

31.27

518.00

1637.02

1286.59

1485.87

1596.21

41.90

658.73

2052.26

1536.25

1799.02

1355.27

56.08

824.50

2508.52

1784.84

2120.23

1547.56

78.52

1046.99

3051.81

2055.13

2481.04

1748.81

142.30

1505.87

3921.44

2437.91

3014.33

2022.66

221.43

1876.91

4395.52

2627.12

3286.83

2152.78

319.46

2184.25

4659.81

2731.91

3440.42

2222.64

435.21

2433.46

4812.09

2783.55

3514.32

2258.44
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geometry (i.e., cylindrical electrodes that are a better representation of a realistic catheter) the
average error is 177%, Fig. 3.3. The measured conductance values from the spherical data are
offset from the analytically calculated data by a significant amount over the original cylinder
electrode model however, this offset is more prominent for larger volumes. The offset decreases
in magnitude when the inner sensing electrodes are simulated as non–conductive spheres and
decreases further when the inner voltage probes are set to points inside the COMSOL environment. The simulation with spherical low conductance electrodes and point voltage probes
produces the closest conductance values compared to the analytical data, which is expected
because the analytical model assumed infinite volume, i.e. non–distorted field lines.
Overall this result indicates that the simplifying assumptions (e.g., spherical vs. cylindrical electrodes) made in the analytical derivation have significant effects on equations (3.4) and
(3.9) accuracy. There are several theoretical reasons to possibly explain this behaviour: the
electric potential is unevenly distributed on the surface of the electrodes, there is an interaction within the top pair of electrodes and within the bottom pair of electrodes, and finally the
constraining volume of the cuvette has an effect on the generated electric field. These effects
are unaccounted for in the analytical derivation. Therefore, the analytical solution (3.4) is too
simplistic to accurately model a conductance–to–volume catheter.

3.2.3

Comparison of Conductance–to–Volume Equations

In the standard simulated geometry and simulation environment (cylindrical electrodes, 1.2F
standard dimensions) each of the three equations is used to calculate volumes based on the
measured conductance values. To simulate the asymptotic conductance, Ginf , the cuvette volume is set to 30 mL, which resulted in the conductance value within 6% of the Ginf in [228].
Since there is no muscle component in the simulation the Ya0 in Dubois’ equation is set to
zero, and it uses conductance values since the complex component is negligible. The resulting
simulated conductance vs calculated volume for each equation is plotted in Fig. 3.4 along with
the reference data set (simulated data).
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Figure 3.4: Comparison of calculated volumes from simulated data.

The volume range extends beyond the typical murine LV volume range to test the accuracy
of the equations in the non-linear section of the conductance–volume relationship. Although
these data is obtained from a simulated mouse catheter that would not measure this volume
range in practice it is reasonable to use this data in comparing the conductance–volume equations since measurements from larger catheters (large animal) exhibit the same nonlinear relationship [228]. In this way each respective equation is tested more rigorously and the conclusions can be extended to the use of larger animal catheters as well. Baan’s linear equation (3.1)
consistently overestimates volumes over the entire conductance range, on average 295%, Table
3.3. This is in accordance with Wei’s results [228] and is explained by the fact that Baan’s
linear equation (3.1) cannot model the non-linear relationship at higher volumes.
Dubois’ equation (3.8) consistently underestimates volumes, on average 80%, throughout
the conductance range. When (3.8) is used to calculate volumes with conductance values generated from (3.9), Fig. 3.3 dataset (a), the calculated volumes match the reference volumes
well, average error less than 1%. This suggests that Dubois’ equation (3.8) is a rearranged version of the analytical equation (3.4) derived from Maxwell’s equations [228], which by itself
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Table 3.3: Comparison between known cuvette volumes (simulated) and volumes calculated
using (3.1), (3.4), and (3.8). Graphical representation Fig. 3.4.
Known Volumes [µl]

Baan (3.1) [µl]

Wei (3.6) [µl]

Dubois (3.8) [µl]

12.99

80.97

14.36

0.33

20.08

120.30

23.05

0.56

30.71

170.99

36.53

0.98

41.34

214.36

50.81

1.52

55.51

262.02

70.58

2.45

77.95

318.76

102.55

4.48

141.73

409.60

191.19

16.02

220.87

459.11

284.18

50.31

318.9

486.72

368.18

147.98

434.65

502.62

436.02

421.98

Avg error [%]

294

21

80

we showed to be oversimplified and inaccurate to model the conductance–to–volume relationship for realistic catheters, Section 3.2.2. Consequently, Dubois’ equation is also determined
to be inaccurate in modelling the conductance–to–volume relationship for cylindrical cuvette
volumes. Volumes calculated using Wei’s equation (3.6) are overestimated and have an average error of 21% relative to the reference volumes yet they are the most accurate compared
to those obtained using the other equations. The error is greatest for mid–range conductance
values since Wei’s equation also uses SV to force the calculated volumes to match the ESV and
EDV. Plotting volumes calculated using Wei’s equation versus the reference volumes displays a
strong linear correlation with an R2 value of 0.98 and a slope of 0.98, Fig. 3.5. This correlation
is the most linear and has a slope with a value closest to unity when compared to similar plots of
volumes calculated using either Dubois’ or Baan’s equation versus reference volume, Fig. 3.5.
This suggests that Wei’s equation (3.6) is the most accurate conductance–volume equation and
should be preferred over Baan’s or Dubois’. Furthermore, the linear correlation suggests that
the error in Wei’s equation can be calibrated for by subtracting a calibration constant from all
the calculated volumes.
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Figure 3.5: Comparison conductance to volume equations vs known cylindrical volumes. Ideal
relationship should be linear.

3.3

In Vitro Catheter Experiments

In–vitro catheter measurement experiments were conducted with available industry catheters
to further analyze the accuracy of Wei’s conductance-to-volume equation (3.6). In addition,
the sensitivity of the electrode geometry was investigated to determine its impact on volume
measurements.

3.3.1

In–Vitro Conductance Catheter Experimental Setup

For the in–vitro measurement setup a radially organized cuvette tray with an integrated guide
was designed, Fig. 3.6, which enabled the to elimination of variations in the catheter’s position
within the cuvette and, therefore, reduce effect on measured conductance [238]. The set of
cuvettes span a volume range of approximately 15 µL to 600 µL and can be used with either
mouse or rat catheters. The entire apparatus is constructed out of Plexiglas and the cuvette
dimensions are measured to within less then 12.7 µm and the volume is calculated to within
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Figure 3.6: Radially organized cuvette tray with an integrated guide for various cylindrical
volume etalons.
0.21 µL in the murine LV volume range and to within 0.6 µL in the rat LV volume range.
Eight custom Transonic Scisense Inc. 1.2F catheters are used in this experiment, five
catheters are manufactured without a pressure sensor (volume only), serial numbers: 190,
315, 507, 587, 590 and three with a pressure sensor, serial numbers 12-870, 12-1146, 121147. A microscope with digital image capture capabilities is used to measure the complete
catheter geometry (a, b, d, L, a0 ), Fig. 3.7, full dimensions are summarized in Table 3.1, while
the peak output current of the catheters is measured as 24.04 µA at a frequency of 20 kHz.
The conductivity of the KCL solution is 0.77 S/m. All catheters are limited to the same depth of
approximately 4 mm when inserted into the guide to ensure minimal field distortion.
The conductance measurements are recorded using an oscilloscope that interfaces with a
Transonic Scisense Advantage ADV500 system [3]. The Advantage system interfaces with the
catheter and outputs the raw admittance signal encoded as two output channels; one for mag-
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Figure 3.7: Catheter 190 under microscope measuring source electrode rings.
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Figure 3.8: Experimental and comparison methodology flow.
nitude and one for phase. The phase is negligible as is expected due to the fact that Plexiglas
has a very low permittivity and the KCL solution should produce no phase shift.
The measurement methodology outlined in Fig. 3.8 is followed for each catheter, where
conductance values are measured from each cuvette shown in Fig. 3.6. Each cuvette volume
is measured four times with the average conductance value used in the calculation of (3.6).
In addition to the in–vitro measured data, COMSOL simulations are also completed with the
respective electrode dimensions, KCL solution conductivity, peak output and frequency current
of the source electrode. Together, these are referred to as the measured geometry and measured
environment.

3.3.2

In–Vitro Conductance Catheter Experimental Results

In–vitro conductance measurements from each catheter are compared to the known volumes
and summarized in Fig. 3.9. In addition, the simulated conductance for each catheter model
is plotted against the measured conductance for the corresponding catheter, Fig. 3.10. All five
catheters (volume only) display a strong linear correlation with an R2 = 0.999, slope of 0.8
and y intercept of approximately 40 µS. The comparison of the conductance values directly
removes possible sources of error such as those in Wei’s conversion equation.
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Figure 3.9: Measured conductance vs known cuvette volumes for each catheter. Each data set
also includes curve fit.
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Figure 3.10: Measured vs. simulated conductance for five catheters (volume only) used in the
experiment.
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Figure 3.11: Measured Conductance for each different conductivity used vs measured conductance using nominal conductivity value of 0.77. Conductivity values swept: 0.74, 0.785, 0.8,
0.83, and nominal 0.77.
The data correlation strongly suggests that the error between simulated conductance and
measured conductance is linear and constant between catheters. This means that it can be
corrected for with a constant scale and shift factor applied to the simulated data. A possible source of error between the measured conductance and simulated conductance that cannot
be accounted for is variance in the conductivity of the saline solution due to evaporation or
residue. To evaluate the possible influence of conductivity on the measurements, a simulation
is performed with one of the catheter geometries with a sweep of plausible solution conductivity values. The simulations show an average spread of 11.7% between maximum and minimum
conductance values across the volume range, Fig. 3.11. The actual effect of varying conductivity on in–vitro measurements is likely greater in magnitude however it can easily be corrected
for once the conductivity of the solution is known. This source of error exists between measured data and simulated data. It does not affect the catheter measurement results because
utmost care is taken to ensure the KCL solution does not change conductivity between catheter
measurements.
There is however a variation between in–vitro and simulated conductance measurements
from each catheter. The magnitude of the variation is much smaller in the simulated results
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Table 3.4: Average Error of Wei’s equation vs known volumes for each catheter when using
(3.6)
Catheter

Avg Error [%]

#190

20

#315

28

#507

20

#587

27

#590

30

#870

26

#1116

30

#1147

29

Average across 8 Catheters

26.25

due to there being fewer variables and sources of error. The only difference between the simulations is the measured geometry simulation contains exact measurements, this suggests that
the difference is related to catheter geometry. The average error in volume calculated from the
measured conductance using Wei’s equation for each catheter when compared to the known
volume is summarized in Table 3.4.
Overall, there is on average a 26.25% error in volume measurements using 8 commercial
catheters with nominal 1.2F catheter dimensions in (3.6). The most accurate conductance–to–
volume equation (3.6) is used to calculate volumes and the catheters have all undergone the
current state of the art in–vitro calibration. The magnitude of this error is much larger than the
currently accepted industry standard of 15%. Thus, the source of the error must be explored.

3.4

Catheter Geometric Sensitivity Analysis

The average standard deviations (σ) in dimensions (a, b) is 22µm and in dimension L is 38 µm,
as measured on the sample of eight catheters (5 volume only, 3 pressure–volume) provided by
Transonic Scisense. The largest difference between different catheters in the same dimension
is 98 µm in L, 53 µm in a, 63 µm in b. Thus, the effects of variation in catheter geometry
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Figure 3.12: COMSOL FEM simulation of a standard geometry catheter in an elliptical cuvette.
(a, b, L) on measured conductance must also be evaluated.

3.4.1

Catheter Sensitivity Geometric Setup

In order to simulate the sensitivity in conductance measurements the standard geometry model
and both standard and a larger elliptical environment are used, Fig. 3.12, while the catheter
geometry is parameterized with dimensions that range ±2σ from the volume only catheter
dimensions (190, 315, 507, 587, 590). Each dimension, (a, b, L) is parameterized individually
and the simulation is run for each configuration. All three parameters are then parameterized
in the model and each is swept between three values: the ideal dimension value, the ideal
dimension value plus 2 σ, and the ideal dimension value minus 2 σ to create the additional
27 data sets for various volumes (a=b=0.45 mm, 0.5 mm, 0.55 mm, L = 4.45 mm, 4.5 mm,
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4.55 mm) The effective volume of the cuvette is calculated based on the distance L between
the inner electrodes, the radius of the cuvette R, and the volume occupied by the catheter body
itself.

3.4.2

Sensitivity Simulation Results

The simulated conductance values vary for each change in catheter geometry, for both the simulations using cylindrical cuvettes and the simulations using elliptical cuvettes. The variation
in calculated volume error using Wei’s equation is investigated to determine the possible correlation between catheter geometry and simulated conductance. The simulated conductance
measurements from each geometric catheter configuration are converted to volume measurements using Wei’s equation (3.6) with ideal geometric parameters. The setup accurately represents the actual application of PV catheters in combination with (3.6) when using the ideal
manufacturer dimensions, as only ideal measurements are used in practice. By studying the
nature of the variation in volume error produced by Wei’s equation (3.6) between data sets, it
is possible to determine: a) the degree to which unaccounted variations in catheter geometry
effect volume measurements; and b) whether there is a correlation between specific catheter
geometry and the resulting volume error.
The plot of root mean square (RMS) volume error generated by sweeping individual catheter
dimensions “a” and “L”, Fig. 3.13 and 3.14, where root mean square is defined by (3.10).

RMS Error =

p
(measured value − known value)2

(3.10)

The error resulting from sweeping dimension “a” alone and dimension “b” alone are identical due to symmetry and as such only one graph is shown. Both plots show strong linear
relationships suggesting that the resulting volume error is significant and correlated to catheter
dimensions instead of being random.
The 3D plot of root mean square volume error in Fig. 3.15 is generated by extrapolating
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Figure 3.13: Root–mean square error versus catheter dimension a.
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Figure 3.15: Root-mean square error versus catheter dimension a versus catheter dimension b
versus catheter dimension L.
the 27 data points generated from the variation of the electrode geometry. The plot shows
a predictable and relatively linear relationship between catheter geometry and the resulting
volume error. Although the magnitude of the error is relatively small (average of 7%) for these
simulated data sets, based on the results in Section 3.3.2, it is likely that the magnitude of this
error would be larger in an in–vivo experiment.
The volumes that were generated from the a, b, L, values in Fig. 3.15 are also plotted against
the correct volumes of the cuvettes. The resulting plots all display a very strong linear correlation with an R2 value greater than 0.99 and a slope of 1. The only distinction between data sets
is the y intercept value that changes in magnitude for each geometric catheter configuration.
This value, also known as the calibration factor is always negative, so the absolute magnitude
is plotted for of the 27 catheter configurations in Fig. 3.16. A linear fit is generated that has an
R2 value greater than 0.9. This result suggests that there is a linear correlation between catheter
geometry and the resulting volume error in volumes calculated by Wei’s equation (3.6). Furthermore such a relationship suggests a constant calibration factor can be calculated for each
catheter based on solely on the dimensions between the inner electrodes and the dimension
between its outer electrode. Since the COMSOL simulations have been proven to correspond
in a linear fashion with data measured in–vitro this result suggests that such an equation can be
developed for actual catheters.
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Figure 3.17: Calibration factor versus catheter dimensions d and L, five volume catheters only.

The analysis described previously is applied to the volumes calculated from conductance
measured in–vitro. The resulting plot is shown in Fig. 3.17, although it does not display the
same linear fit as in Fig. 3.16, this likely due to the fact that 5 sample catheters (volume only)
are used. The equation of the plane in Fig. 3.17 is then used as a calibration factor for Wei’s
equation (3.6).
Vol(d, L) = VolW − (101 L − 56.3 d − 138.5)

(3.11)

This equation is then used to calibrate the volume measurements described in Section 3.3.2.
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Table 3.5: Fitting curve coefficients.
Catheter

x

y

z

#190

1071.932

-0.282

-1.802

#315

463.293

-0.117

-1.533

#507

446.261

-0.110

-1.546

#587

819.810

-0.193

-1.699

#590

4784.047

-1.209

-2.301

With the added correction terms, the volume error of Wei’s equation after calibration compared
to known volumes is reduced to 5% on average. This is 1/3 of the industry accepted level of
error and much lower than the original volume error of 26.25% Table 3.4.
Alternatively, the calibrated curves in equation (3.11) may be approximated by fitting curve
and the measured data, Fig. 3.9, in the form

Vol(Gmeas ) = Gmeas

p
[ z]x + y Gmeas

(3.12)

where, the three coefficients are found to be as in Table 3.5.

3.5

Conclusion

In this chapter, a comparison of currently used conductance–to–volume equations was presented, which reveals that Baan’s linear equation (3.1) is too simplistic and significantly overestimates volume and as such its use is not recommended. Dubois’ equation (3.8) is based on
the analytical equation (3.4) and is therefore very inaccurate. It consistently underestimates
volumes and its use is also not recommended. Wei’s equation (3.6) is the most accurate out of
the three and is therefore the only currently viable equation for conductance–to–volume calculations. However, both simulated data and in–vitro measurements suggest that the error in
Wei’s can be eliminated using a calibration constant.
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Overall, there is an average of 26.25% error in volume measurements when using Wei’s
equation (3.6), experimentally,demonstrated, which is much greater than the industry accepted
value of 15%. Measured data is used to develop a calibration equation (3.11) that can be used
to decrease measurement error to 5% when using Wei’s equation (3.6).
When referring to conductance–to–volume conversion in the rest of this thesis, Wei’s equation (3.6) is used. The remaining chapters will discuss the development and testing of the implantable pressure–volume telemetry system. It is important to understand the volume catheter
from basic measurement principles (conductance and admittance) to volume conversion to create a fully implantable telemetry system.

Chapter 4
Wireless PV Telemetry System∗
A wireless telemetry system is designed that is suited for measuring left ventricle blood pressure and volume data from laboratory animals. The system captures, processes and transmits
this data wirelessly to an end base station for further processing. The main design requirements
for this system are: it must be small in size and have low power consumption. These two criteria allow a system such as this, to be implanted for a long period of time while operating off
of a battery. The overall system is divided into two units: external and implant, Fig. 4.1.
The implantable internal unit is a small application specific system designed to capture
biosensor data using a custom sensor front–end, process and communicate the data back to
the end device for additional processing. The implantable unit contains four main sub–blocks:
power management, processing, RF transceiver, and an custom analog front-end. Each block
is discussed in detail in the following sections. The wireless PV telemetry system architecture
is comprised of the following four blocks that share a common data and DC power bus: power
regulating electronics (PWR), signal processing and control unit (µC), RF transceiver (Rx–Tx),
and PV sensor interface (AFE), Fig. 4.1. These modules communicate with each other through
a commutation bus. Each module has access to this bus, and is described in more detail in
Section 4.3. Physical implementation of the telemetry system is described in Section 4.6.
∗

Portions of this chapter are published in NEWCAS 2013 [239], BIOCAS 2013 [31], and published in
Springer Biomedical Devices Journal [240].
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Figure 4.1: Block diagram of the wireless telemetry system environment consisting of the
external side (PC, microcontroller, RF transceiver) and the implant (Power, RF transceiver,
microcontroller, and analog front end) as well as the pressure–volume sensor.
Additionally, the control architecture and current consumption of the implant are described in
Section 4.7.
The external unit consists of a wireless transceiver, microcontroller, and computer for processing. The computer can be replaced with an application specific system for further reduction
in size. Implementation details of the external unit are provided in Section 4.8.
The following sections describe the design process of the physical implant.

4.1

DC Power Module

This module’s purpose is to provide power distribution from the power supply to the rest of
the implant. The main components in the power module are: a battery, voltage regulators,
and a supervisor device, Fig. 4.2. The power module supplies four voltage rails to the system
through the main bus structure: 1) Microcontroller System Voltage (System Voltage - 3.6 V),
2) RF Transceiver Voltage (VCC HF - 3.6 V), 3) Interface Voltage (Interface Voltage - 3.6
V), and 4) Virtual Ground (Vtrl Gnd - 1.8 V). The system voltage is also referred to as VCC
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Figure 4.2: Full schematic of the Power Module.
EXT throughout the text, as well the interface voltage is referred to as VCC Int in the text. All
modules have access directly to the power module through the communication bus, with each
module’s ground plane connected directly to the batteries ground.

4.1.1

Voltage Regulators

A voltage regulator is used to regulate the input voltage from the battery to some select DC
voltage. The regulator should have a low consumption current (Iq), very low dropout (LDO),
and have a high power supply rejection ratio (PSRR) to ensure that any transients on the power
supply line are not transfered to the systems power supply.

Microcontroller and Transceiver Power Supply
The power module contains three voltage regulators: 1) to provide power to the microcontroller
and transceiver modules, 3.6 V 2) to provide power to the interface module, 3.6 V, and 3) to
provide a virtual ground for the interface module, 1.8 V. The TI TLV70036 is chosen for
regulators 1 and 2. This regulator has a fixed 3.6 V output rather than an adjustable output,
with a typical Iq of 31 µA, 175 mV dropout for a 2.35 V output and a PSRR of 68 dB. In

Chapter 4. Wireless PV Telemetry System

81

addition, the LDO can supply 200 mA to the system. As a result of having a fixed voltage
output, no external resistors are needed to create the regulated output voltage. Although both
the microcontroller and RF transceiver operate at 3.6 V, their respective power supply rails
(VCC EXT, VCC HF) are separated by a passive network. This network used a single inductor
to reduce high frequency noise that may interfere with the transceiver operations.

Interface Power Supply
The Interface modules operates on the same DC 3.6 V power supply as the rest of the system,
however, as sensor may not be active at all times, this module should be powered down when
not in use to reduce the overall power consumption. Furthermore, the microcontroller must be
powered at all times to provide proper timing and cannot be actively switched on and off. This
prevents the use of a single regulator to power the microcontroller, RF transceiver and interface
components. Therefore, a second regulator (3.6 V - TLV70036) is used to provide this voltage
rail (Interface Voltage). The enable on the regulator is used to control the power switching. The
control line used is P12 (GPIO) from the microcontroller. If P12 is low then the output voltage
to the interface modules is off and when P12 is high the output voltage to the interface modules
is on. By using this logic, the interface module’s power supply can be controlled by sending
digital I/O signals from the microcontroller down the bus to the power module to control the
operation of the switch.

Virtual Ground
The need for a voltage reference in the designed wireless telemetry system is to provide a virtual ground to the analog circuitry on the interface modules. A virtual ground is needed to allow
for full voltage swing to occur in the analog signal chain while using single ended devices. If
full voltage swing is needed in any module, a virtual ground of VCC EXT/2 = 3.6/2 =1.8 V
is required. Initially, a series voltage reference was chosen, however, after experimentation it
was determined that additional current sourcing was required for the actual circuit. Therefore,
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a low–power LDO, Analog Devices ADP160, is used instead.
The ADP160 has an output voltage of 1.8 V with a min voltage of 1.7964 V to a maximum
output of 1.8036V and can supply a maximum of 150 mA of current. This LDO is also chosen
for its low supply current of 860 nA with a wide input range. In addition, the ADP160’s enable
is controlled via the same signal (P12) as the interface voltage regulator, thus both regulators
are switched on and off at the same time.

4.1.2

Supervisor Device

A supervisor integrated circuit (IC) is used in the power module to provide circuit initialization
and voltage protection to the microcontroller and battery. The supervisor circuit is connected to
the microcontroller’s reset pin where an internal delay is started to prevent the microcontroller
from powering until the line voltage is stable and above a specific voltage. If the line voltage
or in our system, the output of the battery, drops below the specific voltage the supervisor
chip will cause the microcontroller to reset and prevent damage to the microcontroller. The
supervisor chip used is the TI TPS3838 with a typical power consumption of 220 nA and a
supervisor (threshold) voltage of 2.93 V.

4.1.3

Battery

A battery for an implantable system should be small in size but have a large capacity. It also
should be rechargeable in order to extend the lifetime of the system. Lithium-ion polymer
batteries are chosen for the batteries for this system because of their high capacity and small
size characteristics, as well as being rechargeable.
The Full River 501213 Li–Poly battery is chosen for this project and has a 40 mAh capacity
with a nominal voltage of 3.7 V and a charge condition of 1C. The overall dimensions are 15
mm x 11.0 mm x 5 mm, Fig. 4.3. The overall area is the most important design constraint for
the battery as this directly dictates the system size. The batteries are recharged with a Li–Poly
USB battery charger.
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Figure 4.3: a) Dimensions of the battery used in the implantable system; b) Physical battery.

Figure 4.4: Power Module Physical Implementation.

4.1.4

Power Module Implementation

The ICs and passives are located on the top side of the PCB, leaving the battery to be located on
the bottom, Fig. 4.4. The 40 mAh battery is designed to fit the desired board dimensions and is
soldered on to the bottom of the PCB using two wires and glue for stability purposes. The supervisor IC and the 3.6 V regulators are both no lead packages to reduce the physical footprint
and the 1.8 V regulator is contained in a SOT-23 package. The battery is charged externally
via a 5 V connection to the communication bus, accessed by the development module.
Additional test pads are added to the power module to provide testing and fail safes to the
system. Three test pads are added to test the main power supply voltage, ground and the 1.8 V
voltage reference. These pads are added to test the power module directly without the external
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development board. Two additional pads provide direct access to the battery for charging
purposes. These pads are added to provide charging access to the battery if the vertical bus
happens to fail. It should be noted that an external charging PCB should be used in all battery
charging cases to ensure safe charging. Additional information on battery charger is provided
in Section 4.5.2. If unregulated voltage is directly applied to these pads, the battery may be
damaged due to incorrect voltage and current charging characteristics.

4.2

Processing and RF Modules

Data capture and processing is completed by a low–power microcontroller, Texas Instruments
(TI) MSP430, located in the microcontroller module. The analog data from the PV sensor
interface is digitized by the internal 10–bit A/D converter and the digital PV datastream is sent
via the Serial Peripheral Interface (SPI) bus to the RF transceiver.
RF transmission from the implant to the external unit is completed by the low–power TI
CC2500 radio transceiver. The RF data is transmitted at 2.45 GHz using Frequency Shift
Keying (FSK) modulation, thus, allowing the system to work in the Industrial, Scientific and
Medical (ISM) band. Each module along with its sub–modules will be discussed in detail
below.

4.2.1

Microcontroller Module

The Microcontroller module is the main communications hub between the RF electronics, interface electronics and power electronics, Fig. 4.5. The main duties of this module are to
capture the incoming analog data from the interface module, digitize it and then process the
data for RF transfer. The transfer of digital data to the RF radio is transferred via the SPI bus,
discussed in more detail in Section 4.2.2. The analog data is transferred down to the microcontroller module through the communication bus and connected directly to the microcontroller’s
input pins. This data is then digitized by a 10–bit ADC, processed and sent to the CC2500
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Figure 4.5: Microcontroller Module schematic. Input and output communication through communication bus.
for RF transfer. The microcontroller module is programmed through a external programming
connector that is disconnected after each upload.
MSP430
Various microcontrollers exist that perform basic functions such as general digital input and
output (GPIO), analog input and communication protocols. These microcontrollers come from
a wide range of manufactures such as Atmel, Texas Instruments, PIC, etc. The microcontroller
chosen for this implant is the MSP430 from Texas Instruments. It is chosen for its wide availability, low cost, and low power consumption. The MSP430 comes in may different versions,
each with different features, the MSP430F2274 is chosen for this project. The MSP430F2274
contains a 12 channel 10-bit SAR ADC, SPI communication bus, a 16 MHz internal clock and
many more features within a 40 pin package [241]. All pins of the microcontroller are connected to the main communication bus, allowing each module to communicate directly with
the microcontroller.
MSP430 Timing
The MSP430F2274 contains a clock module which includes three main clock sources, LFXT1CK,
DCOCLK, VLOCLK. Each clock source can be used to drive any of the three main clock signals: ACLK, MCLK, SMCLK. The low–frequency oscillator is the clock source for external
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crystals and resonators, with a frequency range of 400kHz to 16MHz. The internal Digitally
Controlled Oscillator (DCO) is the main clock inside the MSP430, with a maximum frequency
of 16 MHz and is able to be divided internally to create sub frequencies. Finally the VLOCLK
is an internal low–power, low–frequency oscillator in the frequency range of 12kHz. Each of
these clock sources are used to route the clock signals to the MSP430’s internal architecture.
The main clock signal of the MSP430 is MCLK, which is used by the CPU and the supporting architecture. The remaining clock signals, ACLK (Auxiliary Clock), SMCLK (Sub–Main
Clock), are used to control individual peripheral modules.
In the designed telemetry system, the MSP430F2274 is clocked using the internal clock
rather than an external crystal. An external crystal is not used to reduce area and component
count of the system. The MCLK is sourced from the DCO using a internal frequency of 8 MHz
and ACLK, SMCLK are sourced by the VLOCLK. A lower clock frequency is used in the DCO
instead of the higher maximum frequency of 16 MHz to conserve power during active modes
of the MSP430. Additional information is provided in Section 4.7 on how each clock is utilized
within the control architecture.

Analog to Digital Conversion in the MSP430
The analog-to-digital (ADC) conversion module is an essential module for the operation of
the wireless telemetry system. The ADC is used to convert the analog sensor data to usable
digital data. The MSP430 contains a 10–bit successive approximation ADC with eight external
inputs. The voltage reference that is used for comparison can be an external or internal voltage
reference. Any clock in the MSP430 can be used to control the conversion timing.
The main formula used in the conversion of the analog signal to the 10–bit digital signal is
(4.1) [242], where Vin represents the analog input voltage, VR+ indicates the positive voltage
reference used, and VR− indicates the negative voltage reference used, in most cases 0 V.

NADC = 1023 ∗

Vin − VR−
VR+ − VR−

(4.1)
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Table 4.1: TI MSP430 Low Power Modes and Clock Status
Mode
Active
LPM 0
LPM 1
LPM 2
LPM 3
LPM 4

CPU and Clock Status
CPU is active, all enabled clocks are active
CPU, MCLK are disabled, SMCLK, ACLK are active
CPU, CLK are disabled, DCO and DC generator are disabled if the DCO
is not used for SMCLK. ACLK is active
CPU, MCLK, SMCLK, DCO are disabled DC generator remains enabled
ACLK is active
CPU, MCLK, SMCLK, DCO are disabled DC generator
disabled ACLK is active
CPU and all clocks disabled

In this system, three analog inputs are used, with each using VCC (3.6 V) as the positive
voltage reference rather than the external voltage references as less external components are
needed, allowing the reduction of the area of the overall system. The internal ADC oscillator
is used to clock the conversion of the analog to digital signal. The sampling frequency of the
ADC is determined by the control architecture described in detail in Section 4.7.

Power Management
One of the key features of the MSP430 is that its designed for low–power applications, which
makes it an ideal choice for the implantable system. The MSP430 has six different operating
modes designed specifically for low power operation, Active, LPM 0 – 4. These modes range
from 270 µA at 1 MHz, 2.2 V supply to 0.7 µA in LPM4.
The main difference between each mode is the number of clocks in the clocking module
that are active. When in the active mode, all clocks and the CPU are active, while at the other
extreme in LPM4, all clocks and the CPU are disabled. Low Power Mode (LPM) 0 to LPM 3
have various clocks on or off, Table 4.1. Ideally in an implantable system, the MSP430 would
remain in LPM4 for most of the time, only to be placed in one of the other low power modes
when processing is needed, this is done using an interrupt. By using these different operating
modes, the power consumption of the wireless system can be greatly reduced.
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Figure 4.6: Microcontroller Module Physical Implementation.

Firmware

The MSP430 is programmed using IAR Embedded Workbench for MSP430 IDE. MSP430 assembly and C are the main programming languages used in this implantable telemetry system.
For the preliminary tests of the MSP430, assembly language is used to test each register and
specific functions while C language is used for higher level programming.
The MPS430 is programmed using a 6 pin custom connector which contains the pins:
Power, Ground, TX, RX, SBWTCLK and SBWTDIO. The power and ground pins are connected to the USB power and ground to supply power to the microcontroller while programming. The TX and RX pins are the UART data lines used in communication between a computer and the microcontroller. Finally, the SBWTCLK and SBWTDIO pins and used by IAR
Embedded Workbench for programming and resetting the microcontroller. The main telemetry
system control firmware along with power consumption details are discussed in Section 4.7.

Microcontroller Module Implementation

The microcontroller is physically constructed by a single 40 pin no–lead package along with
headers and receptacles for insertion into the communication stack, Fig. 4.6.

Communication Bus
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Figure 4.7: Radio Module schematic with SPI communication through the bus. Matching
network and RF antenna are also included.

4.2.2

Radio Module

The radio module inside the telemetry system enables wireless communication to an end device
and contains four major components: RF transceiver, matching network, antenna, and a clock
source, Fig. 4.7.
This module directly interfaces with the Microcontroller Module through the communication bus, with no other modules interfacing with it. The radio module transmits its data
wirelessly via a RF antenna and FSK modulation. Different wireless protocols exist to transmit
data wireless such as bluetooth, WIFI, non-standard 2.4 GHz, other RF proprietary RF frequencies, etc. A non–standard TI 2.4 GHz protocol is chosen for its low–power features and
its high compatibility with other Texas Instruments components.
The RF transceiver must interface with an external antenna that will allow it to transmit to
a base station. Generally, this must be done through a matching network, matching the output
impedance of the transceiver to the 50 Ω antenna, discussed below.
Along with a matching network and antenna, the RF transceiver must also contain a clock
to correctly time the communication between the RF transceiver and the microcontroller, a 26
MHz quartz crystal is used to achieve this function.
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Figure 4.8: Frequency bandwidth of RF transceiver at a distance of 12 cm, Tx output power =
-12 dBm FCentre = 2.433592 GHz.

CC2500
The CC2500 is a low–power 2.4 GHz wireless transceiver and is designed for the Industrial,
Scientific and Medical (ISM) band along with the Short Range Device (SRD) band, 2400 MHz
– 2483.5 MHz. The CC2500 has a programmable output power up to +1 dBm, with a maximum
data rate of 500 kBaud. The CC2500 acts as a receiver as well, with a sensitivity of -104 dBm.
Typically, when the implant is in normal operation, the transceiver output power is set to -12
dbm within the frequency bandwidth of (2.4320–2.4356) GHz, Fig. 4.8.
The CC2500 is chosen for the RF module for its low current consumption (400nA in sleep)
and minimal external components required. The CC2500 is programmed by the MSP430 directly through the SPI bus discussed below. The CC2500 is clocked using an external 26MHz
crystal, with two 27 pF capacitors connected directly to the IC. Additional external components
are needed for decoupling capacitors, bias resistors and matching network circuitry.
The CC2500 interfaces with a 50 Ω antenna through a balun and matching network. The
RF input and output of the CC2500 is balanced with an impedance of Zout = 80 + j74 Ω. A
balance to unbalanced (balun) network is generally created from passive components to convert
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Figure 4.9: SPI digital communication link between MSP430 and CC2500.
the balanced signal, i.e., differential in/out to unbalanced, i.e., single ended 50 Ω antenna. This
intermediate impedance is then matched to the 50 Ω antenna for maximum power transfer. The
physical implementation of the balun and matching network are described in Section 4.2.2.

Communication Between Microcontroller and CC2500
The digital communication between the microcontroller (MSP430) and the transceiver (CC2500)
is achieved through the SPI bus. Six wired connections make up this bus, four for the main SPI
link and two for interrupts, Fig. 4.9. The four SPI wired connections, SPI SIMO, SPI SOMI,
SPI CLK, and SPI Chip Select send and receive data from the CC2500. SPI Chip select is used
to enable and disable the communications between the two devices. This pin is essential in the
design if additional connections are made to the SPI bus. In this specific case, only a single SPI
device is used. The timing for the SPI communication is preformed by the SPI CLK pin. This
timing is synchronized between both the master and salve devices using this pin automatically.
Finally, the two main data lines, SPI SIMO, SPI SOMI, represent the master to slave communication and the slave to master communication, respectively. In this case, the MSP430 acts
as the master and the CC2500 as the salve device. The CC2500 will send back status packets
along with any data that is received.
The other two connections, are used for interrupts to allow the CC2500 to trigger the microcontroller to wake up from low–power state when a packet is received. The CC2500 refers
to these two pins as GDO0 and GDO2. In the designed telemetry system they are connected to
GPIO pins 2 and 3 on the MSP430. By using these two interrupts, the MSP430 is able to go in
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low–power state while the CC2500 remains in receive mode.
The SPI bus is directly integrated in the main communication bus structure. By doing this,
any module can access the SPI bus to communicate digitally with the microcontroller module,
only an additional chip select pin is needed to determine which device to communicate with.

RF Parameters
The CC2500 includes 47 programmable registers that contain the parameters used in RF transmission. Examples of these registers include configuration for modulation type, frequency,
output power, packet size, etc. These registers are all programmed through the SPI bus from
the MSP430. Upon power up, these parameters are copied to the registers from the MSP430,
as the CC2500 does not store them after loss of power. The CC2500 is configured to use
Frequency-Shift-Keying (FSK) Modulation and an operating frequency of 2.45 GHz. These
parameters can be determined via a TI tool, SmartRF, or manually from the CC2500 datasheet.

RF Module Implementation
The RF module contains the RF transceiver, balun, crystal, antenna, and various required passive components, Fig. 4.10. The RF transceiver, CC2500, is a no–lead package that requires
six decoupling capacitors and a bias resistor. The 26 MHz crystal is packaged in a 2 mm x 1.6
mm (3.2 mm2 ). When miniaturizing the system, traditional passive component balun/matching
networks are too large to fit in the required small PCB footprint. Thus, a commercial ceramic
balun/matching network is used, Anaren BD2425N50ATI [243].
The Anaren BD2425N50ATI is a single 1.05 mm x 1.05 mm x 0.65 mm mutli–layer ceramic structure and 2 external passive components. The Anaren balun along with 2 external
components, 10 nH inductor and 5.6 pF capacitor, is designed specifically for the CC2500 RF
transceiver used in the RF module’s architecture. It is made to convert the balanced output
impedance of the CC2500 to an intermediate unbalanced impedance and then convert it to 50
Ω to be connected to a RF antenna.
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Figure 4.10: Radio Module: Left with external antenna, Right with PCB antenna.

Two versions of the RF module with different antenna configurations are created for testing:
a) with an external connector, Fig 4.10 left, and b) with an internal PCB antenna, Fig. 4.10 right.
First, the use of an miniture RF connector, TE Ultraminiature Coax Connector (UMCC) [244],
allows for the testing of different types of antennas as well as it keeps the internal size of the
implant small. The UMCC connector is 3 mm x 3 mm. The UMCC can interface with various
larger connectors such as SMA, BNC, etc using 50 Ω adapter cables. For this design, a 30
mm 2.4 GHz antenna is attached to the UMCC for use. A detailed phantom tissue test for this
antenna along with transmitted and recevied power details is outlined in Section 5.1.

The second version uses a traditional PCB antenna (2×11)mm that is soldered directly onto
the PCB board. The PCB antenna does not allow for the freedom of different antenna locations
or sizes. However, its benefit is that it is robust and minimizes possible failure points (UMCC
connector or external antenna itself). Additional details are provided in Section 5.1 along with
which version was used in the implant study.

The entire RF module is fits on a 15 mm x 15 mm PCB however, an extension is made to
allow the mated height (2 mm ) of the RF connector or the height of the PCB antenna to not
interfere with the internal clearance of the stack.
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Communications Bus

The telemetry system’s main form of digital and analog communication between each module
and the outside world is achieved through the use of a communications bus. When designing
the bus structure multiple signals are required and must be taken into consideration. These
include: power signals (System Voltage, Interface Voltage, HF voltage), ground signals, I/O,
programming pins, charging pins, etc. With the physical design in mind, the communication
bus is split across two vertical connectors. The designed implant contains a communication
bus with a total of 88 pins, Table 4.2. In this bus, the 88 connections can be broken into the
following groups: power signals, ground, SPI, programming, and general input and output.
The system voltage and HF voltage pins have two pin allocations each. The interface
voltage rail provides power to the interface module through a the 3.6 V and 1.8 V regulators
located on the Power Module, Section 4.1.1. A 5 V power rail is required for USB charging
directly to the battery. There are a total of 44 ground connections used in this architecture of the
Communications Bus. The additional grounds do not affect the overall function of the system
but do provide additional connections on each module, simplifying the layout. Furthermore,
programming and SPI pins are also located on the bus.
Twenty seven I/O pins are connected to the bus. Here, the pins are allocated into six specific
categories: general I/O, enable pins, analog inputs, Interface Module outputs, and Interface
Module separation. There are 16 digital general I/O ports and four analog inputs that are un–
allocated on the bus, for future use if needed. A single enable pin is used to control the Interface
Module’s power supply.
Three signals are used in the PCB seperation of the Interface Module, Gain Stage Out, Q
Gate, and I Gate. The details of these signals are described in Section 4.4. Pins P43, P44, and
P45 are used as the main outputs of this module where P43 represents the Q Out, P44 the I Out
and P45 represents the output voltage related to pressure output.
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Table 4.2: Communication Bus in the second prototype
Pin
System Voltage
HF Voltage
Interface Voltage
1.8 V Reference
Ground
UCB0STE
UCB0SIMO
UCB0SOMI
UCB0CLK
GDO0
GDO2
SBWTCLK
SBWTDIO/RST
TXD0
RXD0
P17, P40, P47, P36, P10, P11,
P13, P14, P15, P16, P41, P42
P46, P25, P20, P21
P22, P37, P23, P24
Gain Stage Out
Q Gate
I Gate
P43
P44
P45
P12

Function
3.6 Volt Rail for System Voltage – From Power Module
3.6 Volt Rail for RF Module – From Power Module
3.6 Volt Rail for Interface Module – From Power Module
1.8 Volt Reference for Interface Module – From Power Module
Ground – Connected Directly to the Battery
Chip Select for SPI Bus
Slave In, Master Out for SPI Bus
Slave Out, Master In for SPI Bus
SPI Clock
Interrupt for communication between CC2500 and MSP430
Interrupt for communication between CC2500 and MSP430
Programming CLLK MSP430
Reset signal to MSP430 / Programming pin
Transmit Pin for Programming MSP430
Receive Pin for Programming MSP430
General I/O – Extra Pin From MSP430
Analog A2, A7, A3, A4
Interface Board Split – Volume
Interface Board Split – Volume
Interface Board Split – Volume
Q Out – Volume
I Out – Volume
Pressure Out – Pressure
Interface Module Enable
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Vertical Connectors – Physical Construction:

Molex micro–connectors [245] are chosen to serve as the vertical connectors in this prototype.
These headers/receptacles are 1.54 mm x 10.26 mm (15.8 mm2 ) and have a mated height of
1.5 mm with a total of 44 pins at 0.4 mm pitch. The mated height of 1.5 mm is the minimum
height to allow for proper clearance for ICs located above and below the specific module.

4.4

PV Sensor Interface Module

The Pressure–Volume (PV) Interface Module provides the stimuli and reference signals to the
pressure and volume sensors located on the medical catheter. In return, it receives the raw PV
signals from the catheter that is directly connected to the telemetry system by seven wires (4
for volume, 3 for pressure) using the common ground path, Fig. 4.11. The signal processing
logic consists of pressure and volume sub–blocks, that is, each sensor’s data is processed individually. The following subsections will describe the catheters used in this design, as well as
both the pressure and volume circuits used.

4.4.1

Catheters

Catheters are an essential part of the wireless telemetry system as they provide the structure
to house the bio–medical sensors along with a direct connection to the telemetry system.
Catheters can contain various types of bio–sensors, in this research project, only two types
of sensors are used, pressure and volume. These sensors can be separated into three catheter
types: pressure only, volume only, and combined PV. This system can be used with any catheter
type as each measurement block is computed individually, however, in this specific design PV
catheters are used.
An example of a pressure–volume catheter used in this system is shown in Fig. 4.12. This
diagram represents a 5 French catheter used for large animal research, with a diameter of 1.7
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Figure 4.11: Simplified block diagram of PV interface module, and the equivalent electrical
diagram of MEMS pressure and conductance based volume sensors themselves; (in reality,
ground line is shared).
mm. It contains four electrode rings and a pressure sensor separated at specific distances. The
top and bottom sets electrodes are separated by a distance of 30 mm with each set separated
by 3 mm. Similarly, a 1.2 French catheter is used for small animal research with a diameter
of 0.4 mm, top and bottom ring seperation of 4.5 mm, and each set separated by 0.5 mm.
The tetra–polar catheter is inserted directly into the test subject’s left ventricle to measure
blood pressure and volume. The two outer electrodes inject current into the blood and the
two inner electrodes measure the voltage created by the electric field inside the left ventricle.
Conductance/admittance is calculated from the known current and measured voltage. The
blood pressure is directly determined from the included pressure sensor.

4.4.2

Pressure Measurement

The pressure measurement sub–block is used to convert the pressure created by the blood on
the catheter (mmHG) to a voltage. This voltage is obtained by the use of a catheter containing
a small MEMS based pressure sensor, Section 4.4.1 and is connected directly to the pressure
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Figure 4.12: Pressure Volume catheter a) inserted into the LV of a heart; b) physical implementation of the 5F catheter; and c) dimensions of the 5F catheter.

Chapter 4. Wireless PV Telemetry System

99

SR1

MEMS
Pressure
Sensor

Excitation
Source

Instrumentation
Amplifier

Pressure Out

SR2

Rbal1

Rbal2

Figure 4.13: Traditional pressure measurement block.
block electronics for processing using three wires, SR1, SR2 and COM. These wires are used
to excite the pressure sensor and provide voltage measurement, Fig 4.13. The specific pressure
sensor used in this telemetry system is the GE P161 Pressure sensor [246]. This is a MEMS
based sensor and contains two pressure sensitive resistors with a nominal resistance of 800 Ω.
Two measurement techniques are used in this design: traditional wheatstone bridge, and digital
IC with the digital IC version utilized in the in–vivo study.

Traditional Wheatstone Bridge
The wheatstone bridge is an combination of four branches of resistors used to measure an
unknown resistance, by balancing two branches of the bridge circuit, with one branch including
the unknown resistance, Fig. 4.11, top right. Nodes N1 and N2 represent the measurement
points, the excitation signal is shown within the pressure processing block . The top two
resistors, P1 , P2 , in the bridge represent the pressure sensor and the bottom two R1 , R2 , are
external matching resistors. If the measured voltage between nodes N1 and N2 is zero then the
bridge is balanced, in other words there is no pressure exerted.
When pressure is exerted on the sensor, the resistance of P1 and P2 will increase or decrease
based on the difference in pressure from the calibrated pressure. The calibrated pressure is
when the bridge is balanced i.e., no measured output voltage. The sensor resistor P1 will
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increase when P2 decreases and vice versa, this causes the bridge voltage to be linearly based
on the pressure exerted. The voltage difference is measured using a high gain instrumentation
amplifier, typically 50 – 60 dB or higher and is directly proportional to the pressure exerted.
Drive Source: In most wheatstone bridge configurations the bridge is driven by a voltage
source rather than a current source. In this system, a current source is used as it has various
advantages. The first is that current driven wheatstone bridges have the advantage of not introducing measurement errors when the excitation circuit is far away from the sensor. In this
telemetry system, the catheter is located away from the main electronics and could introduce
measurement error due to the increased wire length and wire resistance if voltage driven circuits are used. The second benefit is the pressures sensitivity is directly linear to the excitation
current, allowing the sensitivity to be controlled. Finally, the temperature at the sensor node
can be measured and compensated for when using the current driven method. If using the
voltage driven method an additional temperature sensor is required. A downside to using current driven bridges are the additional components and power consumption required to create a
stable current source.
The current source is constructed using an OP-Amp, a diode and two resistors, Fig. 4.14.
This current source is located next to the interface electronics and is directly connected to the
pressure sensor through the COM pin on the sensor. The constructed current source is designed
to provide ∼580 µA of current as required by the pressure sensor. The current source used is a
simple diode and sense resistor configuration. The voltage drop of the diode across the resistor
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R2 provides the correct current to the sensor.

Compensation: The external resistors of the wheatstone bridge (R1 , R2 ) must be completed
based on the specifications of the pressure sensor. As the pressure sensor contains two nominal
800 Ω resistors, the bridge completion resistors must be close to 800 Ω to balance the bridge
correctly. The bridge completion resistors are generally tuned or trimmed to get the resistance
needed to complete the bridge. Typically, exact 800 Ω resistors are not used as some adjustment
must be made to offset the effects of wire resistance, temperature, etc.

In most cases, sets of high precision resistors are connected in parallel to balance the bridge
more effectively rather than single resistors. If the overall volume allows, analog potentiometers (POTs) are used to provide additional resistance trimming capabilities. However, these are
larger in size and create additional noise. The benefits of using standard resistors or analog
POTs are that they provide very accurate results as well as generally costing less and no additional ICs are used. The additional space increase for potentiometers and mechanical noise is
a downfall of this method. As well, if only precision resistors are used no additional resistance
trimming can take place once the circuit is constructed.

An improved method to trim the bridge completion resistors is to tune them digitally. Instead of a mechanical potentiometer that is much larger and cannot be tuned from outside of
the implant, a digital potentiometer can be used. A digital potentiometer is a small IC, that
contains several resistance steps from 0 Ω to the maximum resistance and is controlled via SPI
or I 2C. These POTs are generally connected with additional high precision resistors in parallel
to get the exact bridge completion resistance. The digital POTs allow for constant resistive
trimming to the bridge during operation. Downsides to using digital POTs over their analog
counterparts are the additional area required for the IC packages (SOIC, MSOP, TSSOP, etc)
and the additional power consumption and programming required.
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Figure 4.15: ZDMI ZSC 31015 based Digital Pressure Measurement Method.

Digital Pressure IC
An alternative to the traditional wheatstone bridge method is to use a digital IC to perform
the excitation, sensing, and compensation to the bridge, Fig. 4.15. The ZMDI ZSC 31015
Digital pressure measurement IC, [28], is used in this design to perform this task. An internal
block diagram of the ZSC 31015 is provided in Fig. 4.16. The basic functionality of the bridge
remains the same, the bridge is excited, resistance changes based on pressure and a voltage
is measured. Only three external components are required for the IC to operate: two bridge
completion resistors and a single DC decoupling capacitor. When using this method, the bridge
is voltage driven by V DD rather than by a current source and will have the same drawbacks
of traditional voltage driven bridges however, the ZSC 31015 calibrates these inaccuracies out
during the calibration process. The instrumentation amplifier is located within the ZSC 31015
rather than as a separate component and its gain can be programmed. Furthermore, the ZSC
31015 provides onboard compensation including temperature (if external diode is used), gain
and offset, etc. The measured voltage can be output as a ratio from 0 - 1 V, 0 - V DD, or
digitally via the ZMDI custom one wire interface. In this system 0 to V DD is chosen as it
allows the remaining components of the system(wiring, ADC, firmware) to remain unchanged
if a traditional wheatstone bridge configuration is used. The COM pin from the catheter is
connected to the BS ink pin of the ZSC 31015 to provide additional power savings. The BS ink
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Figure 4.16: ZDMI ZSC 31015 Internal Block Diagram [28]. Copyright c ZMDI.
pin is connected to an internal switched transistor to interrupt the bridge current when not
sensing. The switch is synchronized to the internal ADC of the IC and is only opperational
during conversion. The power consumption savings is dependent on the sample rate of the
ADC and can reduced from 20% to 1%, typical current consumption is 250 µA. Additional
features include 24-bit identification, and the ability to be used in die form. These features are
not used in the current implementation of the system.
The ZSC 31015 is configured using a separate programming module provided by ZMDI.
Once connected, all features of the IC can be configured, including gain, sample rate, offsets,
calibration, etc. Section 5.3.1 provides details into the pressure configuration and calibration
process for the implantable telemetry system. The calibration data is stored in EEPROM and
recalled into memory upon on power-up.
By using this digital IC in the pressure measurement block all the disadvantages of traditional approach is avoided or can be calibrated out. Additional control is also gained in the
signal conditioning chain and if connected digitally, can be programmed in test for better programability. Although, this method has great advantages, the fact that additional hardware and
software are required to program and setup the device is a disadvantage and adds complexity
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to the design over simple mechanical POTs. However, the signal resolution and multi-point
calibration enable much higher quality signals to be measured and as a consequence provide
improved results over the traditional wheatstone setup.

4.4.3

Volume Measurements

The volumetric section of interface uses the admittance methodology to measure the blood
volume in the LV, that is, both magnitude and phase of the measured voltage are extracted. The
volumetric sensor itself (i.e. the four rings (a, b, c, d)) is excited by voltage reference ACvref
that is converted into current reference ACiref , Fig. 4.11. Phase sensitive detectors along with
a quadrature oscillator are used to extract DC In Phase and Quadrature voltages (I and Q) that
are proportional to the raw in phase and quadrature voltage signals at the PV sensor. The I and
Q signals are sampled by the microcontroller and transmitted to the external device. Further
processing is required to convert these signals into calibrated magnitude and phase values and
used to compute the volume signal and will be discussed in Sections 4.8.
In the following subsections the background theory on lock–in amplifiers will be introduced, followed by circuit implementation details of the volume interface, Section 4.4.3.

Lock–In Amplifier Background Theory
Traditional approaches in measuring the admittance signal in the LV rely on active bandpass
filters to reduce noise from the measurement signal, however, any noise not fully suppressed
impacts the magnitude measurement. An alternative technique to measure admittance is to
use phase sensitive detectors also known as Lock–In Amplifiers. Furthermore, this improved
technique allows for the direct extraction of the phase signal where as traditional approaches
require additional hardware and pulse width analysis to determine the phase.
Lock–in amplifiers are used to measure low voltage AC signals (µV to nV) within noisy
environments (e.g., animal body) and amplify them to produce a useable signal. These noise
signals can be many times larger than the signal of interest and a lock–in amplifier is still able
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Figure 4.17: Block diagram of a Lock–In Amplifier.
to extract such a signal [247]. Recall, standard AC voltage measurements measure all voltages
at the measurement input, including all noise signals as well as the signal of interest. This
can cause signals of interest to be lost or overwhelmed with noise. Lock–in amplifiers are
different from these AC voltage measurements because not only is a excitation signal provided
to the experiment but a reference signal is also provided [248]. This signal must be phase and
frequency locked with the original excitation signal for the amplifier to work correctly. The
lock–in amplifier uses the reference signal to locate the measured signal of interest within the
noisy environment, while disregarding all signals that are not of the same frequency as the
reference signal. This technique is known as phase sensitive detection [249]. This is the main
reason that a lock–in amplifier can measure very small experimental voltage amplitudes in an
environment that contains noise signals much greater. Lock–in amplifiers are used in many
different applications from gas monitors [250] to wireless embedded applications [251–253].
The basic lock–in amplifier structure, Fig. 4.17, contains seven main components: excitation source, experimental system, signal conditioning, reference generation, phase sensitive
detector (PSD), low pass filter (LPF), and DC amplifier [248].

Time Domain Analysis: The excitation signal Vext (t) = Vo cos(2π fo t) is fed into the test
system to initiate the measurement. The measured signal is first directed through the signal
conditioning block. Here, the measured waveform is amplified and filtered to remove unwanted
frequencies above and below the frequency of interest, fo . The output of the signal conditioning
block is (4.2), where Gac is the gain of the signal conditioning block, Vo is the amplitude of the
signal of interest, fo is the excitation frequency, and θ s is that possible phase shift of the signal.
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Figure 4.18: Ideal mixer implementation.

This represents one input to the PSD.

Vac (t) = Gac Vo cos(2π f0 + θ s )

(4.2)

The phase sensitive detector is a specific type of frequency mixer (multiplier). A frequency
mixer in the most basic sense multiplies two signals V1 (t) and V2 (t) to form a new signal. As
stated previously, one input is (4.2) and the reference voltage, Vre f (t), is the other. A mixer can
be implemented in many forms including transistors, diodes, or any non linear device. However, in a simple implementation, the mixing circuit can be described by Fig. 4.18 [251]. Here,
the measured signal, (4.2), is split into the in–phase 0◦ and the anti–phase 180◦ components,
where a switch controls the output. This switch is controlled by the reference signal, Vre f (t).
This configuration offers the widest dynamic range to maximize the signal recovery [249].
The reference signal is chosen to be a square wave with a gain of 1 to control the switch in
the PSD. In different mixer circuit configurations the reference signal can be a general sinusoid.
The reference signal is phase and frequency locked to the original excitation frequency Vext (t)
and is represented by (4.3).

Vre f (t) =

4
1
1
[cos(2π fo t + θR ) − cos 3(2π fo t + θR ) + cos 5(2π fo t + θR ) . . .]
π
3
5

(4.3)
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When two signals of frequencies f1 and f2 are multiplied together, two additional signals
are created with one equal to f1 + f2 and another equal to f1 − f2 , along with harmonics.
Therefore if (4.2) and (4.3) are multiplied (4.4) is created, where ωR = 2π fre f , ωS = 2π fmeas
and θR , θS represent the phase shifts of the respective signals.
√
2 2 VoGac
[cos(ωR t ± ωS + θR ± θS )
VPS D (t) =
π
1
− cos(3ωR t ± ωS + 3θR ± θS )
3
1
+ cos(5ωR t ± ωS + 5θR ± θS ) . . .]
5

(4.4)

If the assumption that the measured signal and reference signal are frequency locked ( i.e.,
ωR t = ωS t) is made and that the subsequent low pass filter cuts off well below the reference
frequency ( i.e., removes upper harmonics) then (4.4) reduces to (4.5).
√
2 2 VoGacGlp f
VPS D (t) =
cos(θR − θS )
π

(4.5)

Equation (4.5) is directly proportional to the amplitude of the signal of interest Vo along
with a phase difference of θR − θS . However, if the experiment does not introduce a phase
shift, then this component can be ignored. In addition, the LPF block acts as an integrator to
remove any additional noise created at the output of the mixing circuit. Further DC gain can be
obtained through a DC amplifier. All factors are known except for Vo , therefore, the measured
signal can be extracted from the noisy environment using the final DC output, (4.6).

VPS D

√
2 2 VoGacGlp f G DC
=
π

(4.6)

Magnitude and Phase Measurements: The previous lock–in amplifier design will detect
the magnitude of the measured signal only when θR − θS = 0◦ . If phase change occurs, the
above system cannot measure it. Four examples are provided that illustrate the difference in
the output waveform VPS D when: a) there is no phase shift present between the reference signal
Vre f and the input signal Vac , Fig. 4.19a; b) 180◦ out of phase, Fig. 4.19b; c) 90◦ out of phase,
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Fig. 4.19c; and d) 60◦ out of phase. The output of the low pass filters in each example is not
shown and is the mean of the VPS D signal. Furthermore, if the amplitude of the input signal
Vac changes, increase or decrease, while Vre f and Vac are in phase, the output of the LPF will
change accordingly. However, if the amplitude and a phase shift occur (θR − θS , 0◦ .) at
the same time it is impossible to distinguish the effect the original amplitude change vs phase
shift’s effect on VPS D at the output of the LPF. This is due to the mean of VPS D changing in
both cases. By viewing VPS D ’s shape it can easily be seen if a phase shift is occurring, just not
measurable at the output of the LPF. Thus, a different method is required to measure both the
magnitude change and the phase change at the same time.
To measure the phase shift created by the experimental process, two phase sensitive detectors are required [249] [247], Fig. 4.20. The second PSD requires a reference signal shifted
by 90◦ from the original excitation signal. This allows quadrature signals to be measured or In
Phase and Quadrature components (I and Q). The second PSD’s output is (4.7).

√
2 2 VoGacGlp f G DC
VPS D2 (t) =
sin(θR − θS )
π

(4.7)

By using equation (4.5) and (4.7) the magnitude and phase of the measured signal can be
calculated using simple trigonometry. The magnitude is calculated by (4.8) and the phase is
calculated by (4.9).

Magnitude =

p
(VPS D1 )2 + (VPS D2 )2

Phase = tan

−1

VPS D2
VPS D1

(4.8)

!
(4.9)

Using this technique the magnitude and phase of a specific signal can be measured inside a
noisy environment.
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Figure 4.19: Phase Sensitive detector examples where the output VPS D (black) is shown with
Vac (red) and Vre f (blue) at different phase shifts: a) in phase; b) 180◦ ; c) 90◦ ; and d) 60◦ . The
output of the low pass filter is not shown.

Chapter 4. Wireless PV Telemetry System
VExt

Experiment

Vmeas

Signal
Conditioning

110

Vac
PSD1

Low Pass
Filter

DC
Amplifier

VPSD1 = VoCosØ

Low Pass
Filter

DC
Amplifier

VPSD2 = VosinØ

VRef

Reference

Vac
PSD2

90o
Phase Shift

VRef

Figure 4.20: Dual Lock–In Amplifier block diagram.
Lock–In Amplifier Circuit Implementation
The circuit implementation of the volume interface is realized by the block diagram in Fig. 4.21
where nine stages are used to excite the catheter and extract the DC In Phase and Quadrature
voltages to calculate the complex admittance. The outputs of the volume interface (I,Q) are
connected via the communication bus to the microcontroller to be sampled. Each stage’s implementation is described below.

Quadrature Oscillator: A quadrature oscillator is designed, Fig. 4.22 to generate sine and
cosine signals at 19.866 kHz centred around the virtual ground of 1.8 V. As discussed in Section 2.3.2, exciting the heart with a frequency of ∼20 kHz causes the blood to become purely
resistive and the heart muscle to contain both resistance and capacitance properties, allowing
only the blood volume to be measured. This implementation uses six passive components
(three 820 pF capacitors and three 9.76 kΩ resistors) and two operational amplifiers. Other
oscillator configurations were researched such as phase shift and Wien Bridge oscillators [254]
however to achieve the required frequency, dual output (sin and cos) and full voltage swing
required more discrete components to create the equivalent circuit.
High slew rate amplifiers are needed to achieve the required frequency and switching speed
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Figure 4.22: Quadrature Oscillator (outputs sine and cosine signals) designed with a F0 =20
kHz.
of the oscillator. Texas Instruments LMV554 Op-Amps are chosen for this design as they
provide a high gain bandwidth product (GBP) of 3 MHz, a slew rate of 1 V/µs, high rejection
ratios (CMRR, PSRR), and still having low supply current of 37 µA. Additional Op-Amps
were tested providing either very low power sub–100 µA or high GBP (5 MHz) but not both.
The LMV554 is used as the Op-Amp in all remaining designs.

Reference Generation: The reference signals for the analog multiplier are created using two
comparators. The inputs to these comparators are the generated sin and cos waveforms and
the virtual ground. To reduce component count Op-Amps are used in open loop configuration
rather than separate dedicated comparators. The resulting output signals are frequency locked
square waveforms providing a phase reference for the excitation signal and are connected to
the analog switch.

Voltage to Current Converter: The in phase or cosine signal is used to directly excite the
heart through a voltage to current (V-to-I) converter. This V-to-I converter uses three resistors (20 kΩ, 12 kΩ, and 1 MΩ) and one operational amplifier to achieve 61 µA of alternating
current, Fig. 4.23. This current is calculated by (4.10). Additional DC offset compensation is
achieved through resistor R5 . The two input rings on the catheter (a,d) are connected to the
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Figure 4.23: Voltage to Current converter implemented.
output of the V-to-I converter through two 1 µF DC blocking capacitors and a 1 MΩ resistor separating the two nodes of the circuit. This excitation current generates an electric field
between the two outer rings (a,d) , Fig. 4.11, enabling a voltage to be measured.
Vrms
R
1.22 Vrms
I=
20 kΩ
I=

(4.10)

I =61 µA

Signal Conditioning: The voltage created by the electric field through the LV is measured by
an instrumentation amplifier (IA), Fig.4.24. Two 10 nF capacitors are used to decouple any DC
offset created from the electrode rings during measurement. In addition, two 100 kΩ resistors
are used to restore the virtual ground offset to the incoming AC signal. The voltage difference
is amplified with a gain of 20 dB by the IA. The IA used in this design is the TI INA333, with
low current consumption of 50 µA and high CMRR of 100 dB. A benefit of using this IA
over other options is its high accuracy, low power and single gain resistor required. However,
it cannot provide high gain, greater than 20 dB, at and above 20kHz. As a result, the gain of
the IA must be kept at 20 dB and an additional gain stage of 17 dB is used for a total stage
amplification of 37 dB.
Along with the desired voltage waveform the electrode rings will also measure the electrical
signals created from the surrounding heart nerves and muscles causing additional unwanted
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Figure 4.25: ECG bandpass filter to remove ECG signals measured from surrounding heart
nerves.
noise in the signal. A bandpass filter is used to remove the ECG signal and additional noise
contained in the measured AC signal. A 4th order, two stage multiple feedback bandpass filter
is designed with a total gain of 12.04 dB and is centred around 18.59 kHz with a passband of
4 kHz. A total of 10 passive components (6 resistors and 4 capacitors) and two OP–Amps are
used to implement this filter, Fig. 4.25. This amplified and filtered signal is the main input to
the next stage of lock–in amplifier – the phase sensitive detector.

Mixer: Two main blocks of the phase sensitive detector are the mixer and low pass filter. As
mentioned previously one of the simplest forms of a mixer is an inverter/switch combination,
Fig. 4.18. The designed interface module implements this mixer configuration and an active
low pass filter design. The inverter block is implemented by an unity gain inverting amplifier
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configuration, Fig. 4.26. To extract both I and Q values, two analog switches are needed,
the Analog Devices ADG787 is used to complete the mixer configuration. The input to each
switch is the inverted and the non–inverted filtered signal with the frequency locked square
waves providing the switching controls, Fig. 4.26. IPS D and QPS D are the outputs of the switch.
Span and Offset: The high frequency harmonics of the output waveform are removed using
a low pass filter to reduce the waveform to a DC level that is directly proportional to the
magnitude and phase of the voltage signal. To obtain maximum SNR, the DC signal must span
the full input range of the microcontroller (0 – 3.6 V). This is achieved by removing the virtual
ground offset of 1.8 V and amplifying the DC output to span between 0 and 3.6 V. A 2nd order
Bessel active low pass filter with a cut-off frequency of 127 Hz is designed with a gain of 13.46
dB and resistors to remove the DC offset, Fig. 4.27. Each switch output, IPS D and QPS D , is
connected to a separate active low pass filter block, each with separate offsets (R18 and R19
are swapped from what is shown in Fig. 4.27 for Q out LPF) to achieve maximum scale for
both I and Q outputs.
The outputs, I and Q, are connected to the communications bus and sampled by the MSP430.
The I and Q signals are sent to the external device with no additional processing. Calibration,
admittance, and volume calculations are done on the external device. More information on this
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Figure 4.27: 127 Hz Low Pass filter with gain and span included.
is outlined in Section 4.8.

4.4.4

Interface Module - Implementation

The physical implementation of the interface module consists of the pressure signal conditioning, volume measurement blocks and catheter attachment pads. Due to the large component
count of the volume measurement electronics the PCB area will be large. Rather than extend
the area of a single printed circuit board it is more beneficial to extend the design to two separate PCBs. This increases the overall volume slightly however, it does not change the shape of
the system, as it still remained cubic shaped. Design decisions are made on how to separate the
design across two PCBs, this includes which signals are connected to the communications bus,
which packages are used, and where the catheter pads are located. In addition, this module’s
power supply (LDO on the power module, 3.6 V and 1.8 V) is controlled via the microcontroller.
The catheter attachement pads are located on the top PCB board and are 1.5 mm x 1.5 mm
to allow for easy mounting of the catheter. As mentioned above the TI LMV554 is used as
the OP–Amp in this design and is packaged in either a TSSOP14 (Quad Op–Amp) or MSOP8
(Dual Op–Amp). The TI INA333 is packaged in a no lead package measuring 3 mm x 3
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Figure 4.28: Interface Module – Pressure and Volume PCB: Top PCB, left, and right inner
PCB.

mm. All passive components are 0201 size and the remaining analog switch is a MSOP10
package. The pressure module consists of a few passive components and the ZMDI ZSC31015
is packaged in a SOIC8 which is the largest component in the interface module. A die version
is available however, it is not used at this time.
As interface module is split across two PCBs, multiple signals are to be routed to the communication bus to be connected to the second PCB in the stack. When choosing which signals
are to be connected, the physical packages of the components are considered. In this design,
there are a total of 11 OP-Amps, 1 IAs and 2 switches that are used by the volume electronics
and a single ZMDI ZSC31015 in the pressure section. A single Op-Amp SOT23 package must
be used in order to achieve the exact total number of Op-Amps required for this design. However, this extra component will add a significant amount of area and volume to the design (pads,
height, etc). Alternatively, the physical amount of Op-Amps placed on the PCB is increased
by 1 such that the OP-Amps are split up into different combinations of quad and dual packages
(i.e., 3 quads or 2 quads and 2 duals, etc). The extra Op-Amp is left unconnected on the PCB.
Therefore, taking these considerations and analyzing the schematic to view logical separation
points it is determined that three signals are used for separation purposes, IGate , QGate and the
output of the gain stage after the IA. IGate and QGate represent the output of the comparators
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to create the Lock–In reference signals for the I and Q signal chains. In addition, all pressure
components are on placed on single PCB and the output pressure sent to the communication
bus.
Using these three signals along with output pressure, the interface module is split into two
PCBs created using a total of seven packages. The first PCB contains four packages: 1 quad
OP-Amp, 1 dual OP-Amp, a single instrumentation amplifier, and the ZMDI ZSC31015 IC.
The second PCB contains three packages: 1 quad OP-Amp, 1 dual OP-Amp and 1 dual analog
switch. The complete pressure section is located on the top PCB along with the catheter pads.
The second PCB contains the outputs I and Q which are connected to the microcontroller
through the communications bus. The two PCBs are fabricated on 15 mm x 15 mm FR-4
boards and shown in Fig, 4.28 for the first and second board.

4.5

Testing Platform

As the implant’s physical size is small and it is not practical to probe the internal boards while
in use, a test platform is developed to allow for full programming, charging, and debugging of
the wireless telemetry system. This system consists of two PCBs, a breakout board and a full
featured development board.

4.5.1

Breakout Board

The breakout board’s main purpose is to route all the signals from the communication bus to
two additional connectors. These connectors are located on the opposite ends of the board compared to the vertical communication bus, Fig. 4.29(a). Flat flex connectors (FFC) are chosen for
the breakout connectors, more specifically 26 pin 0.5 mm pitch Molex FFC connectors [255].
These are right angle flat cable connectors with a mated height of 2 mm. The overall PCB size
is increased to 25 mm x 21 mm to facilitate the new FFC connectors and avoid all clearance
issues associated with the increased mated height and the system stack. Two identical FFC

Chapter 4. Wireless PV Telemetry System

(a) Breakout Board

119

(b) Development Board

Figure 4.29: (a) Breakout board and (b) Development boards of the second physical prototype.
connectors are placed on the development board to transfer the signals from the vertical bus to
the development board. Flat flex cables, 0.305 m, Fig. 4.29, 4.30, are used for this connection.
No additional components are placed on this PCB, only the two FFC connectors and the vertical connectors. The breakout board provides only signal routing to the development board and
serves no other functional purpose inside the system stack.

4.5.2

Development Board

The second board in the testing platform is a much larger PCB that contains programming,
charging and debugging capabilities. This PCB receives the communication bus signals from
the FFC cables and distributes them to various sections of the boards, Fig. 4.29(b). These sections are separated into battery charging, power management, USB programming, and testing
components.

Battery Charging
A mini USB connector is added to the PCB to provide a direct connection to USB power for
the MAX1811 USB charging IC. Test pins are provided to test the input voltage from the USB
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Figure 4.30: Development and Breakout Module connected via flex cables.
connector and the output voltage of USB charging IC. This power signal is routed directly to
the FFC connectors and directly connects to the external battery to charge it. An LED is also
used to indicate when the battery is being charged.

Power Mangement - Development Board
Power management and testing functionality is also designed into the development board. The
main telemetry system can be powered through the attached battery or by the development
board in testing. The power signals are routed to test points along the PCB to test for correct
voltages for the system voltage, interface voltage and 1.8 V reference. Another design feature
of this PCB is enabling an external power connection to the development board, which in turn
can power the whole system without the use of a battery. This feature is extremely important in
testing and debugging the system as precise current consumption can be calculated. All three
main telemetry system voltages can be applied externally through custom 2 pin connectors
located on the PCB. Additional connectors are added to switch between battery power and
external power as to not damage the electrical components.

Programming and Testing - Development Board
A programming interface is provided on the development board to program the MSP430 from
IAR Workbench The programming interface also provides external power to the system and
must be disconnected from any additional power source when connected.
Finally, multiple debugging connections are added to the PCB. There are a total of six
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LEDs that are directly connected to the pins of the microcontroller and are controlled when
testing. Furthermore, test pins are provided for all outputs of the interface module as well as
various other inputs and outputs of the microcontroller. Lastly, all the signals from the FFC are
also routed to a larger external breakout connector. This is 50 pin connector that is used for
additional pin out or connection to an external board. The breakout and development boards
provide all the testing functionality to the wireless telemetry system along with USB charging
and programming features.

4.6

Telemetry System Assembly Implementation

The system prototype is designed with the primary aim to explore physical limitations of the
state–of–the–art discrete components technology in respect to the minimum possible physical
size, and the system’s power consumption requirements. As a secondary goal, we designed
the development RF telemetry platform based on a modular topology, which enables us: a) to
explore and optimize the overall system performance; b) to verify the system’s in–vivo performance with medium animal subjects (e.g., large rat or a rabbit); and c) to further reduce the
system’s size by replacing each module with a custom single die IC design. With this strategy,
the current prototype will serve as the development platform, where the newly designed IC
modules will be tested within the real system.
The telemetry system can be optimized for different structures (i.e., planar, flex-rigid PCB,
cubic, etc.) for different animal types or for commercialization purposes where the goals may
be different (design for manufacturability, disposable, etc.). These different structures allow
specific attributes of the telemetry system to be optimized i.e., volume reduction only, antenna
structure, implant location, etc. In this design, a cubic structure was chosen for the implant.
This structure allows volume to be minimized by having each module stacked on top of each
other and allows for a full modular topology.
The telemetry system is assembled vertically, creating a cubic structure using five separate
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Figure 4.31: Close up 3D rendering of stacked vertical connectors (left), and exploded view of
the telemetry system with 5 PCBs from the PV sensor interface at the top, to the power supply
module at the bottom (right).
PCB’s with a thickness of 0.4 mm and dual micro–sized connectors with a mated height of
1.5 mm, Fig. 4.31. The stack up of the system from top to bottom is as follows: interface module board 1, interface board 2, RF module, microcontroller module, and power module. 3D
modelling was completed on the prototype to ensure clearance and overall construction before
the physical prototype was manufactured. The system including the battery is (15×15×11)mm3
(i.e., 2.475 cm3 ). During testing the breakout board is added to the stack to connect the communications bus to the development board. To ensure full clearance the breakout board must
be connected directly above the power module to allow for clearance between the breakout and
RF boards. The final assembled wireless telemetry system is shown in Figure 4.32, comparing
it to the 3D rendering.
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Figure 4.32: Full 3D rendering of assembled wireless telemetry system with battery (left), and
photograph of fully assembled prototype (without battery) next to a Canadian dime (right).

4.7

Control Architecture and Current Consumption

The analog output signals of the PV sensor interface module: I, Q, and Pressure are processed
by the microcontroller using a 10–bit SAR A/D converter. This implant is designed for medium
sized hearts, with a peak heart rate of ∼240 bpm or 4 Hz. The highest nyquist tone of the heart
beat is captured by a sample rate of 10ms (100 Hz). The sample rate is controlled by an internal
timer clocked by an internal VLO set to trigger an interrupt every 10ms. The implant control
architecture is separated into two main sections: 1) Main CPU operation and 2) Timer interrupt,
Fig. 4.33. The CPU loop’s main function is to either send a data packet to the external receiver
or turn the transceiver into Rx mode from sleep. Various command flags are used to determine
these operations, i.e., TX and RX. These flags are controlled by the control flow inside the
timer interrupt.

4.7.1

Implant Initialization

The implant is initialized in three steps: a) board initialization; b) calibration of Low-Power
Oscillator (VLO); and c) transceiver configuration. The implant initialization is completed in
27ms with the corresponding instantaneous current profile shown in Fig. 4.34. First, the configuration of the ADC, clocks, counters, and GPIO are completed during board initialization.
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Figure 4.34: Implant initialization: Board Initialization, Calibration of VLO, and Transceiver
Configuration.
The VLO must be calibrated to ensure the proper sample rate, which is achieved by calibrating
the temperature and process dependent VLO to the more accurate factory calibrated main clock
of the microcontoller. This method ensures that sample rate is 10ms each time the implant is
powered on. To ensure proper calibration and minimal drift over time, the same procedure may
be repeated while the system is implanted. Lastly, the RF parameters of the transceiver are
configured and the implant placed into sleep mode.

4.7.2

Data Acquisition

The implant is designed to operate in three distinct operational modes: 1) Continuous, 2) Duty–
Cycle, and 3) Sleep cycle. These modes control the data acquisition and receive modes. Within
the acquisition cycle, Fig. 4.33, data acquisition occurs in three stages. First, all appropriate
counters are increased, followed by the sampling and conversion of the analog input signals (I,
Q, Pressure) and lastly, the data is compressed. Rather than use three separate integer values
(16 bits) to represent three 10–bit samples (48 bits), the data is merged into a single 32–bit
value per acquisition, i.e., the payload for the system. In addition, a receive mode is used to
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accept instructions from the base station. Regardless of what acquisition mode the implant
is in, the system always checks whether the device should enter receive mode. This is done
through the use of two counters, RXTimeOFF and RXTimeON . These counters are independent from
each other and can be set to any time frame, for example 20min off and 1min on. Receive mode
takes priority over data acquisition if they occur at the same time.

The average current consumption is reduced by using a digital I/O port on the microcontroller to disable the PV interface electronics after data acquisition, and by the microcontroller
and transceiver entering sleep mode once a packet is sent. Furthermore, a memory buffer is
used to store each payload before its transmission. The maximum size of this buffer is based
on the available memory inside the microcontroller, in this MSP430, 856 bytes or 214 payloads.
There is no reduction of average current consumption if the buffer size is 1 or 214 payloads,
due to the increased transmission time required to send more payloads at once. However, the
maximum buffer size is used in cases where the transmission window (i.e., receive window) is
only available at a specific time rather than always listening. At a heart rate of 180 bpm, a fully
loaded memory buffer contains approximately 8.5 PV loops, while the total acquisition time
is 109ms (not including processing and transmission). Additional on-board memory would
increase the buffer size thus reducing the requirement of an continuous receive window.

When the memory buffer is full, the RF transceiver is turned on and the data payload is
transmitted to the external unit, Fig. 4.33 Main CPU. The output power level is set to -12dBm
within the frequency bandwidth of (2.4320–2.4356)GHz. The total time for one data acquisition cycle (1 payload) to complete is 4.45ms, 508µs for acquisition, 2.32ms for processing, and
1.62ms for transmission. The telemetry system is in a sleep state between measurement cycles,
where the microcontroller and RF transceiver are placed in their respective low–power modes
supplied by the main 3.6 V regulator. The VLO (12 kHz) remains on to provide a timing base
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for the interrupt. Hence, the total current consumption in sleep (4.11) is 40 µA.
ISleep = IµC/RF Sleep + IVreg Main

(4.11)

= 8 µA + 32 µA = 40 µA.

Continuous
In this mode, the PV interface electronics are powered on and sampled, followed by RF transmission. The instantaneous current consumption profile of the telemetry system in this mode
with a RL = 100 Ω and an output power of -12 dBm, Fig. 4.35, indicates that the telemetry
system consumes 40 µA in sleep, 3.46 mA sampling, 2.2 mA processing and 15mA during
RF transmission. This mode is repeated until RXTimeOFF is expired and at such time the RF
transceiver is switched to receive mode for a predetermined amount of time, RXTimeON . Due
to the transmit power level (-12 dBm) and high receiver sensitivity (-102 dBm), when the
transceiver operates in the receive mode it has higher instantaneous current consumption of 20
mA, which causes an increase in the average current.

Duty Cycle
In this mode, the implant operates similar to the continuous mode however, it is controlled
by two counters DutyON and DutyOFF . These counters are configurable and set during implant
initialization. For example, the duty cycle can be 6 min On and 54 min off or 10% duty cycle.
The system enters sleep state once duty cycle window is over.

Sleep Cycle
In this mode, the implant is in sleep mode. The microcontroller and transceiver are powered
down to reduce power consumption. In addition, the PV electronics are also shut-down. The
system will stay in this mode indefinitely unless awaken via the RX mode. The instantaneous
current consumption of the telemetry system in sleep cycle is 40 µA in sleep and 20 mA when

128

20

72

18

64.8

16

57.6

14

Transmission

50.4

12

43.2

10

36

Processing

8

28.8

Sampling

6

21.6

4

14.4

2

7.2

Sleep

0
0

1

Sleep
2

3

4
5
6
Time [msec]

7

8

9

Instantaneous Power Consumption [mW]

Instantaneous Current Consumption [mA]

Chapter 4. Wireless PV Telemetry System

0
10

Figure 4.35: Instantaneous current and power consumption of the full telemetry system during
a single data acquisition and transmission cycle through air with a load of RL = 100 Ω and
output power of -12 dBm. Total time per acquisition: Sampling - 508µs, Processing - 2.32ms,
Transmission - 1.62ms.
the transceiver is in RX mode. The RX on time will increase the average current consumption.

4.7.3

Current Consumption

The average current consumption along with the overall operational time of the telemetry system is found for each data acquisition mode separately, i.e., the implant would operate in one
mode and continuously take measurements for the duration the battery life capacity, 40 mAh.
For example, if the implant acquires data once every hour, i.e., 1 sample, to abide by the current
profile in Fig. 4.35, the average current consumption is 40 µA calculated by (4.12), where the
instantaneous current measurement is separated into sampling (IInterface and IAcq ), processing
(IProcess ) and transmission (ITxA and ITxB ).
As the telemetry system is only active for 4.45ms per measurement and in this example per
hr, the dominant contribution to the average current is the sleep current. As indicated in (4.11),
the main 3.6 V regulator’s current consumption attributes the most to the sleep current hence,
the most to the average current in a single measurement mode as well. Reducing the voltage
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regulator current consumption will scale down the average current of the telemetry system in
this measurement mode.
IMeasurement = IInterface ∗ (395.2µs) + IAcq ∗ (112.8µs)
+ IProcess ∗ (2.32ms) + ITxA ∗ (797µs)
+ ITxB ∗ (826.2µs)
= (2.8 mA) ∗ (395.2µs) + (3.46 mA) ∗ (112.8µs)
+ (2.2 mA) ∗ (2.32ms) + (12 mA) ∗ (797µs)
+ (15 mA) ∗ (826.2µs)

(4.12)

= 28.56 µAs
IAvg = IMeasurement ∗
=

1hr
#Meas
∗
+ ISleep
1hr
3600s

28.56 µAs
+ ISleep
3600s

= 40 µA
A summary of the average current consumption for different measurement cycles along
with the total life cycle of the telemetry system with a 40 mAh battery is shown in Table. 4.3.
During continuous and duty cycle operation, the interface module is kept powered throughout
the measurement cycle to ensure the proper startup conditions are met. It is observed that as
the number of measurement cycles per hour is increased, the influence of the main voltage regulator’s current consumption is reduced, placing more dominance on the instantaneous current
consumption, mainly the Tx and Rx current consumption. There is no optimal cycle type/time
and is to be optimized for the specific research protocol. For example, in some situations it is
best to measure a 10 sec window every hr where others it is best to measure 1 hr continuously.
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Table 4.3: Average Current Consumption and Battery Life
Cycle Type

IAvg

Battery Life [hr]

Notes

Continuous

5.59 mA

7.16

100Hz sample rate
1 Min On

Duty Cycle

132 µA

302.07

59 Min Off
No Rx
2 Min On

Duty Cycle

3.24 mA

12.35

2 Min Off
1 Min Rx

Sleep

4.8

373 µA

107.18

1 min/hr Rx

External Receiving Unit

An external receiving unit (Rx Unit) that consists of a microcontroller, wireless transceiver, and
hardware UART board is designed to receive the transmitted data signals from the implanted
system, Fig. 4.36. The data transmitted from the implant is received via the hardware wireless
receive block and sent to UART module to be transmitted to a PC. The PC can be any desktop,
laptop or other embedded device such as a Raspberry PI that is able to receive serial data.
In this thesis, the PC is used is a Windows based system. The PC will then display the data
received in either a terminal window or a custom based application like LabView. Each section
of the External Receiving Unit will be discussed in the following subsections.
RF Link

Program
Connector

UART
Module

USB
PC

Wireless Recieve Block

Figure 4.36: RX Unit Block Diagram that includes: the Wireless Receive Block, UART Module, and PC.

Chapter 4. Wireless PV Telemetry System

131

Figure 4.37: Wireless receive block including MSP430 programmer (right) and ez430-RF2500
(left) [29]. Copyright c Texas Instruments.

4.8.1

Wireless Receive Block

The wireless receive block contains the same microcontroller, transceiver and PCB antenna as
the implantable system, MSP430 and CC2500, Fig. 4.36. This block receives the incoming
data from the implant, decodes packets and sends the data to the UART module. The MSP430
and CC2500 are configured similarly to their implantable system counterpart. The RF settings
(carrier frequency, channel, etc) on the external device are identical to the implant to ensure a
proper connection. The external CC2500 is configured to its highest sensitivity of -108dBm for
maximum range. The ez430-RF2500 is used as the external wireless receive block, Fig. 4.37.
A custom PCB can be created with external antennas and boost ICs to increase the range if
required.
When data is received by the CC2500, an interrupt is triggered allowing the MSP430 to
receive the data over the SPI bus and process it. As the incoming data is in the form of a 32-bit
packet, it must be separated into each channel (I, Q, P) by using bit masking before it can be
sent the PC. Each channel is a 10-bit ADC sample and is stored in a 16-bit integer. Although,
each channel’s binary data can be sent to the PC directly, it is more beneficial to convert each
digit to ASCII characters for improved viewing on the PC. This has various benefits such as
improved readability on the PC, no conversion required on PC software, and each digit can be
sent in a single 8-bit UART transfer. In addition, by sending ASCII characters only, a simple
text GUI can be created for the user. However, there two disadvantages to this method. First,
additional space is required to store each channel. As described in Section 4.7.2, the maximum
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value for each channel is 1024 (decimal) or 3.6 V VDD. In binary, this is represented by a 10-bit
value, stored in a 16-bit integer, however if each digit is converted to its corresponding ASCII
character the size will be 4 bytes, or double the required storage per channel. For three channels
(I, Q, P) and two additional characters for new line and carriage return, the total number of
bytes to be sent to the PC per sample is 14 bytes. This leads to the second disadvantage,
the increased BAUD rate required for MSP430 to PC transfer. Recall, in Section 4.7.2 that
when each transmission occurs, a maximum of 214 samples are sent to the end unit. This data
must be received by the external CC2500, processed by the MSP430 and sent to the PC and
displayed before the next payload arrives. The minimum time required is when transmission
occurs after each payload sample or 10 ms, Fig. 4.35. As a result, the above steps must be
completed in this time or data will be delayed within UART buffer on the PC. If the researcher
is just logging data and not viewing it in real-time this is not much of a concern. However,
when viewing data in real-time, the research may be required to act on the data received, for
example change catheter location or record specific event. Thus, it is essential that the data be
processed in a specific time frame.
The CC2500 and MSP430’s processing are a fraction of the total time required in this
process. The main bottleneck is the transfer speed of the serial connection to the PC also
known as the BAUD rate. This is illustrated in the following calculations:

S ample per sec =

1
10ms

(4.13)

S ample per sec = 100

Bytes per sec(AS CII) = S ample per sec × 14 Bytes
Bytes per sec(AS CII) = 1400 Bytes per sec
BAUD(AS CII) = Bytes per sec(AS CII) × 8
BAUD(AS CII) = 11200 BAUD

(4.14)
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Figure 4.38: UART Hardware Module Block Diagram that includes the USB connector to send
the PC data, FTDI IC, and Program connector to interface with the MSP430.

Bytes per sec(Binary) = S ample per sec × 6 Bytes
Bytes per sec(Binary) = 600 Bytes per sec

(4.15)

BAUD(Binary) = Bytes per sec(Binary) × 8
BAUD(Binary) = 4800 BAUD

The required BAUD rate for ASCII transmission is 11200 and 4800 for Binary transmission. New line and carriage return characters are omitted from the binary transfer case. Typically, serial communication is done at 9600 BAUD, which can be emulated by software very
easily and is the case for the standard MSP430 USB programmer. The programmer is included
with the ez430-rf2500 and can be used to program any MSP430 using spy-by-wire. However,
it’s UART to PC transfer interface is not implemented by hardware, rather it is emulated by
software, limiting the BAUD rate to 9600. As illustrated by the above calculations, significant
delay will occur if this BAUD rate is used. Therefore, a hardware UART module is required
that is able to achieve a BAUD rate greater than 9600.

4.8.2

UART Module

A custom made UART module is created with the following sub–blocks: USB, FTDI IC, and
programming connector, Fig. 4.38.
The UART module receives the 1 byte UART packets from the external MSP430 via the
programming connector. This connector is the same one used as on the development module.
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Figure 4.39: UART Hardware Module PCB.
The UART data lines are connected directly to the FTDI IC, FTDI FT232RL. The IC acts as
an interface between the UART data lines of the MSP430 and the USB bus of a PC. The output
pins of the FTDI FT232RL are connected to the data lines of a USB port, a mini USB jack is
used. Power to the UART module, MSP430, CC2500 is provided via the 5 V USB voltage.
The FTDI FT232RL contains a 3.3 V regulator used to power the MSP430 and CC2500.
A USB FTDI COM driver is required on the PC for proper operation of the module. These
are readily available from the FTDI website, [256]. This driver enables the UART module to
be viewed as a simple COM port on the PCB. Once installed, the FTDI IC is configured with
the proper serial data transfer settings of 115200 BAUD rate. Additional settings can be set
including hardware handshaking, buffering, etc. The UART module is manufactured on a 3
cm × 3 cm two layer PCB, Fig. 4.39. Holes are added to the design for mounting to a cage or
external enclosure.

4.8.3

PC / External Unit

As the UART module acts as a simple COM port to the PC, the data can be read via any COM
port reader such as Putty or a terminal (Mac OS X, Linux, etc). The incoming data is ASCII
formatted as IIIIQQQQPPPP, where I, Q, and P represent the in phase (I) and out of phase (Q)
signals from the volume measurement system and P representing the pressure output. There
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DisplaygFormat
IIIIQQQQPPPP
IgOutg=g0516
QgOutg=g0518
Pressureg=g0533

Datagwillgcontinuegtogscrollgdown
Nogprocessinggdonegatgthisgstage

Figure 4.40: Raw Data Streamed to PC via Putty.

are are 4 characters per channel representing the maximum 1024 value. A total of 14 characters
are sent with each sample, 12 data bytes and two new line characters. When viewing the data
in a terminal window, each sample will appear as a single line with each new sample appearing
below, Fig. 4.40. This viewing method is useful for testing the operation of the wireless link,
data speed and ADC on the input side. However at this point, the incoming data to the terminal
is not processed (raw voltages) and must be converted to admittance (magnitude and phase)
and then to a volume. In addition the pressure must be converted to its calibrated value.

A custom application is created in LabView to further process the implant data. All three
signals I, Q, and Pressure are saved and displayed numerically and graphically for the surgeon/medical technician to view, thus indicating catheter location during the implant procedure. In addition, the wireless receive unit is used to send instructions to the implant to change
transmission power, acquisition mode, duty cycle and Rx duty times. A full in depth description of application and how its used within the in-vivo study is provided in Section 6.1.
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Conclusion

In this chapter, the design of the wireless implantable telemetry system is discussed. The system consists of four modules: power, signal processing, RF transmission, and analog front
end. In addition, the communication bus and development module are discussed. Furthermore,
details of the analog front end architecture are presented including an analysis into lock–in
amplifiers and the pressure measurement system. Each module’s physical implementation is
presented culminating with the assembled telemetry system. The control architecture is presented indicating an average current consumption of 40 µA and various measurement cycles
are explored. Finally, the receiving unit is examined as well as how the data is displayed on the
PC and further processed.

Chapter 5
In–Vitro Characterization ∗
In this chapter, the in-vitro (non-implanted, external of body) characterization of the implantable
telemetry system is presented. A phantom tissue study to model the effects of implant conditions and to determine the appropriate RF transmit power from the Pressure–Volume (PV) prototype [257] is described in Section 5.1. In Section 5.2 details of the implant capsule design for
the PV system are presented, along with results from a 98 day water immersion study [258].
Calibration methodology is presented for both pressure and volume measurement circuits in
Section 5.3. Lastly, dynamic PV system testing is discussed in Section 5.4.

5.1

Phantom Tissue Evaluation

Extensive research has been documented outlying various tissue properties and standards [102,
147–150, 259–261]. It is well documented that the effect of tissue on a biomedical implant
will impact its RF performance. Therefore, a phantom tissue study is undertaken to model the
effects of implant conditions and to determine the appropriate RF transmit power from the PV
prototype. A phantom tissue is a medium that mimics the electrical properties of real tissue. In
some cases, researchers [262,263] have used meat prepared as food as a substitute for phantom
∗

Portions of this chapter are published in BIOCAS 2014 [257], Analog Integrated Circuits and Signal Processing journal [258], and Springer Biomedical Devices [240].
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Table 5.1: Phantom Tissue Ingredients [32]
Ingredients
Distilled Water
Agar
Sodium Chloride
TX–151
Polyethylene Powder
Boric Acid (Preservative)

Muscle [g]
3375
104.6
39.4
84.4
337.5
39.4

tissues. This can provide a crude method of evaluating an antenna in an implantable setting
however, it has several drawbacks including the lack of repeatability, and not knowing the
process in how the meat has been prepared. Thus, a custom created chemical phantom tissue is
created to ensure repeatability and accurate results. The outcome of this study is to determine
the minimum RF output power that the transmitter (T x ) needs to provide to still receive data
from the implant while having minimum power consumption in a typical medical measurement
environment, i.e., instrument noise, non ideal antenna matching, spectrum interference, etc.
Along, with RF output power, the maximum distance separating the implant and the R x unit
before data loss is also an important specification for a biomedical implanted system.

5.1.1

Phantom Tissue Study Setup

The tissue equivalent phantom is created from Agar, distilled water, Sodium Chloride, TX151, Polyethylene powder and Boric Acid (Preservative), Table 5.1 [32]. The agar allows the
phantom to retain its shape and prevents water separation. The conductivity of the phantom is
directly controlled with Sodium chloride and the relative permittivity is adjusted via Polyethylene powder. TX-151 is added to increase the viscosity of the medium and Boric Acid is used
as a preservative. The mixing procedure is modified from [32] to suit the specific mixing environment and equipment available, this included the use of a microwave rather than gas burners.
The conductivity and relative permittivity of the phantom tissue are modelled to match
that of muscle with a conductivity (σm ) of 2.21 S/m and relative permittivity (r ) of 47 at
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Figure 5.1: Phantom tissue used in study. 4 cm × 4 cm × 3 cm.

2.45 GHz [264]. A full range of conductivity and relative permittivity of different biological
mediums across a wide range of RF frequencies are available in the literature [147–149].
The phantom tissue is cut into a 4 cm × 4 cm × 3 cm structure, Fig. 5.1, where the antenna
is inserted, as the typical antenna implant depth under the skin is in the range of 1 cm to
5 cm [259, 261], Fig. 5.2. The designed implant is expected to be placed at a similar depth
underneath the skin in a in–vivo setting. This model emulates the tissue through which the
transmitted RF signal must pass through while being transmitted from within the body. In a
realistic implant setting the tissue will be made from a multi–layer structure comprised of skin,
fat, muscle, bone, etc. To simplify our model, the tissue is modelled as muscle only.
An antenna attached to a spectrum analyzer is used as the R x unit in this experiment and
the PV prototype with and without phantom tissue is used as the T x unit. Transmission of
the PV implant is monitored with the distance range from 120 cm to 5 cm in steps of 20 cm
between the T x unit and the receiving antenna, with and without the phantom tissue inserted
into the transmission path. The transmit power (T x RF output power) is set to 0dBm, −12dBm,
−16dBm, and −20dBm to model a wide range of typical output power levels. An example test
measurement setup is illustrated in Fig. 5.3.
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Figure 5.2: Implant antenna inserted into phantom tissue.

2.45 GHz Antenna
Spectrum Analyzer

Phantom Tissue
Implant Unit

Figure 5.3: Experimental Measurement Environment used in study. Shown: Spectrum analyzer, R x antenna, PV prototype with antenna inserted into 4 cm phantom tissue 10 cm away.
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Figure 5.4: Designed 2.4 GHz monopole antenna used in EM simulations. Left: Electric Field
Distribution with 0dBm input power.

5.1.2

EM Simulation Model

A simplified EM model of the antenna and phantom tissue is created in HFSS to simulate the
ideal measurement environment. In this model, the antenna on both the T x and R x side are
matched to 50 Ω and identical, the measurement environment is free of spectrum and measurement interference. The antenna implemented in the EM simulations is created from the
physical and electrical parameters of the antenna used in the PV prototype. The antenna is a
30 mm monopole antenna that resonates at 2.442 GHz, Fig. 5.4. The VSWR and S11 of the
modelled antenna are shown in Fig. 5.5 and 5.6, respectively.
The simulation model follows the measurement procedure outlined in Section 5.1.1 where
the distance is swept from 120 cm to 5 cm at power output levels of 0dBm, −12dBm, −16dBm,
and −20dBm, with and without phantom tissue. The phantom tissue is modelled with the
conductivity and permittivity at 2.45 GHz representing the same electrical characteristics as
realized in the experimental setup, σm = 2.21 S/m and r = 47. An example electric field

Chapter 5. In–Vitro Characterization

142

3

VSWR

2.5

2

1.5

1
2.3

2.35

2.4

2.45
2.5
Frequency [GHz]

2.55

2.6

Figure 5.5: VSWR of 3D simulated antenna.
distribution of the T x antenna is shown in Fig. 5.4, with an input power of 0dBm. The corresponding S 21 plot of transfer link through phantom tissue at a distance of 20 cm is shown in
Fig. 5.7.

5.1.3

Phantom Tissue Results

Power loss without the phantom tissue (Ploss ), power loss with phantom tissue (Plosst ) and
power absorbed by tissue (Pab ) are measured, Fig. 5.8 with the measurement setup outlined in
Section 5.1.1. Ploss represents the power losses due to the air transmission medium alone,
Plosst is the power losses due to the addition of phantom tissue with the air transmission
medium and finally, Pabsorb is the power absorbed due to the phantom tissue alone (5.1), where
Pr represents the power received without tissue and Prt the power received with phantom tissue
.

Pabsorb = Pr − Prt

(5.1)

As the transmit power decreases (T x ) and the distance from R x increases, the power re-
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Figure 5.6: S11 of 3D simulated monopole T x R x antenna.
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Figure 5.7: S21 of 3D simulated phantom tissue environment at a distance of 20 cm with T x
antenna inserted into phantom tissue model.
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Figure 5.8: Calculation of absorption losses of phantom tissue.

ceived (R x ) decreases, Fig.5.9. The received power approaches the sensitivity of the CC2500,
−104dBm, when the transmit T x power is set to −20dBm. Although, the R x sensitivity threshold of the power is not reached while transmitting without phantom tissue, with the phantom
tissue in the transmission path, at −20dBm R x power, this sensitivity limit is approached, i.e.
the bit–error rate of the transmission becomes easily visible.
For an output T x power of −12dBm the measured power losses along with simulated phantom tissue absorption are shown, Fig. 5.10. The power loss due to the air transmission medium,
Fig. 5.10 (d), is significantly larger than the power absorbed by the phantom tissue, Fig. 5.10
(g). This indicates that the majority of the power loss from T x to R x is due to the air transmission medium. However, the loss due to the phantom is not negligible and is an average of
8.39dBm across the used distance range, hence the power absorption loss has to be accounted.
In comparison, the simulated phantom tissue absorption loss is on average 8dB higher than the
experimental tissue absorption loss. This difference may be attributed to the non–ideal phantom tissue model mixture, the simplification of the simulation model, and the variation of σm
and r of the simulation compared to the experimental phantom.
In addition, the power consumption of the transmitter is measured for output power levels
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Figure 5.9: Comparison of different RF output power levels with and without the phantom
tissue inserted. Without phantom tissue: (a) 0dBm, (b) −12dBm, (c) −16dBm, (d) −20dBm;
With Phantom Tissue: (e) 0dBm, (f) −12dBm, (g) −16dBm, (h) −20dBm.
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Figure 5.10: Receive power with and without phantom tissue for output T x power level of
−12dBm. (a) Pin – Incident Power, (b) Pr – Power received without tissue, (c) Prt – Power
received with phantom tissue, (d) Ploss – Power loss without phantom tissue, (e) Plosst – Power
loss with phantom tissue, (f) Pabsorb−sim – Power absorbed by tissue simulation,(g) Pabsorb−exp
– Power absorbed by tissue experimental.
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Table 5.2: Power consumption of Transmitter (CC2500) at various T x output powers, VDD
= 3.6 V
Output Power [dBm]
0
−12
−16
−20

Power Consumption [mW]
80.64
43.92
42.48
39.96

of 0dBm, −12dBm, −16dBm, and −20dBm, Table 5.2. There is a 2.52 mW difference between
−16 and −20dBm T x output power and a 1.44 mW difference between −12 and −16dBm T x
output power. The optimum output transmit power is a function of power consumption of
the transmitter, receive power and distance of PV implant. A conservative choice is made
for the output transmission power, −12dBm, which allows the implant to achieve full data
transfer with and without phantom tissue at a distance of 120 cm, well within the −104dBm
R x sensitivity range of the CC2500. This power level choice has lower power consumption in
comparison to 0dBm. In comparison, the output power levels of −16 and −20dBm offer lower
power consumption at the cost of a decrease in the received power and higher risk of possible
data loss at distances further away from the receive unit.
The phantom tissue study was completed for RF module with the external antenna only due
to the complexities of placing the PCB antenna and the complete implant inside of a phantom
while still operating the implant successfully. Although, the absolute results would be different
as the antenna shape and size are different, the operating frequency is still the same and similar
tissue absorptions would occur. Similar power output levels would be required when the PCB
antenna is used. Further discussion on the differences between the external and PCB antenna
is presented in the following Section 5.2.
The outcome of this study helped to determine the minimum RF output power that the
transmitter (T x ) needs to provide to still receive data from the implant while having minimum
power consumption in a typical medical measurement environment. To achieve an optimized
system, a specifically designed implantable antenna should be used, subject to future work.

Chapter 5. In–Vitro Characterization

147

This work was published in the Journal Analog Integrated Circuits and Signal Processing,
Springer under the title “In-Vitro RF Characterization of Implantable Telemetry System” in
2014 [257].

5.2

Implant Package Design and Evaluation

In this section, the design and experimental details of a custom 3D bio–compatible implantable
capsule that is used to house the wireless telemetry system designed in Chapter 4 is presented
[30, 31]. The capsule is designed specifically for the dimensions and shape of the PV system
and is 3D printed in four different materials: ABS, RDG720 Transparent Acrylic, ABS–M30i,
and 316L Stainless Steel. Results of a 98 day long–term water bath immersion study and a 1
week short term study are shown to validate the design and encapsulation process. The aim is
to design a minimum volume system that includes the electronic, the package, and the antenna.
In this work, although four different materials are evaluated, with the focus on the package
version made of bio–compatible ABS–30i and sealed with silicone to prevent leakage and
contamination; this package version will be used in the in–vivo experiment.
The rest of this section is organized as follows. In Section 5.2.1 the design of the 3D
implant capsule are presented; in Section 5.2.2 details of the implant capsule preparation and
immersion study results are described.

5.2.1

Biomedical Implant Capsule Design

Previous research has indicated various ways to protect the implanted electronics. Two mainstream methods found in the literature are: a) design of a customized capsule to house the
internal electronics, and b) creation of direct silicone epoxy barrier on the PCB by using silicone dip method, [21, 88, 158]. In order to reduce the amount of risk for in–vivo applications
and potential damage to both the system and the host subject a customized 3D capsule is designed in SolidWorks. The designs were manufactured using two 3D printers, one for plastic
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Figure 5.11: 3D Printed Plastic Packages for Pressure–Volume Implant from left to right: PV
Telemetry system [30, 31], thin wall acrylic, thick wall acrylic, thick wall ABS–M30i (ABS
not shown).
materials and one for metallic materials. Although larger in size than the direct silicon dip
method, the capsule method results in much smoother edges of the overall system, thus less
risk for possible fractures in the silicone coating in comparison to the sharp corners of the
coated PCB system. In addition, the implant capsule allows for the electronics to be removed
after in–vivo tests, thus prolonging the life–cycle of each implant.
The implant capsules are designed to accommodate the discrete PV system outlined in
Chapter 4 [30, 31] and they consist of a front port hole for catheter access, a side antenna
access hole, and is split into top and bottom halves, where the battery and the implant system
are placed in the bottom half. Starting from a custom SolidWorks model, four plastic packages
and one metal package are 3D printed using four different materials: 316L stainless steel, ABS,
RDG720 Transparent Acrylic, and ABS–M30i, Fig. 5.11 , Fig. 5.12 (ABS not shown).
The first experimental package was made from acrylic with very thin side walls, thus only
slightly larger than the prototype itself, Fig. 5.14(left). However, the reduced size of the acrylic
walls, whose thickness was designed to be 0.79 mm, poses a great challenge as the walls are
difficult to form correctly. The outside package dimensions are designed to approximately
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Figure 5.12: 3D Printed metal packages for pressure–volume implant: thin wall 316L stainless
steel top (left) and bottom (right).

24 mm by 18 mm. In addition, the tolerances of the port holes for the antenna and catheter are
difficult to control with this material at this scale. This is illustrated when two identical copies
of the top half are printed, Fig. 5.13. Both parts have the same size and shape, however, the
capsule on the left has issues with the wall thickness and the version on the right has errors
in both the port hole and the smoothness of the side walls. Instead, the thin walled version
of the package is printed using stainless steel, which does not have the manufacturing and
repeatability issues that the thin walled acrylic version has. The Stainless Steel thin version is
then used in this experimental evaluation.
A second, slightly larger, version of the package is created in ABS, RDG720 Transparent
Acrylic, and ABS–M30i, Fig. 5.11. That is, the size tolerances are increased as well as the
side wall thickness (designed to be 1.26 mm), to prevent cracks from forming and to increase
its overall robustness, Fig. 5.14(right).
The three plastic materials are selected based on their compatibility with the ISO 10993–6
bio–compatibility standard (ABS–M30i); availability from a wide range of 3D printers (ABS);
and the transparent nature of the material, thus enabling the internal cavity to be directly monitored throughout the study (RDG720 Acrylic). Although, heavier than the plastic materials,
316L Stainless Steel is selected to evaluate the 3D metallic printer’s ability to create the small

Chapter 5. In–Vitro Characterization

150

Wall thickness
failure

Non smooth wall
Port hole tolerance
control

5mm

4mm

2.31mm

1.38mm

2.31mm

1.26mm

18mm
Thin Wall
Version

32mm

24mm

0.79mm

4.51mm

Figure 5.13: Examples of errors when 3D printing the thin wall version in plastic.

20mm
Thick Wall
Version

Figure 5.14: Implant package cross-section view: Thin wall package with 24 mm by 18 mm
outer dimensions (left); and thick wall package with 32 mm by 20 mm outer dimensions (right).
Outer wall thickness noted by hatched lines.
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Table 5.3: Summary of 3D capsules printed
Thin Version

Thick Version

Wall Thickness

0.79 mm

1.26 mm

Outer Dimensions

24 mm x 18 mm x 18 mm

32 mm x 20 mm x 20 mm

Materials Printed

Weight

RDG 720 Transparent Acrylic Material
316L Stainless Steel
316L = 18.88 g
RDG 720 = 2.37 g

RDG 720 Transparent Acrylic Material
ABS
ABS–M30i
RDG 720 = 6.35 g
ABS = 5.50 g
ABS–M30i = 5.35 g

implant capsule, Fig. 5.14 (left) and the material’s interaction with the epoxy and silicone used.
This printer will be used to print bio–compatible Titanium in future revisions of the implant
capsule to create a stronger lighter weight implant enclosure. A summary of the 3D capsules
printed along with the weight of each in Table 5.3.
Thus, in the following subsection the evaluation results of four different packages for their
ability to prevent moisture from penetrating the implant cavity are presented.

5.2.2

Implant Capsule Water Bath Test

In order to emulate the effects of a typical implant environment on the prototype, a water
bath immersion study is performed. All implants are prepared with the same capsule preparation procedure outlined in Section 5.2.2 and placed into a temperature controlled water bath,
Fig. 5.15. Each capsule is opened to determine the effects of water on the implant over short
(one week) and long–term (98 days) exposure to water.

Implant Capsule Preparation
The implant capsules are first cleaned with water to remove any debris that may have formed
on the capsules during the 3D printing and post–processing phases. The 5F size catheters are
placed inside the catheter opening of the implant and sealed with Loctite 4311 epoxy to secure
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Figure 5.15: Experimental test setup – six liter water bath set to (40 ± 0.2)◦ C, implants are
submersed into water and held there for the duration of the study.
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the catheter inside the implant and to prevent entry to the inner cavity. The process is repeated
for the exterior of the catheter entrance. In addition, the catheter tip and end points are sealed
to prevent air from traveling into the implant cavity. In this experiment the antenna is not
included, the antenna port’s main purpose is to provide a viewing port for the included water
sensitive paper, thus the antenna access hole is also sealed with Loctite epoxy. Subsequently,
the catheter and antenna are UV cured two times for a duration of 30 seconds each.
Chlorophenol detection paper is used to detect if any water enters the internal cavity of
the implant capsule. The water detection paper is cut into strips and placed into each capsule
half, top and bottom, Fig. 5.16 (a). The two halves of the implant capsule are then sealed
with Loctite epoxy and UV cured for 1 minute, rotating the implant throughout to ensure a
uniform cure of the capsule. The internal cavity of the implant is isolated from water entry due
to the epoxy however, if it or the enclosure itself were to fail, the implant itself is not protected
from its environment, thus it must be encapsulated. The implant capsule is dipped into a large
volume of Loctite 5091 silicone three times and hung for 10 minutes to remove excess silicone
from the capsule. Subsequently, the implant is cured for 2.5 minutes at multiple angles to
create a full bio–compatible sealed implant capsule, Fig. 5.16(b). A close up of the transparent
acrylic material with internal chlorophenol water strips is shown in Fig. 5.17.

Experimental Setup
A six liter water bath is set to 40 ± 0.2◦ C, which is typical animal body temperature, Fig. 5.15.
Each implant is placed into the water bath and weighted down to prevent it from floating. The
Stainless Steel packaged is tied down to prevent the heavier implant from sinking to the bottom
of the container. The external view of the water bath setup along with the internal view of the
weighted down implants are shown in Fig. 5.15 and 5.18, respectively.
Two studies are completed, a long–term 98 day study and a short–term 1 week test. The
long-term study consists of the ABS printed implant only and the remaining three materials are
tested in the short term study. The internal Chlorophenol detection paper is monitored through
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Figure 5.16: (a) Chlorophenol water test strips placed inside top and bottom cavities of implant
capsule. The paper turns purple when in contact with water. (b) Fully sealed implant capsules
with Loctite 4311 epoxy and Loctite 5091 silicone.

Figure 5.17: A closeup of the thick walled capsule 3D printed in RDG720 transparent acrylic
material displaying internal chlorophenol water strips.
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Figure 5.18: Internal view of water bath setup with each implant weighted down to prevent
floating.
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the antenna port hole or through the transparent material. The water bath is regularly refilled
due to the evaporation of the water.

Water Bath Results
The detection paper was initially checked daily in the early stages of the the long–term study,
however, after 1 week the detection was monitored on a week by week basis. After 98 days,
to coincide with the end of the short–term test, the ABS capsule was opened to reveal no
noticeable moisture inside the package. Due to the length of the study, the detection paper
began to dehydrate, noted by the white locations on the paper, Fig. 5.19 (far right).
Throughout the short–term study, the detection paper was monitored through the antenna
port hole four times daily for the one week period. After 7 days the capsules were opened to
determine the outcome of the experiment. The RDG720 transparent Acrylic material yielded
similar results to the ABS package; no visible moisture was found on the detection paper,
Fig. 5.19. The ABS–M30i contained noticeable moisture localized to the region near the antenna port; the remaining Chlorophenol detection paper was unaffected, Fig. 5.19. It is hypothesized that the failure point was due to the curing process of the Loctite 4311 near the location
of the antenna port and not due to the design of the capsule or the material selected as the
moisture was minor and localized.
The 3D printed stainless steal package yielded much different results in comparison to the
plastic capsules. After one day of water immersion, the Stainless Steel began to react on the
exterior of the package, Fig. 5.20, although the package is sealed the reaction still occurred.
The metal package was placed inside a quarantine cylinder to prevent possible contamination
from the other plastic capsules in the water bath for the remainder of the test. The reaction
continued on the package outer walls and took approximately 1 day for new reaction locations
to form. Inspection of the Chlorophenol detection paper determined that no water moisture
transferred through the epoxy barrier into the implant cavity.
All four materials provided sufficient water protection for in–vivo experiments however,

RDG720
Transparent Acrylic

ABS-M30i

ABS

Figure 5.19: Water Bath Study Detection Paper Results: from left to right : Stainless Steel 316L, RDG720 Transparent Acrylic, ABS–
M30i, ABS. Water moisture located in corner of ABS–M30i package.

Stainless Steel
316L

Water Moisture
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Stainless Steel
Reaction Locations

Figure 5.20: Stainless Steel 316L reaction locations at the catheter port hole and along the
exterior shell.
additional material interaction studies are required to determine the cause of the reaction on
the stainless steel package and the exact failure point of the ABS–M30i package, subject of
future work. Furthermore, it can be hypothesized that the reaction most likely occurred due
to the stainless steel not being completely polished leaving impurities located on the exterior
of the enclosure. It has been shown that 316L stainless steel is safe to be used inside the
body [265, 266] and thus is mostly an issue of the post-processing of the 316L enclosure.
Moreover, the availability of a 3D metallic printer enables us to print stainless steel and other
metals with high precision. Most importantly, the 3D metallic printer can also print titanium
(Ti) and will allow the design of a complete hybrid implantable package with bio–compatible
printable metal for a custom antenna solution and 3D printed plastic for the overall implant
structure, subject of future work.

5.2.3

Enclosure for In-Vivo Study

For the in–vivo experiment, a modified implant package is designed without the antenna port
and with suture holes to allow the implant capsule to be secured to the test subject, Fig. 5.21.
This enclosure is based on the thick walled version, Fig. 5.14 to ensure the implant is not
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Figure 5.21: a) 3D rendering of the final package design with internal PCB boards, catheter
and suture holes shown; b) 3D printed prototype prior to surgery.

damaged by the weight of the animal while implanted. The antenna port is removed for two
reasons. First, it is removed to prevent a possible failure point. As the antenna port must
be sealed with epoxy and dipped with silicone, it also must pass the flexible external antenna
through. Although, similar to the catheter hole, the antenna is much smaller in diameter and
is weaker than the catheter tubing which may lead to not bonding correctly with the epoxy /
silicone. Furthermore, the epoxy around the antenna may prevent flexibility on the antenna
leading to failure of the antenna or bio material entering the cavity. The second reason for
removing the port hole is the external antenna itself. Although the antenna is designed to
be flexible, it was observed to bend and in some cases fail when inserted into the phantom
tissue. In an in-vivo situation the antenna could bend at the output of the antenna port if forced
into tissue and cause significant failure of the implantable system. Therefore, the antenna and
antenna port are removed and replaced with an internal PCB antenna, Fig. 4.10(right). This
new package is printed in ABS–M30i plastic to ensure full bio–compatibility with the animal
subject and is more robust containing less failure points.
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PV System Calibration

This section will discuss the calibration process for both the pressure and volume electronics
where each block is calibrated again known loads.

5.3.1

Pressure Calibration

The pressure calibration is performed in three main stages. First, the telemetry system and a
PC running the ZMDI software are configured. This is followed by the pressure chamber setup
and culminating in a fully calibrated MEMS pressure sensor.

Electronic Setup
The electronic setup consists of: 1) the PV system that requires calibration; 2) the PV system
development module and breakout board; 3) ZMDI communication module; and 4) a Windows
PC to run the ZMDI software, Fig. 5.22. The PV system with ZMDI ZSC 31015 is connected
to the development module via the breakout board as described in Section 4.5.
The ZMDI communication module is connected to the development module using four
wires: VDD, GND, OWI, and Tr-D2, Fig. 5.23. Power and ground are supplied to the implant
via the VDD and GND pins on the communications module and programming the ZDMI IC
is achieved with the OWI and Tr-D2 pins. Power to the communications module is supplied
through the connected USB cable from the PC and the OWI pin is connected directly to the
pressure out pin of on the development module. Recall that the pressure output pin on the ZSC
31015 is also multiplexed with ZMDI’s custom one wire interface (OWI), along with additional
analog outputs which are used while the implant is in operation. To use the OWI for programming the additional pin, Tr-D2, is required. Tr-D2 is a GPIO pin controlled automatically in
the ZMDI software and is connected through a 3.3 kΩ resistor to the pressure output pin.
When the ZMDI calibration software starts, the user must open the COM port associated
with the connected communication module and initialize the hardware. When the user selects
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Figure 5.22: Pressure calibration experimental setup. Shown: PV system, Development Module / Breakout board, PC, Software. Not shown: ZMDI Communication Module.
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Figure 5.23: ZMDI Communication Module connection to Development module and PV system.
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Figure 5.24: ZMDI evaluation software kit software [28]. Copyright c ZMDI.
the initialize hardware button on the ZMDI software, Fig. 5.24 [267], the communication module will pulse the Tr-D2 pin causing the OWI pin to communicate with the ZSC 31015 IC,
placing it into read/write mode. At this stage, the user can change the IC’s output mode from
digital to analog, read the temperature data (if attached) and read the measured voltages. More
importantly, the IC can be put into calibration mode, where the specific calibration settings can
be changed.

Pressure Calibration Chamber Setup
The MEMS absolute pressure sensor is calibrated inside a fluid–filled pressure chamber that
allows for variations in temperature and pressure, Fig. 5.25. The catheter is inserted into one of
the six attached introducers integrated into the chamber. The pressure is controlled via a pneumatic pump and temperature is controlled by cycling water through a separate temperature
controlled tank. The pressure is cycled at a very low frequency sub–Hz for calibration. This
is to ensure there is ample time to make measurements in the ZMDI software when changing
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Figure 5.25: Pressure chamber used in pressure calibration.
pressures within the chamber. Temperature change from maximum to minimum typically takes
about an hour to cycle through due to the limits of the hardware used. An additional calibrated
temperature and pressure sensors are inserted into the chamber to provide an absolute pressure
and temperature reference for the calibration process. These sensor are measured on a separate PC running LabScribe [268] measurement software. This setup is used for all pressure
calibrations.

Pressure Calibration Process
Four point calibration is used to calibrate for the variation of the wheatstone bridge offset over
temperature and variation of the bridge gain over temperature thereby providing 1 st order temperature compensation. All calibration data is stored within the ZMDI ZSC 3105 IC at two
temperatures, 22.8◦C and 43.2◦C representing a wide range of temperature operation. However, in practice inside the animal, the sensor should see little variation due to the stability of
body temperature of 39◦C. The sensor is calibrated over a 450 mmHg pressure range, from
-135 mmHg to 315 mmHg. This range allows the pressure sensor to work within the expected physiological range of the swine left ventricle with headroom for atmospheric pressure
changes.
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The calibrated parameters are stored on the internal EEPROM located on the ZSC 31015
and are recalled upon startup. The pressure circuit is set to span the complete voltage range of
0 V–3.6 V, thus 8 mV per mmHg with a -135mmHg pressure offset, (5.2).

Pressure =

5.3.2

Voltage Output
− 135 mmHg
8mV/mmHg

(5.2)

Volume Calibration

The PV interface produces real and imaginary or in–phase and quadrature (I and Q) voltages
that are functions of the measured load, in this case the left ventricle blood impedance/conductance.
The PV interface is calibrated in two steps: a) creation of a calibration matrix to generate calibration coefficients and b) generation of system phase shift and voltage magnitude calibration
curves.

Volume Calibration Setup
The volume component of the PV sensor interface is calibrated against known RC loads instead
of the actual PV catheter. Since the current implementation of the PV interface module is best
suited for medium size animal hearts with typical volumes ranging from approximately 35 ml
to 85 ml, whose corresponding conductance values range between 10 mS–30 mS, resistive
loads in the RL = 30 Ω–100 Ω range are used. In addition, a variable capacitor value between 0
nF – 30 nF is used to represent the phase shift of the myocardium. Each known RC “standard”
is then connected between electrodes b and c of the catheter, Fig. 4.12 of the catheter to emulate
the ideal admittance value of the heart. This setup is used throughout the volume calibration
process.

Calibration Matrix
A calibration matrix or transformation matrix is created to transform the measured real and
imaginary voltages to the theoretical voltages at the sensor input, (5.3) where ITheo , QTheo rep-
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resent the theoretical voltages at the sensor input, (a) through (d) represent the calibration
coefficients and IMeas , QMeas represent the measured voltages of the PV interface output. The
theoretical voltages at the sensor input are derived from the excitation current IDrive , excitation
frequency in radians ω and the known R and C load, (5.4), (5.5).


 


I  a b I 
 Theo  
  Meas 

 = 


Q  c d Q 
Theo
Meas

ITheo =

R · IDrive
· R2 · ω2 + 1

(5.4)

C · R2 · ω · IDrive
C 2 · R2 · ω2 + 1

(5.5)

C2

QTheo = −

(5.3)

Thus, ITheo and QTheo are both functions of IMeas and QMeas . Two separate measurements
taken from the PV interface for two different load values will generate (5.6) from the calibration
matrix.
I1 = a · IMeas1 + b · QMeas1
Q1 = c · IMeas1 + d · QMeas1

(5.6)

I2 = a · IMeas2 + b · QMeas2
Q2 = c · IMeas2 + d · QMeas2
I1 , I2 , Q1 , Q2 are the theoretical real and imaginary voltages at the sensor interface found
by (5.4) and (5.5); IMeas1 , IMeas2 , QMeas1 , QMeas2 are the measured voltage outputs at the known
loads from the PV interface module thus calibration coefficients a, b, c, d are calculated from
(5.7) – (5.10).
The calibration coefficients used in the in–vivo experiment are found in Table 5.4 and 5.5
along with the RC loads, excitation current and frequency used to generate the coefficients.
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a=

IDrive · (QMeas2 · C2 2 · R1 · R2 2 · ω2 − · QMeas1 · C1 2 · R1 2 · R2 · ω2 + QMeas2 · R1 − QMeas1 · R2 )
(IMeas1 · QMeas2 − IMeas2 · QMeas1 ) · (C1 2 · R1 2 · ω2 + 1) · (C2 2 · R2 2 · ω2 + 1)
b=−

c=−

d=

166

IDrive · (IMeas2 · C2 2 · R1 · R2 2 · ω2 − · IMeas1 · C1 2 · R1 2 · R2 · ω2 + IMeas2 · R1 − IMeas1 · R2 )
(IMeas1 · QMeas2 − IMeas2 · QMeas1 ) · (C1 2 · R1 2 · ω2 + 1) · (C2 2 · R2 2 · ω2 + 1)

(5.7)

(5.8)

IDrive · ω · (QMeas2 · C1 · C2 2 · R1 2 · R2 2 · ω2 − · QMeas1 · C1 2 · C2 · R1 2 · R2 2 · ω2 + QMeas2 · C1 · R1 2 − QMeas1 · C2 · R2 )2
(IMeas1 · QMeas2 − IMeas2 · QMeas1 ) · (C1 2 · R1 2 · ω2 + 1) · (C2 2 · R2 2 · ω2 + 1)
(5.9)

IDrive · ω · (IMeas2 · C1 · C2 2 · R1 2 · R2 2 · ω2 − · IMeas1 · C1 2 · C2 · R1 2 · R2 2 · ω2 + IMeas2 · C1 · R1 2 − IMeas1 · C2 · R2 )2
(IMeas1 · QMeas2 − IMeas2 · QMeas1 ) · (C1 2 · R1 2 · ω2 + 1) · (C2 2 · R2 2 · ω2 + 1)
(5.10)

Table 5.4: In–Vivo Calibration Coefficients for PV Volume Interface.
a

b

c

d

1.07E-3

1.09E-3

-1.16E-3

6.21E-05

Table 5.5: In–Vivo Calibration Data for PV Volume Interface.
R1 [Ω]

R2 [Ω]

C1 [nF]

C2 [nF]

IDrive [µA]

Frequency [kHz]

33

100

0

30

46.5

20

110
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Figure 5.26: Ideal |Z| vs a) |Z|Calc ; b) |Z|Cal Method 1; c) |Z|Cal Method 2. The trend line is also
shown.
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Figure 5.27: Ideal φZ vs a) φCalc ; b) φZCal Method 1; c) φZCal Method 2. The trend line is also
shown.
Calibration Curves
Although, the calibration matrix transforms the measured output voltages to calculated values
at the sensor input, the matrix is truly only accurate at the two calibration points, |Z| = 33 Ω and
|Z| = 93.79 Ω, due to the inherent phase shift of the system, φSystem , Fig 5.26a and Fig 5.27a,
where |Z|Calc and φCalc are the calculated magnitude and phase of the impedance calculated
from the calculated output voltages from the calibration matrix with no additional calibration
across the calibration range. The system phase shift is measured by (5.11)
φSystem = φIdeal − φCalc

(5.11)

where φIdeal and φCalc are the ideal and calculated phase of the voltage signal at the sensor
for each load point. The system phase shift, φSystem , is not constant throughout the calibration
range, i.e, different loads will have different system phase shifts. More precisely, φSystem is a
function of the load itself, Fig. 5.28 and must be calibrated out to ensure accurate impedance
measurements.
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Figure 5.28: Ideal Load Resistance vs Ideal Load Capacitance vs System Phase Shift φSystem .

However, as the impedance is the intended signal of measurement, the exact relationship
to phase shift cannot be calculated directly with just the voltage values calculated at the sensor
input. Instead, solved RCalc and CCalc values from (5.12) and (5.13), where ICalc , QCalc are the
calculated voltages of the sensor input after matrix transformation, are used to calculate the the
system phase shift. Similar to the ideal case, the relationship between RCalc , CCalc , and φSystem
is found such that the system phase shift at any load point can be determined, Fig. 5.29.

a · IMeas + b · QMeas = ICalc =

RCalc · IDrive
CCalc 2 · RCalc 2 · ω2 + 1

(5.12)

CCalc · RCalc 2 · ω · IDrive
CCalc 2 · R2Calc · ω2 + 1

(5.13)

c · IMeas + d · QMeas = QCalc = −

A 3rd order xy polynomial fit (5.15) is used to approximate the surface where RCurve and
CCurve are normalized by the mean and standard deviation of their respected variables RCalc ,
CCalc (5.14). φSystemCalc , along with φCalc are then used to fully calibrate the phase of the
measured signal, φCal (5.16).

System Phase Shift [°]
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Figure 5.29: Calculated Resistance RCalc vs Calculated Capacitance CCalc vs System Phase
Shift φSystem .

RCalc − 54.49
25.99
CCalc − 32.05e−8
=
14.78e−8

RCurve =
CCurve

(5.14)

φSystemCalc = −4.862 + (−4.95 ∗ RCurve + (21.19 ∗ CCurve ) + (7.515 ∗ RCurve 2 ) + (12.58 ∗ RCurve ∗ CCurve )
+ (−1.687 ∗ CCurve 2 ) + (−1.386 ∗ RCurve 3 ) + (−0.1469 ∗ RCurve 2 ∗ CCurve )
+ (−1.692 ∗ RCurve ∗ CCurve 2 ) + (0.1044 ∗ CCurve 3 )
(5.15)

φVCal = φCalc + φSystemCalc

(5.16)

The voltage magnitude is also calibrated with a similar process to the phase. The calculated
voltage magnitude at the sensor is subtracted from the ideal voltage magnitude to obtain the
magnitude difference at each calibration point (5.17).

|V|Difference = |V|Ideal − |V|Calc

(5.17)

As with the phase shift, the magnitude difference is used along with RCalc and CCalc to

Voltage Sensor Magnitude [mV]

Chapter 5. In–Vitro Characterization

170

2
1
0.5
0

50

40

30

20

Capacitance Calculated [nF]

10

0

30

40

50

60

70

80

90

100

Resistance Calculated [ohm]

Figure 5.30: Calculated Resistance RCalc vs Calculated Capacitance CCalc vs |V|Difference .
create a surface fit, Fig. 5.30. A 3rd order xy polynomial fit (5.18) used to approximate the
surface, RCurve and CCurve are calculated in (5.14)

|V|DifferenceCalc = −124.5E −6 + (−751.9E −6 ∗ RCurve ) + (656.8E −6 ∗ CCurve ) + (411.4E −6 ∗ RCurve 2 )
+ (725.6E −6 ∗ RCurve ∗ CCurve ) + (−8.016E −5 ∗ RCurve ∗ CCurve 2 ) + (101.2E −6 ∗ RCurve 3 )
+ (317.4E −6 ∗ RCurve 2 ∗ CCurve ) + (9.603E −5 ∗ RCurve ∗ CCurve 2 ) + (4.296E −5 ∗ CCurve 3 )
(5.18)
For each calibration point the calculated |V|DifferenceCalc is added to |V|Calc to obtain the
calibrated |V|Cal at the sensor input (5.19).

|V|Cal = |V|DifferenceCalc + |V|Calc

(5.19)

Thus, the calibrated impedance is calculated with |V|Cal , φVCal and IDrive . The average
phase error across the calibration range is 0.2◦ with a strong linear correlation with a R2 value
of 0.9983 compared to the ideal phase, φIdeal , expected, Fig. 5.27b. The average impedance
magnitude error across the calibration is 0.211 Ω with a R2 value of 0.9998 compared to the
ideal impedance magnitude, |V|Ideal , expected, Fig. 5.26b.
Although, the above calibration method is very accurate in obtaining calibrated impedance

|V|Difference Prime [V]
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Figure 5.31: Measured Voltage Magnitude |V|Measured vs Measured Voltage Phase φMeasured vs
|V|Difference 0.
values, the process to solve RCalc and CCalc is computationally intensive. A secondary calibration method that does not involve RCalc and CCalc is developed. This method involves mapping |V|Measured and φMeasured (5.20) (5.21) to |V|Difference 0 and φSystem 0, respectively. Recall,
|V|Measured and φMeasured are the direct outputs of the PV system.

|V|Measured =

q

IMeas 2 + QMeas 2

φMeasured = tan−1

Q Meas 2
IMeas 2

(5.20)

(5.21)

Note that |V|Difference 0 and φSystem 0 are different calculations (5.22) (5.23) in this calibration
method compared to the previous method due to the values they are calibrated to, hence, the
prime notation.

|V|Difference 0 = |V|Measured − |V|Ideal

(5.22)

φSystem 0 = φMeasured − φIdeal

(5.23)

Similar polynomial fit equations, (5.25) (5.24) are used such that |V|Difference 0 and φSystem 0
can be calculated from |V|Measured and φMeasured , Fig. 5.31 and Fig. 5.32.
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Figure 5.32: Measured Voltage Magnitude |V|Measured vs Measured Voltage Phase φMeasured vs
φSystem 0.

φSystemCalc 0 = 79.82 + (10.1 ∗ |V|Curve ) + (21.88 ∗ φCurve ) + (−1.394 ∗ |V|Curve 2 )
+ (4.942 ∗ |V|Curve ∗ φCurve ) + (−1.106 ∗ φCurve 2 ) + (0.3014 ∗ |V|Curve 3 )
+ (0.02437 ∗ |V|Curve 2 ∗ φCurve ) + (1.612 ∗ |V|Curve ∗ φCurve 2 ) + (0.7769 ∗ φCurve 3 )
(5.24)

|V|DifferenceCalc 0 = 2.38 + (0.5885 ∗ |V|Curve ) + (687.4E −6 ∗ φCurve ) + (247.8E −6 ∗ |V|Curve 2 )
+ (698.4E −6 ∗ |V|Curve ∗ φCurve ) + (5396E −6 ∗ φCurve ∗ φCurve 2 )
+ (−2.63E −5 ∗ |V|Curve 3 ) + (361.4E −6 ∗ |V|Curve 2 ∗ φCurve )
+ (326.9E −6 ∗ |V|Curve ∗ φCurve 2 ) + (536.3E −6 ∗ φCurve 3 )
(5.25)
where

|V|Measured − 2.384
0.588
φMeasured − 69.33
=
16.58

|V|Curve =
φCurve

(5.26)

This results in the calculation of the calibrated sensor voltage magnitude and phase (5.27)
and (5.28).
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|V|Cal 0 = |V|Measured − |V|DifferenceCalc 0

(5.27)

φCal 0 = φMeasured − φSystemCalc 0

(5.28)

The average errors across the calibration range are 0.2139 Ω and 0.2263◦ for the impedance
magnitude and phase respectively. The R2 values are 0.9997 and 0.9976 for the second calibration method’s impedance magnitude and phase respectively, Fig. 5.26c and Fig. 5.27c .
It can be seen that the second method is slightly less accurate in producing calibrated values
however, it is less computational intensive thus faster to implement. For the in–vivo experiment described in this thesis, the first calibration method was used as all data processing was
done offline thus computation complexity was not an issue and data accuracy was of great importance however, for on-chip calibration implementation the second method should be used.
Conversion to admittance and then to a volume is not discussed in this section and will be
discussed in the following chapter.

Calibration Methods Calculation Summary
A summary of each calibration method is shown below. Both the inital generation of calibration
curves along with how to calibrate and calculate any measured load.
Calibration Method 1:
Generation of calibration curves:
1. Generate transformation coefficients a, b, c, d
2. Calculate RCalc , CCalc , Ideal sensor voltage |V|Ideal φIdeal , φSystem , |V|Difference at each
calibration point
3. Generate polynomial fit for:
(a) RCalc vs CCalc vs φSystem
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(b) RCalc vs CCalc vs |V|Difference
Find calibrated impedance, |Z|Cal and φZCal , at any value after initial calibration curves
generated:
1. Calculate ICalc , QCalc , with transformation coefficients a, b, c, d
2. Solve for RCalc , CCalc using known frequency, current, ICalc , and QCalc
3. Plug RCalc , CCalc into polynomial fit equations to solve for φSystemCalc and |V|DifferenceCalc
4. Calculate calibrated sensor voltage |V|Cal and φCal
5. Calculate calibrated load impedance |Z|Cal and φZCal
Calibration Method 2
Generation of calibration curves:
1. Calculate ideal voltages (|V|Ideal , φIdeal ) and measured voltages (|V|Measured φMeasured ) at
each calibration point
2. Calculate|V|Difference0 and φSystem 0 using ideal and measured voltages
3. Generate polynomial fit for:
(a) |V|Measured vs φMeasured vs |V|Difference0
(b) |V|Measured vs φMeasured vs φSystem 0
Find calibrated impedance, |Z|Cal 0 and φZCal 0, at any value after initial calibration curves
generated:
1. Calculate |V|Measured and φMeasured using the output voltages of the volume module I Meas
and Q Meas .
2. Plug |V|Measured and φMeasured into polynomial fit equations to calculate |V|DifferenceCalc0
and φSystemCalc 0
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3. Calculate calibrated voltages |V|Cal 0 and φCal 0
4. Calculate calibrated impedance |Z|Cal 0 and φZCal 0

5.4

Dynamic PV Loop Evaluation

Prior to the in-vivo study the PV system must be evaluated dynamically to test various aspects
of the system including battery life, pressure volume loops, control architecture, etc. Static
testing is relatively easy to achieve, for example, static pressure tests can be completed by
placing the catheter inside a sealed tube and creating a vacuum. Static volume tests are also
relatively simple to complete. Typically a cuvette containing salt water with a set volume is
used. Here, the catheter is placed in the cuvette and the corresponding output values from
the PV system are measured. Combining both pressure and volume as well as making them
change at the same time is more difficult. A pneumatic system is used to achieve this. Designed
in-house by Transonic Scisense, this “Volume Pulser’ is designed to change its pressure and
volume at a set frequency, Fig. 5.33. Similar professional solutions exist, [269], however, they
are quite costly, thus not used here.
Due to design constraints the “Volume Pulser” is only able to emulate very low heart rates
and medium sized volumes, however, it is still able to generate proper cycles to measure PV
loops. The catheter, attached to the PV system, is inserted into the fluid filled volume chamber
where the catheter is able to measure the change in pressure and volume. The PV system is
typically wired into the development module to allow access to the power supply and additional
testing signals. The measured data is sent to the Rx Unit, Section 4.8, where the data is received
and processed. The processing and viewing software developed in LabView will be discussed
in the following chapter.
Battery life testing is performed using this setup and the implant is placed in a combination
of the three modes described in Section 4.7.2. Various tests were run to confirm the current
consumption results in Section 4.7.3. For example, the implant was placed in duty cycle mode

PressuredCalibration
Chamber

Catheterd
Introducer

PVdTelemetrydSystem

PulserdPVd
Chamber

Figure 5.33: Volume Pulser with PV implant, Catheter, PV chamber, Labview interface shown.

LabViewdCustomdProgramd
fordDatadProcessing

PVdTelemetrydSystem

Wirelessd2.4dGhzd
RFdDatadTransfer

40dmAhdBattery
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Figure 5.34: Measured battery life with a duty cycle of 2 min on and 2 min with various Rx
cycles.
operating on a 2 min on, 2 min off cycle with additional Rx cycles mixed in, lasting approximately 16.5 hours, Fig. 5.34. An additional longer test with a different duty cycle is also
shown, Fig. 5.35. Here, the battery lasted approximately 58 hours. These tests were repeated
with different measurement intervals along with different RF power settings to give an outline
of the typical battery life.
Along with battery life, the control architecture is also tested at this stage. Various aspects
of the system are tested including timing, data operation and validity, implant range, etc. In
addition, the implant is tested inside its enclosure to ensure no data loss occurs. Testing in the
“Volume Pulser” is the final stage before implanting the system inside a live animal.
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Figure 5.35: Battery life of implant in an extended duty cycle.

5.5

Conclusion

In this chapter the in-vitro characterization of the implantable telemetry system is presented.
The outcome of the phantom tissue study [257] study helped to determine the minimum RF
output power that the transmitter (T x ) needs to provide to still receive data from the implant
while having minimum power consumption in a typical medical measurement environment,
i.e., instrument noise, non ideal antenna matching, spectrum interference, etc.
A custom implant capsule was designed and printed with four materials (3 plastic, 1 metal).
The implants were evaluated by a 98 day and 1 week water immersion study. Although minor moisture occurred, ABS–M30i is chosen for future implant capsules as to ensure bio–
compatibility, high strength and precision when compared to ABS and RDG720. The stainless
steel capsule provided the highest precision among the four materials however, additional post–
processing time is required. Further studies are required to determine the cause of membrane
reactions and the exact failure point of the ABS–M30i package.
Calibration of the pressure and volume electronics were presented. The MEMS absolute
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pressure sensor was calibrated inside a fluid–filled pressure chamber that allows for variations
in temperature and pressure. Four point calibration was used to calibrate for the variation of
the wheatstone bridge offset over temperature and variation of the bridge gain over temperature
thereby providing 1 st order temperature compensation. All calibration data is stored within the
pressure IC at two temperatures, 22.8◦C and 43.2◦C representing a wide range of temperature
operation. The sensor was calibrated over a 450 mmHg pressure range, from -135 mmHg to
315 mmHg.
Two calibration methods for the volume electronics were presented. The average errors
across the calibration range for the first calibration method are 0.211 Ω and 0.2◦ for the
impedance magnitude and phase respectively. The average errors across the calibration range
for the second calibration method are 0.2139 Ω and 0.2263◦ for the impedance magnitude and
phase respectively. The first calibration method is used in the in–vivo study.
Dynamic PV loop evaluation was provided through the use of a custom designed system,
“Volume Pulser”. Here, battery life, dynamic PV loops and control architecture were tested.
This is the final stage of testing before implanting inside of a live animal subject.

Chapter 6
In–Vivo Implant Characterization ∗
In this chapter, details of the in-vivo study are presented. The PV telemetry system designed in
Chapter 4 was evaluated in a 65kg swine (pig). The implant study was performed by a trained
group of surgeons at Western University Veterinary Services in accordance with the approved
ethics protocol AUP Number: 2014-003. The study was designed to evaluate the PV system
in a non–anaesthetised test subject, i.e., freely moving animal. In addition, the study was
completed to determine initial catheter-heart interaction. Data was collected via the RF link
from the implant to an external laptop. The implant is designed to transmit raw voltages, thus
additional data processing is completed at the receiver side to process the data into calibrated
pressures and volumes.
This chapter is separated into two major sections. First, design details of the custom measurement application are presented in Section 6.1 followed by a comprehensive analysis of the
in-vivo study in Section 6.2.

6.1

LabView Custom Measurement Application

In Chapter 4 details of the wireless receiver unit were discussed with a focus on the hardware
development. The initial software solution for data viewing was presented, however, the soft∗

Portions of this chapter are published in BIOCAS 2015 [270] and Spring Biomedical Devices journal [240].
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Figure 6.1: Custom application front end: Receive data interface.

ware was only able to display the raw I, Q, and P values and did not include any additional
processing, calibration, or graphing capabilities. In addition, viewing the raw data in a serial
communication window is not ideal in a surgical environment. As traditional pressure–volume
(PV) measurement systems are directly tethered to their end communication boxes, real–time
data can be viewed and captured with no impact on battery life or signal quality. In implantable
devices sending a constant stream of data to display will have a great impact on battery life.
Nevertheless, the data displayed is of great importance to the operating surgeons who may have
to adapt their movements to the incoming data.
To overcome these challenges, a custom application is created in National Instruments
LabView to further process, log, and display the implant data, Fig. 6.1. Furthermore, it is also
important to send information back to the implant in order to change various aspects of the
control system including transmission power, acquisition mode, etc, Fig. 6.2. The following
subsections describe the serial protocol setup, reading data transferred from the implant, writing data to the implant, and finally some limitations with the initial version of software.
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Figure 6.2: Custom application front end: Send data interface. Application can change Tx
power, acquisition modes, receive and duty cycle times using a single byte transmission.
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Serial Port Setup

All serial port settings are setup through the graphical user interface (GUI) of the application.
Rather than hardcode these into the application, it is more appropriate to have these settings
change by the user. The main information that the user must provide to receive data are the
baud rate and the COM port used. This allows different hardware receivers with different baud
rates to be used. In addition, the COM port will change based on which USB port is used, thus
it is important the user be able to change the COM port used. The serial port is setup to receive
data at a baud rate of 115200 with no hardware handshaking. If the setup fails or the receiver
is disconnected at any point during the programs opperation, an error flag is presented asking
the user to reconnect or check the serial settings.
An array is used to buffer the incoming data before it is processed by the internal program.
This is to ensure any delays caused by the graphing or data logging in the internal program will
not cause dropped packets or a loss of information. All data will be received unless the user
chooses to send information to the implant via the send button.

6.1.2

Data Read

The incoming data from the wireless receive unit is processed in five steps: 1) string splitting,
2) covert integers to voltages, 3) log data, 4) convert to real and imaginary voltages, ) and
graphing end data, Fig. 6.3.
Recall from Chapter 4, that the incoming packet format is IIIIQQQQPPPP (12 bytes), this
incoming string must be first separated into individual I, Q and P values. A separate VI (LabView sub-program) is used to complete this function. Offsets are used to separate each 4 byte
ASCII representation of I, Q, P.
Following string splitting, each string is converted into their corresponding integer value.
Each integer represents a register value from the ADC and thus must be converted into a voltage
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Figure 6.3: LabView application block diagram including sub-blocks: Rx Unit, serial config,
read, split string, convert to voltage, convert to |Z|Meas and φMeas , calibrate pressure, and XY
plot.

using (6.1).
Voltage =

Input
1023/3.6V

(6.1)

At this stage, the raw I Meas , Q Meas , and pressure voltages are graphed in both short and long
term graphs, Fig. 6.1. The graphs are useful, in that they enable the user to ensure that there
is incoming data, however, they do not indicate any true physiological values at this point,
due to lack of calibration, Section 5.3.1 and 5.3.2. Major failures or data inconsistances can be
detected at this point. For example, if both I and Q values are railed at 3.6 V there is most likely
an issue with the implant. Similarly, if both are grounded there also may be an issue. Viewing
both the volume output channels I Meas , Q Meas and Pressure output channel (voltage) can also
indicate possible failures, as the measured data is from the heart and therefore periodic, all
channels must match the same frequency or heart rate. If one or more channels is incorrect
then most likely a failure has occurred.
All raw data is saved to disk at this point in the application before any additional changes
are made to the raw data. This allows the data to be modified and fully calibrated after the experiment is complete. In initial implementations of this application, the data was saved to disk
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in Microsoft Excel format. This allowed for ease of use when reading back the information and
simple processing. However, the speed of the program was greatly impacted. The delay was
due to the opening and closing of Excel each time a data point is saved, rather than the application itself. Furthermore, if Excel is used, the update delay will increase over time impacting
if the user needs to react to the changing signal. For example, when Excel data logging was
used the delay increased to minutes after a five minute period of data logging. Therefore, it is
reccommended to use Excel data logging only for very slow signals where signals do not need
to be reacted to. Alternatively, LabView’s proprietary format, TDMS is used. The main reason
to use the TDMS format over the Excel format is that a TDMS file can be left open throughout
the whole data logging process. The files are created when the application begins and all write
operations are done on these files without opening or closing the main file. The files are all
closed when the application is ended by the stop button. Another advantage is that if there is
a connection failure midway through the data logging process, all data is still saved based on
the TDMS format architecture. Date and time information is saved as header information in
the file as well. A disadvantage of using this format is that it requires a special plugin from
National Instruments in order to read the files in Excel. Once opened, each file can be saved in
any format (CSV, Excel, Txt, etc) required by the user.

At this stage, I Meas , Q Meas are converted to |Z|Meas and φMeas for display purposes only. They
are displayed in graphs for the user to view, Fig. 6.1. Although not calibrated, the measured
signals will display patterns in the measured signal including phase increases. For example,
the phase will greatly increase if the catheter is close to the left ventricle wall regardless if the
system is fully calibrated. The pressure calibration (6.2) is hard coded into the application as
it calibrated separately and not computationally intensive unlike the volume calibration.
Pressure =

Voltage Output
− 135 mmHg
8mV/mmHg

(6.2)

The calibrated pressure is displayed in both a graph and in a large numeric indicator, Fig. 6.1.
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The numeric indicator’s purpose is to provide a straightforward view of the pressure value in
mmHg. This value will indicate to the surgeon if they have guided the catheter into the LV,
based on the expected pressures..
The calibrated pressure signal is plotted against |Z|Meas to create a loop, Fig. 6.1. Although,
this is not a pressure vs volume loop, the size and shape are still useful information for surgeon.
The volume and admittance are not shown in this version of the application as calibration is
done offline (after the experiment). Furthermore, this version’s main use is to indicate the
implant is operational and that the catheter has entered the LV. Data quality and accuracy of
the system is determined after the calibration and data analysis are completed.

6.1.3

Remote Implant Data Write

The LabView application also provides the ability to send commands back to the implant to
change various aspects of the system including three main categories: transmission power,
acquisition mode, and receive mode. The user selects which commands are to be sent from the
application GUI, Fig. 6.2. The user is able to select if any of the three main categories should be
changed in the implant, each with its own sub-settings to send to the implant. The commands
are encoded into a single byte packet in order to conserve battery and limit the amount of
transmissions required. Thus, only a limited amount of combinations and commands can be
sent. In some cases, bits will be multiplexed, more on this below. Transmissions can be sent at
any time during the program by configuring the drop down menus and hitting the send button
on the application. However, they will only be received when the implant is switched into
receive mode, i.e., implant transceiver is in Rx. Described in Section 4.7, the implant will enter
receive mode at set time intervals determined by the user before implantation. As a result, it is
very important to keep track of the time when the implant will enter receive mode for the first
and subsequent times.
The packet format is X7 X6 X5 X4 X3 X2 X1 X0 with each bit’s function described in Table 6.1.
The acquisition mode type is determined by the bit X0 . If this bit is 0 the implant will enter
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Table 6.1: Rx to Implant Packet Format
Bits

Function

X0

Acquisition Mode Type

X2 X1

if X0 = 1 – Duty cycle mode times
if X0 = 0 – Rx duty cycle times

X3

Change implant Tx power

X4

Change Rx Duty Cycle

X5

Change Acquisition Mode

X7 X6

Implant Tx Power Level

continuous mode, i.e., sample and transmit continuously until a set Rx timer, or if 1 the implant
will enter duty cycle mode. Bits X4 and X5 are used as control switches to change Rx Duty
Cycle and Acquisition Mode, respectively. These bits must be 1 in order for X0 and X2 X to be
valid.
Bits X2 X1 are used to control the specific time intervals (on and off) in the Rx and Duty
Cycle modes. Rather than only four time options available (2 bit) and used for both Rx and
Duty Cycle modes, the bits are multiplexed to allow for different options for each with only 2
bits. A combinational logic switch is used to ensure only 1 mode is valid at a time and if both
(change Rx and change Duty Cycle) are set to high, Rx duty cycle changes will take priority,
Fig. 6.4. The truth table is shown in Table 6.2. If both modes required to be changed, two
transmissions are required. The LabView application does not directly send timing information
as it only sends a 2 bit combination that the implant will decode into a specific on and off time.
These on and off times must be hard corded into the implant before use. A wide variety of on
and off times are chosen for the in-vivo study, Table 6.3, providing the user with flexibility in
acquisition modes.
The implant transmission power is changed when X3 is set to 1. Bits X7 X6 are used to
control the specific Tx output power level used. Power levels are chosen based on the results of
the phantom tissue study, Section 5.1.3, and range from a minimum of -12dBm to a maximum
of 1 dBm. As with the Rx and Duty cycle modes, the Tx output power levels are hardcoded
into the implant’s control code before implantation.
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If output = 0
Rx Duty Cycle
Times = X2X1

Acquisition Mode
Change Acquisition
Mode

If output = 1
Duty Cycle
Times = X2X1
Change
Rx Duty Cycle

Figure 6.4: Combinational logic used such Rx changes take precedence over Duty cycle
changes for bits X2 X1 .

Table 6.2: Combinational Logic Truth Table
Acquisition Mode

Change Acquisition Mode

Change Rx Duty Cycle

Output

0

0

0

0

0

0

1

0

0

1

0

0

0

1

1

0

1

0

0

0

1

0

1

0

1

1

0

1

1

1

1

0

Table 6.3: Duty Cycle and Rx On and Off times used in in-vivo experiment
Bits

Duty Times

Rx Times

00

1 min Sampling, 9 min off

1 min on in Rx, 30 min off

01

30 sec Sampling, 9.5 min off

2 on, 1 hr off

10

5 min Sampling, 5 min off

5 min on, 2 hr off

11

1 min Sampling, 59 min off

30 sec on, 2 min off

Chapter 6. In–Vivo Implant Characterization

189

When the implant receives this data, the packet is decoded and each option is processed
separately. The implant will remain in receive mode until the Rx timer expires, enabling multiple commands to be sent and received from the external unit. This implementation of the
custom LabView application is used in the in-vivo study.

6.1.4

Limitations of Application V1

This initial application, although much improved over the basic raw data viewer, still has several limitations. First, as all the calibration is completed offline, there is no built in calibration
into the program. This prevents real time calibrated admittance and volume to be displayed.
Furthermore, true PV loops cannot be displayed without the volume being converted in real
time. A major limitation of using LabView to create a custom application is its lack of resolution scaling. It is very difficult to view all graphical data, implant settings and file settings all
in a single window, hence, the requirement of tabbed windows. Moreover, additional graphs
and data logging points should be added to provide the user with more beneficial information.
In terms of receive unit to implant communications, it is not ideal for the user/surgeon to know
ahead of time the possible measurement cycles or power levels required. Thus, it would be
better to directly send the value rather than selection flags, i.e sending the register value for
1dBm. However, by using this method, the Rx unit to implant packet size would increase.

6.2

In–Vivo Study

The PV system designed in Chapter 4 and characterized in Chapter 5 is evaluated in–vivo using
a swine also known as a pig. An initial experiment involving a pig was completed, however
it was unsuccessful due to medical complications with the animal unrelated to the experiment.
The animal was euthanized in accordance to the ethics protocol. All procedures and results of
described in this chapter refer to the second in-vivo implantation with a similar sized pig.
This section presents all aspects of the study including implant preparation, data collection,
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tissue analysis, etc. A detailed discussion is provided explaining the issues encountered in the
study along with future recommendations. A comparison to previous published works is also
provided in the discussion.

6.2.1

Experiment Overview

The implant study was performed at Western University Veterinary Services by a trained surgical and technical team. This team consisted of Filip Konecny (Transonic Scisense Inc.),
Alexander El-Warrak (Veterinary Services, Western University) , Heather Cadieux-Pitre (Veterinary Services, Western University ), Tracy Hill (Veterinary Services, Western University ),
and Chad Hodgson (Transonic Scisense Inc.). All surgical procedures were performed by Filip
and Alexander with assistance provided by Heather and Tracy. Additional technical support
was provided by Chad Hodgson. The medical procedure and monitoring was performed in accordance with the approved ethics protocol AUP Number: 2014-003. The study was designed
to evaluate the PV system in a non–anaesthetised test subject, i.e., freely moving animal. In
addition, the study was completed to determine initial catheter-heart interaction.

6.2.2

Implant Preparation

To plan for any possible hardware failures, two implants were prepared for the in–vivo surgery.
Each implant was identical and calibrated using the process described in Section 5.3. The
catheter is inserted into the enclosure and the 7 sensor wires are attached to the top pads on the
telemetry system, Fig. 6.5. The catheter opening is sealed inside and out to prevent the catheter
from moving when in use. Prior to full encapsulation, the system is tested inside the volume
pulser and various sized cuvettes to ensure no hardware faults are observed.
The implant is placed in a custom power up routine where the system will enter duty cycle
(1 min on and 2 min off) mode for 7 min at which time the implant enters receive mode to
receive instructions from the Rx unit. This routine includes multiple data collection cycles to
ensure the implant powers on properly after battery connection and that no hardware faults oc-
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Figure 6.5: Seven sensor wires fed through the catheter into the enclosure attached to the
telemetry system.
curred when reassembling the PV system. Entering receive mode during the start up sequence
enables the user to choose the measurement cycles at later time rather than hard code them into
the control architecture before encapsulation. More importantly, this receive window allows
the user to change the Rxtime off to a longer interval to reduce power consumption, i.e. 1 h, and
the user is able to place the implant in sleep mode. This is important as the implant is fully
encapsulated typically 24 h before implantation, the implant must be in sleep state to prevent
excessive and unnecessary power loss during non-operational times. An Rxtime off interval of 1
h and Rxtime on of 1 min are used in this experiment while the implant is cured. Both implants
are sealed and encapsulated as per the process described in Section 5.2.2 and allowed to cure
for 24 h. Once cured the implants are placed in sealed packages for transport, Fig. 6.6.

6.2.3

Telemetry System Implantation Procedure

A 65 kg Yorkshire farm pig was placed under general anesthesia on a dorsal side position. The
animal was kept heparinized to achieve an active clotting time of more than 250 seconds. The
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Figure 6.6: PV telemetry system fully enclosed in ABS-M30i package and dipped in silicone.
Package used for transport.

right carotid artery (RCA) was exposed through a 7-9 cm long standard ventral neck surgical
approach. The artery was isolated using stay sutures to allow the insertion of a 18-gauge, 2
3/4-inch Seldinger needle. Round tipped 0.038-inch Seldinger guidewire was inserted through
the needle’s lumen into the RCA. The needle was withdrawn and a guidewire used to direct the
ClassicSheathTM splittable haemostatic introducer (Merit Medical Systems Inc. UT, USA), of
the luminal size 7F to accommodate the 5F catheter. Prior to insertion into the LV, the implant
and PV catheter were sterilized with Cidex disinfectant solution (Advanced Sterilization Products, USA). The catheter was secured in place with multiple sutures. The catheter, Fig. 4.4.1,
was fluoroscopically guided into the LV via the carotid artery. The position of the catheter sensors was achieved by fluoroscopy and by obtaining an optimal pressure, I, Q values via the RF
link, Fig. 6.7. It was noticed on fluoroscopy that the tip of the sensing electrode was fractured.
Based on the readings it was decided at this point to secure the catheter to the muscle layer
using multiple anchoring sutures to prevent the catheter from exiting the LV. The telemetry
system and the remaining excess catheter tubing was coiled and placed in the neck region and
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Figure 6.7: Fluoroscope image of 5F PV catheter inserted in the left ventricle.
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Figure 6.8: PV system implanted in neck region of test subject PV catheter inserted into LV
via carotid artery.

anchored with simple interrupted sutures. The surgical site was closed using simple continuous
patterns on the muscle and subcutaneous layers using a 3-0 Vicryl, Fig. 6.8, where 3-0 is the
size of the suture fiber and Vicryl is the type of suture.
The skin was closed using a subcutilar pattern using 4-0 Vicryl and tissue glue. The final
implant location of the implanted telemetry system was confirmed with fluoroscopy, Fig. 6.9.
The neck region was selected for the implant location due to its proximity to the carotid
artery. Alternative options were explored which included locating the implant in the backside
of the animal with a tunneled catheter to access the carotid artery, however, this can cause
unnecessary trauma to the animal and was not used. An alternative approach to access the LV
is through the apex of the heart. Open heart surgery is required for this method and is preferred
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Figure 6.9: Fluoroscope image of wireless pressure–volume system implanted inside swine
model.
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Table 6.4: Physiological and Physical Paramaters used in Volume Conversion Using Wei’s
Equation
ρ [Ω − m]

σ/

Segmentation Length [mm]

Stroke Volume (SV) [ml]

1.3

800k

30

54

by some surgeons. If the apex of the heart is chosen as a access route to the LV, an alternative
implant location should be explored. Ultimately, it is the decision of the surgeon of where the
implant will be placed and how the left ventricle is accessed.

6.2.4

Implant Data Collection

Data collection is separated into two observation periods: a) acute and b) freely moving where
a) represents data collection while the animal was under anaesthesia and b) represents live
data collection from the freely moving swine model. During both observational periods, no
abnormal clinical nor behavioural changes were detected. The subject was monitored with
accordance to the approved ethics protocol.
In both observation periods, raw data was collected and converted to volumes offline. Pressure was converted in real-time as described in Section 5.3.1. Raw values were calibrated
and converted to impedance using the method described in Section 5.3.2. Following calibration, the impedance was converted into admittance and finally into a volume using Wei’s
equation [228, 229, 231], Section 3.1.2. In this study, the parameters: electrical conductivity
and permittivity of the myocardium and blood resistivity are determined based on previous
research [33, 231]. These along with the physical catheter measurements are used to the conversion from admittance to volume using Wei’s equation (3.6), Table 6.4.

Acute Observation
The acute observation period represents the typical data collection environment utilized by
commercial PV systems where the animal is anesthetized and a trained surgeon operates and
controls the catheter placement within the LV. The implant was placed in duty cycle mode (2
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Table 6.5: Extracted Physiological Data From PV Loops
Observation

SV

EDP

ESP

EDV

ESV

EF

HR

Period

[mL]

[mmHg]

[mmHg]

[mL]

[mL]

[%]

[bpm]

Acute

50.9

10.42

118.30

77.32

26.44

65.8

156

Free Moving

46.0

4.90

111.08

71.30

25.70

64.1

174

Distorted

9.71

4.42

128.85

56.72

47.01

17.1
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min on and 2 min off) while the surgeon guided the catheter into the LV, data was displayed
in the custom LabView application on an external laptop. Data was observed prior to surgical
closure to ensure proper data quality and catheter location within the LV, Fig. 6.10.
As noted above, the telemetry system was secured in the neck region, this was due to
surgical recommendations. Although the telemetry system was more secure in this location, the
additional tissue in this region impacted the default transmission power. This was not a major
issue during initial measurement periods while the surgical opening was exposed allowing
the antenna to radiate freely. However, once closed, the additional tissue greatly degraded
the signal strength, and in turn reduced the receive range from meters to a few centimeters.
Therefore, the output transmission level had to be increased to from -12dBm to 1dBm to ensure
a high quality data link.
Furthermore, various physiological events were monitored including the animals breath
held. Average stroke volume (SV), End Diastolic Pressure (EDP), End Systolic Pressure (ESP),
ejection fraction (EF), and heart rate (HR) during the acute observation period are shown in
Table 6.5.
The goal of this study is to evaluate the PV system in a freely moving animal and not to
perform drug based studies. Thus, there were no drug infusions in this study, only baseline
measurements are made while the animal is anaesthetised. Furthermore, multiple animal studies are required for a more comprehensive physiological study. In this study, aspects of the
PV telemetry system are evaluated with respect to its overall performance and not the specific
physiological changes in the animal. However, it is still greatly important to evaluate the efficacy of the PV telemetry system versus traditional tethered approaches. It is only valid to

LV Pressure [mmHg]
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Figure 6.10: A sample of data collection during acute measurement phase where a) LV pressure; b) LV Volume; and c) PV loop.
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Table 6.6: Comparison of Physiological Paramaters with those from [33]
Works
[33]
This work
(Acute)

EDV

ESV

EF

[mm]

[mm]

[%]

72.7

39.8

47.13

77.32

26.43

65.8

compare approaches in the typical measurement environment of an anaesthetised subject with
a fully open wound. Ideally, the most suitable method of comparison would be to insert a traditional catheter into the LV that is tethered to an external Advantage ADV500 processing unit
(Transonic Scisense Inc.), Fig. 1.4 [3], and perform baseline measurements, Chapter 1. This
setup is used in most measurement environments. However, by doing this, it would introduce
additional risk to the animal and would jeopardize the main goal of the in–vivo study. Instead,
the implantable PV system’s measurement values, more specifically, volumes are compared to
ones found in [33]. Kutty et. al. [33] presented a detailed study comparing the LV volumes of
8 pigs measured using the admittance technique (same catheter technology used in this thesis)
and using real-time three-dimensional echocardiography. This paper is chosen as a comparison because similar catheters and equipment are used as what is used in this in-vivo study.
Furthermore, similar sized pigs are used in [33] as is in this study. Kutty et al. demonstrates
that admittance measurements have acceptable correlation with real-time three-dimensional
echocardiography. Thus, it is valid to compare our measured data with the baseline data for
admittance found in [33] for initial validation only. A comparison of End-diastolic volume
(EDV), End-systolic volume (ESV) and EF values from [33] and measured data from the acute
observation period is shown in Table 6.6. Note, the values from [33] used in Table 6.6 are
averaged values taken from 8 pig measurements during baseline, Table 1 in [33]. The volume measurements from the PV telemetry system correspond with those measured using the
traditional admittance catheter approach.
The variation in the ESV and EF is most likely due to animal to animal variability and
does correspond with individual pig measurements found in [33]. It is expected that our PV
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telemetry system would exhibit similar results over a larger animal study. The comparison is
not valid for infusion as our study does not involve additional drugs. It should be noted that, as
every animal is slightly different, each will exhibit slightly different physiological parameters.
Furthermore, depending on the specific surgery performed, it may impact measurement results.
A larger study involving multiple animal subjects is planned in future work to further evaluate
the PV system and to do a full comparison with other measurement methods. However, it can
be shown that our implant achieves the same data quality as traditional methods while unders
similar measurement and surgical conditions.
A similar study published by Van Hout et al. [236], compared admittance based pressurevolume loops vs magnetic resonance imaging in 14 pigs. The results of this study indicate that
admittance based measurements moderately overestimates LV volumes but is very accurate for
ejection fraction when compared to MRI. A different measurement protocol was used in [236],
thus it cannot be compared directly with this work. All animals underwent a procedure to simulate a myocardial infraction followed by a 8 week recovery time. No baseline measurements
are provided. However, this represents a valid resource when comparing admittance based PV
loops vs MRI.

Free Moving Observation
The animal was allowed to recovered fully before data collection to occur. This was to ensure
that any effect of the anaesthesia left in the animal’s system did not impact measurement results.
Furthermore, it was critical during this time to monitor the animal closely by veterinarian
technicians to ensure no health complications occurred. This period lasted approximately 2
hours and no significant health issues were observed during recovery. The pig was paced in a
(206 cm × 107 cm × 187 cm) (LWH) steel cage for further health and data monitoring.
Data was continuously observed for 24 hours in the postoperative period via the RF link to
the external unit , Fig 6.11. The implant was placed in various duty cycles to ensure battery
life was extended to maximum. Initial data quality and PV loops while the animal was freely
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Figure 6.11: Live data collection of left–ventricle pressure–volume signals from a freely moving swine model.
moving around inside its cage corresponded to that of the acute study. For example, measured
LV Pressure and Volume signals are shown along with the corresponding PV loops while the
subject was walking and eating for a 12 second period, Fig. 6.12. Similar measurements were
recorded throughout this period. A slight reduction in measured stroke volume, EDV, ESV and
EF was detected while monitoring the freely moving animal, Table 6.5. The variation in physiological signals is most likely attributed to the animal still feeling the effects of of the surgical
procedure, including general pain and the effects of a catheter inserted in its cardiovascular
system. All medication delivered during this period is in accordance with the approved ethics
protocol.
Distortions in the volume signal were observed while the subject would perform neck
movements and when abruptly sitting down. This movement was consistently observed throughout this period and believed to have occurred due to the volume catheter rings contacting the
LV walls during movement. The consistent movement causes the catheter to move within the
LV and either become fixed on the LV wall or not centered within the LV. This directly effects
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Figure 6.12: A sample of 12 seconds of data collection during free movement where a) LV
pressure; b) LV Volume; and c) PV loop.
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Figure 6.13: A four second sample demonstrating a) distorted PV loops; b) LV pressure.
the measured volume signal by significantly distorting the signal until not being measured at
all. However, the pressure signal is unaffected by the catheter movement as it is a MEMS based
pressure sensor and not reliant on an electric field. Furthermore, the increased movement of the
catheter within the LV created an increase in HR from the additional stress on the animal. An
example of the distorted PV loops are shown in Fig. 6.13 along with the measured LV pressure.
The extracted physiological parameters for the distorted PV loops demonstrate that once the
catheter becomes dislodged from the center of the LV, the extracted parameters that rely on
volume are no longer accurate, heart rate can be determined by pressure only, Table 6.5.
The study lasted for a total 48 h which included 24 h of data collection and a combination of 24 h of additional recovery and monitoring time before and after data collection. The
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approved ethics protocol dictated the total number of days of the study, along with approved
measurement equipment and drugs that were administered. Thus, additional live Fluoroscopy,
Computed Tomography (CT), or other scans following the surgery and during the monitoring
period were not allowed. This resulted in the lack of a full internal view of implant and catheter
system after a 2 day monitoring period.
Due to the length of the study it was determined to optimize battery life and measurement
data. For the duration of the monitoring period the implant remained in duty cycle mode measuring data every 2 min and off for 18 min with a receive cycle occurring every 1 h. This lead to
a total battery life of approximately 48 h including initial implant configuration, encapsulation,
receive cycles, higher Tx power (+1dBm), and measurement time of the study.

6.2.5

Implant and Catheter Tissue Impact

Another goal of this study was to determine the effect that the implant had on the surrounding
tissue as well as the effects of the catheter in the left ventricle and surrounding areas. A macroscopic observation of the tissue was completed following euthanasia, and a full histopathology
study was completed on select areas of tissue.

Macroscopic observation
After the euthanasia (based on ethics protocol), a partial necropsy focusing on the heart and
immediate large vessels was performed. Initial observations of the implant location indicated
clotting around the implant and coiled catheter, Fig. 6.14. The implant, heart, and portions of
the carotid artery were separated from the rest of the body for further analysis, Fig. 6.15. The
heart, mainly the left ventricle, was cut open to inspect damage caused by catheter movement
throughout the study, Fig. 6.16. Areas of bruising and superficial hemorrhage; clot adhesion in
the heart; and large vessels were detected, Fig. 6.16. Furthermore, by visually inspecting the
catheter, it was confirmed that the catheter tip (pig tail) did break off during surgery, Fig. 6.16.
Additional areas of clotting were determined in the carotid artery next to the area where the
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PV Implant
Fully Intact

Tissue Growth
on Catheter Tubing

Figure 6.14: Initial implant explant. Tissue growth observed on catheter coil.
catheter was inserted, Fig. 6.17. Tissues were collected from areas that macroscopic lesions
were identified. Tissue samples of the left cardiac ventricle, aortic valve, and carotid artery
were processed for microscopic evaluation.

Tissue sample preparation for microscopic evaluation:
Tissue preparation was completed by Veterinary Services technicians at Western University.
All tissues were placed in tissue cassettes in 10% Neutral Buffered Formalin (Fisher Scientific Company, Kalamazoo, USA). After 5 days, the tissues were taken for tissue processing
using an automated tissue processor (Leica ASP 300 Tissue Processor). The cassettes were
loaded into the tissue processor (Leica ASP 300). Dehydration and paraffin infiltration were
performed. Within 1 hour of completion of this procedure, the tissues were embedded in paraffin using the embedding console system (THERMO Shandon HISTOCENTRE 3) and assorted
base molds (Fisher HistoPrep Stainless-Steel). Once the paraffin solidified, the embedded
tissue blocks were removed from the base molds and any excess wax was scraped from the
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Carotid Artery
Aorta
Pig Heart
Tissue Growth

PV Implant
Close-up
Implant

Figure 6.15: Explanted implant, heart and portions of the carotid artery. Close-up of implant
and tissue growth is shown.
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Aortic Valve
Left Ventricle

Broken Pigtail
on Catheter

Figure 6.16: Dissection of left ventricle displaying broken catheter tip and aortic valve.

Clotted Blood

Carotid Artery

Figure 6.17: Carotid artery with clotted blood. Tissue sample used in microscopic evaluation.
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Figure 6.18: An example of Left ventricle: a) ulceration and hemorrhage with b) early granulation tissue as noted by a pathologist.
edges. Tissue blocks were cooled on ice. Sectioning of the blocks was performed on a rotary
microtome (Leica RM2255). Following trimming, 5 µm sections of each of the tissue blocks
were taken and mounted on positively-charged glass slides (Fisher Scientific). Slides were
heat-fixed in an incubator overnight and stained the following morning in an automatic stainer
(Leica Autostainer XL) using hematoxylin and eosin Y solutions. This work was completed
in partenership with The Toronto Centre for Phenogenomics (TCP) - CMHD Pathology Core
and Dr. Hilbert Adissu (Pathologist) and Dr. Alex El-Warrak (Surgical Team). All work was
completed by trained technicians.

Histopathology Results
A total of thirteen slides were provided by TCP with a full detailed report and analysis for the
LV (6 slides), aortic valve (4 slides) and carotid artery (3 slides). The results of the microscopic
evaluation corroborated with the macroscopic observations. It was found that segmental ulceration and hemorrhage occurred in the left ventricle endocardium, aortic valve, and the carotid
artery, Fig. 6.18, Fig. 6.19 Fig. 6.20.
The results of the histopathology study indicate that the lesions are consistent with a super-
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(b)

Figure 6.19: An example of Aortic Valve with ulveration and hemorrhage with early granulation tissue. Issues of concern as noted by a pathologist: (a) fibrin, (b) activated fibroblast, and
c) hemosiderin.

Figure 6.20: An example of Carotid Artery with ulceration and hemorrhage, necrosis of intima,
disruption and inflammation of the tunica adventitia as noted by a pathologist.
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ficial traumatic injury/laceration of the endothelium and endocardium by a foreign body/device
(catheter / implant). The superficial myocardium is minimally involved from inflammatory and
reparative processes (granulation). These results also indicate that the lesion was recent, i.e.,
from this experiment and not a pre-existing condition due to the presence of early granulation
tissue and hemosiderin, Fig. 6.19.

6.2.6

In-Vivo Study Discussion

The histopathological findings corroborates with the assumption that the lesions (tissue damage) may have been caused by the catheter insertion and also by the tip of the electrode that
broke while insertion. Further analysis of the damaged catheter, Fig. 6.16 was completed post–
mortem. The initial damage to the catheter tip occurred when the smaller 5F pigtail became
entrapped inside the introducer. Furthermore, the forces of the LV caused further damage
to incur on the catheter tip. The catheter could have been replaced to minimize the foreign
body inflammatory and reparative processes (granulation). However the decision to not do so
was made based on the limited availability of telemetry system implants and the positioning
achieved while insertion and the optimal initial readings obtained. To prevent catheter failure,
better mating of the introducer and the outer diameter of the pigtail is recommended.
Although the catheter utilized in this study performed correctly throughout the acute and
free-moving observational periods, over time the movement of the subject created significant
impact on the measurement quality of the volume signals, Fig. 6.13. Furthermore, the catheter
itself is designed for acute studies and not designed for free-movement of the subject. Therefore, a catheter that is designed and optimized to be used with an implanted PV telemetry system is required for long-term chronic use within the LV. Future studies should be undertaken to
determine full effect of catheter-heart interaction. These studies should include multiple animal
subjects (large and small) as well as a longer term study i.e., 1 month.
In general, the PV telemetry system performed quite well. There were however, limitations
and issues throughout the measurement period. As previously mentioned, the transmission
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power had to be increased due to the additional tissue. Furthermore, the location of the antenna
within the enclosure created its own set of challenges. As the antenna radiated outwards, it was
essential that the implant remain facing out toward the exterior of the body. It was unknown if
the implant rotated within the cavity further degrading the transmission power. It is important
to create a marker to indicate antenna direction on the enclosure. Another issue which impacted
the battery life was the start up sequence. The implant requires the battery to be connected at
time of enclosure, thus consuming power possibly days in advance of a surgery. This directly
effects the total time of a study. To overcome this issue, a magnetic switch should be used to
control the power delevery to the implant. In this version, of the implant, the battery size was
kept at a minimum to conserve space. If a longer study is required a much larger battery should
be used or large reductions in power consumption must be made. Another issue is the lack of
on board calibration and full detailed PV loops within the custom measurement application.
These issues among others should be addressed in future versions of the PV telemetry system
to improve data quality and measurement time.
A comparison of the presented PV system to published works is summarized in Table 6.7.
The PV telemetry system designed and tested in this thesis achieved significant reduction in the
overall size and weight along with reported power consumption. For instance, in comparison
with the latest reported research [25], this design is 58% smaller in volume, 44% in weight
and 55% reduction in sampling power. In addition, future versions of the device will utilize
sub-GHz bands to decrease tissue absorption and increase transmission range. Subsequently,
with the addition of a custom designed PV catheter suited for implantable applications the PV
system will be further improved. The successful data obtained with this initial experiment and
the uniqueness of being the one of the first real-time recordings of a conscious swine subject
in its natural environment confirms the need for longer term observational periods.
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Conclusion

In this chapter the custom measurement application built in Labview was presented. In–vivo
results are presented that demonstrate the validity of our RF pressure–volume telemetry system. The PV sensor was implanted into a pig’s left ventricle while the encapsulated unit was
secured in the neck region. Live data was captured in both an acute and a freely moving setting
over a 24 hour period. Further improvements in catheter design as well as improvements in
the implantation methodology will improve the data quality and safety of the subject. This
real–time implantable technology allows for researchers to quantify cardiac pathologies by
extracting real–time pressure-volume loops, wirelessly from within freely moving subjects.

Chapter 7
Conclusion
The aim of this thesis is to develop a miniature, low–power wireless implantable telemetry
system that is designed to measure left ventricular pressure and volume physiological data. In
correspondence to this goal, a fully implantable telemetry system capable of measuring left–
ventricular blood pressure and volume (PV) was created. This chapter provides a summary of
the main contributions made by this thesis, plus suggestions on future work.

7.1

The Contribution of the Thesis

In this thesis, the following achievements are made:
• In this thesis a comparison study of the three conductance–to–volume equations is presented, that revealed Baan’s linear equation (3.1) is too simplistic and significantly overestimates volume and is not recommend. Dubois’ equation (3.8) is based on the analytical equation (3.4) and is therefore very inaccurate. It consistently underestimates
volumes and its use is also not recommended. Wei’s equation (3.6) is the most accurate
out of the three and is therefore the only currently viable equation for conductance–
to–volume calculations. Overall, it is experimentally shown that there is an average of
26.25% error in volume measurements when using Wei’s equation (3.6) using a sample
214
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set of commercial 1.2F catheters, which is much greater than the industry accepted value
of 15%. Measured data is used to develop a calibration equation (3.11) that can be used
to decrease measurement error to 5% when using Wei’s equation (3.6).
• To overcome the challenges and limitations that existing commercial PV systems have,
a fully implantable telemetry system was developed. The PV telemetry system architecture consists of four system level blocks (modules) that share a common data and DC
power bus: power regulating electronics (PWR), signal processing and control unit (µC),
RF transceiver (Rx–Tx), and PV sensor interface [239]. A PV interface was designed to
provide stimuli and reference signals to the pressure and volume sensors. The pressure
sensor is based on a MEMS Wheatstone bridge structure that is excited by a DC voltage
reference. The voltage reference and measurement are completed through a commercial
IC for pressure sensing applications. Similarly, the volumetric section of interface uses
the admittance methodology to measure the blood volume in the LV, that is, both magnitude and phase of the measured voltage are extracted. The volumetric sensor itself is
excited by an AC current reference. Phase sensitive detectors along with a quadrature
oscillator are used to extract DC In Phase and Quadrature voltages that are proportional
to the raw in phase and quadrature voltage signals at the PV sensor. This approach allows for the direct extraction of the phase signal where as traditional approaches require
additional hardware and pulse width analysis to determine the phase. Data capture and
processing is completed by a Texas Instruments (TI) MSP430 with the analog data from
the PV sensor interface digitized by the internal 10–bit A/D converter. RF transmission
from the implant to the external unit is completed by a low–power TI CC2500 radio
transceiver. The RF data is transmitted at 2.45 GHz, thus, allowing the system to work in
the Industrial, Scientific and Medical (ISM) band. Furthermore, the control architecture
is presented indicating an average current consumption of 40 µA (over 1 sample) and
5.59 mA in continuous sampling mode. In addition, various measurement cycles were
explored. The physical implementation of the PV implant was designed with the pri-
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mary aim to explore the physical limitations of the state–of–the–art discrete components
technology in respect to the minimum possible physical size, and the system’s power
consumption requirements. The size of the complete wireless PV telemetry system, including the Li–Poly battery, is 15 mm × 15 mm × 11 mm(i.e., 2.475 cm3 ) and it weighs
4.0 g [239].

• A phantom tissue study was performed to model the effects of implant conditions and to
determine the appropriate RF transmit power from the PV prototype [257]. The conductivity and relative permittivity of the phantom tissue are modelled to match that
of muscle with a conductivity (σm ) of 2.21S/m and relative permittivity (r ) of 47 at
2.45 GHz [148]. The phantom tissue was cut into a 4 cm × 4 cm × 3 cm structure, where
the antenna is inserted. This model emulates the tissue through which the transmitted RF
signal must pass through while being transmitted from within the body. The outcome of
this study helped to determine the minimum RF output power that the transmitter (T x )
needs to provide to still receive data from the implant while having minimum power
consumption in a typical medical measurement environment, i.e., instrument noise, non
ideal antenna matching, spectrum interference, etc.

• Implant capsules were designed to accommodate the manufactured implantable PV telemetry system, they consist of a front port hole for catheter access, a side antenna access hole,
and are split into top and bottom halves, where the battery and the implant system are
placed in the bottom half. A custom SolidWorks package model was 3D printed in four
different plastic and one metal packages using the following materials: 316L stainless
steel, ABS, RDG720 Transparent Acrylic, and ABS–M30i. Each material was evaluated
for leaks by a 98 day water immersion study [258]. The stainless steel capsule provided
the highest precision among the four materials however, additional post–processing time
is required. For the in–vivo experiment, we used a package with suture holes so that the
implant capsule is secured directly to the animal. This package was printed in ABS–
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M30i plastic to ensure bio–compatability with the subject’s tissue.

• Complete calibration of the pressure and volume sensing front-end was presented. The
MEMS absolute pressure sensor was calibrated inside a fluid–filled pressure chamber
that allows for variations in temperature and pressure. Four point calibration was used to
calibrate for the variation of the Wheatstone bridge offset over temperature and variation
of the bridge gain over temperature thereby providing 1 st order temperature compensation. The sensor was calibrated over a 450 mmHg pressure range (-135 mmHg to 315
mmHg) and over a 20.4◦C temperature range (22.8◦C - 43.2◦C). Two calibration methods for the volume electronics were presented. The average errors across the calibration
range for the impedance magnitude and phase for each method are: 1) 0.211 Ω and 0.2◦ ;
and 2) 0.2139 Ω and 0.2263◦ . It can be seen that the second method is slightly less accurate in producing calibrated values however, it is less computational intensive thus faster
to implement. For the experiment described in this thesis, the first calibration method
was used as all data processing was done offline thus computation complexity was not
an issue and data accuracy was of great importance however, for on-chip calibration
implementation the second method should be used.

• To receive the transmitted data signals from the implanted telemetry system an external
receiving unit (Rx Unit) that consists of a microcontroller, wireless transceiver, and hardware UART board was designed. The data transmitted from the implant is received via
the hardware wireless receive block and sent to UART module to be transmitted to a PC.
In this thesis, a Windows based system was used and can display this data in a traditional
terminal window or a custom based application like LabView. Both options were explored and discussed in this work. The initial software solution was only able to display
the raw I, Q, and P values and did not include any additional processing, calibration, or
graphing capabilities. In addition, viewing the raw data in a terminal is not ideal in a
surgical environment. To overcome these challenges, a custom application was created
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in National Instruments LabView to further process, log, and display the implant data.
Complete protocol setup, reading data transferred from the implant, writing data to the
implant, and finally some limitations with the initial version of software were discussed
in this thesis.
• The PV system designed and characterized in this thesis was evaluated in–vivo using
a pig. The implant study was performed at Western University Veterinary Services by
a trained surgical and technical team. The medical procedure and monitoring was performed in accordance with the approved ethics protocol AUP Number: 2014-003. The
study was designed to evaluate the PV system in a non–anaesthetised test subject, i.e.,
freely moving animal. In addition, the study was completed to determine initial catheterheart interaction. In–vivo results were presented that demonstrate the validity of the RF
pressure–volume telemetry system. The PV sensor was implanted into a pig’s left ventricle while the encapsulated system was secured in the neck region. Live data was captured
in both an acute and a freely moving setting over a 24 hour period. Another goal of this
study was to determine the effect that the implant had on the surrounding tissue as well
as the effects of the catheter in the left ventricle and surrounding areas. A macroscopic
observation of the tissue was completed following euthanasia, and a full histopathology study was completed on select areas of tissue. The results of the histopathology
study indicated that lesions were found on the heart and carotid artery. These lesions
may have been caused by the catheter insertion and also by the tip of the electrode that
broke while insertion. Furthermore, the forces of the LV caused further damage to incur
on the catheter tip. To prevent catheter failure, better mating of the introducer and the
outer diameter of the pigtail is recommended. Further improvements in catheter design
as well as improvements in the implantation methodology will improve the data quality
and safety of the subject.
This thesis presented the complete development of a fully implantable pressure–volume
measurement telemetry system. All aspects of the design were presented culminating in an
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in–vivo study. In its present form, the telemetry system has a total volume of 2.475 cm3 with a
weight of 4.0 g and is suitable for commercial application in medium sized subjects (large rats,
rabbits, pigs, etc). The designed system is 58% smaller in volume, 44% in weight and has a
55% reduction in sampling power over the last reported research in PV telemetry [25, 26]. The
achievements in this work advances the field of implantable medical devices forward with the
intention to be eventually used Safety Pharmacology drug studies to detect real–time changes
in contractility using PV loop analysis. Furthermore, this thesis has created a benchmark to
enable further advancement of micro–wireless telemetry systems through the use of a variety
of sensors, not limited to cardiac monitoring, as well as allowing for future benefits in eHealth
monitoring systems for humans.

7.2

Future Work

• Additional in–vivo studies should be undertaken to investigate the full potential of this
system. These studies should include multiple animal subjects (large and small) to study
the animal to animal variability in free moving animals as well as a longer term study i.e.,
1– 3 months (protocol dependent). In addition, the full effect of catheter-heart interaction
should be studied.
• To achieve long-term in–vivo studies, an updated intermediate implant overcoming the
limitations of the existing system should be developed and optimized for these types of
studies. Application software should also be improved for the additional studies. Initial
designs of this implant have been undertaken and include the following design changes:
lower transmission frequency of 915 MHz to reduce power consumption, improved temperature compensation to mitigate possible drift within the animal, an improved magnetic
activation switch to reduce startup errors, and improved calibration methods to increase
the accuracy of measurements. The current implementation of this longer-term implant
is designed on a single PCB and is shown in Fig. 7.1. The physical prototype is de-
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Figure 7.1: Improved version of PV telemetry system designed on a single PCB optimized for
long–term studies.

Figure 7.2: Improve LabView measurement application interface.
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signed around a much larger battery to facilitate the long–term tests, requiring a larger
enclosure to be designed. This enclosure contains improvements such as visible antenna
orientation markers. In addition, an updated labView application has been created that
includes built in calibration and volume conversion as well as an improved user interface, Fig. 7.2. This version, following long-term tests, should be reduced down in size
including all improvements to achieve a volume similar to the one outlined in this thesis.
• Application measurement software should be developed outside of LabView to ensure a
more professional experience. For example, one could develop the application in Java,
C++, or Qt. This would remove delays and graphical issues found in LabView software.
• A wireless power solution should be developed to remove the battery. The first implementation would be to use inductive wireless power transfer. Future versions would
utilize a full cage solution based on Helmholtz coils and magnetic resonance energy
transfer, currently being explored by other members of this research group [136]. Furthermore, design and testing of custom power management circuits (LDO, Bandgap, and
Rectifier) are also underway [130, 271], which will be fully integrated with a wireless
power solution, Fig. 7.3.
• Future hybrid implant capsules should be designed. This would include Titanium and
plastic to create an RF integrated implant package solution. Furthermore, different materials should be explored to determine optimal mechanical properties for an implantable
device.
• A custom integrated circuit of the RF transceiver should be developed. The power consumption will be optimized specifically for implantable devices, further reducing the
systems overall power consumption. Additionally, an RF startup switch should be developed to reduce power consumption and ensure that the implant is not activated until
required by the user. This switch would be integrated into a full RF front-end solution.
Initial work on the RF switch has been published in [272].
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Figure 7.3: Custom test IC with Wireless power sub-blocks and ADC test blocks.
• The microcontroller should be replaced with a custom low power application specific
integrated circuit. This processor should be designed only to perform the tasks needed by
this application, allowing power consumption to be optimized specifically for the low–
power requirements of this implantable system. Initial work on this custom controller
has been published in [273].
• A integrated circuit (IC) of the sensor interface should be developed and tested. This
would greatly reduce the size and weight of the implant enabling further miniaturization
of the complete system. This IC should be developed in conjunction with the custom
controller IC. Additional blocks should be created including analog-to-digital converters(ADC) and other interfaces. A low–power 9-bit ADC has been developed in collaboration with The University of Zagreb that has been fabricated and tested, Fig. 7.3. Results
have been published in [274]. This serves as an initial building block in the development
of a custom sensor interface IC.
• Finally, all subsystems should be integrated together using state–of–the–art semiconduc-
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tor and packaging technologies. This would enable significant reductions in weight and
volume over the implant presented in this thesis. This device would only contain a single IC along with an antenna and sensor connections, thus enabling the encapsulation of
the system into a single biocompatible implantable package. The culmination of these
advancements would enable a long-term data monitoring solution for small animals in
Safety Pharmacology drug testing.
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M. Schalij, A. Gittenberger-de Groot, and P. Steendijk, “Left ventricular function in

BIBLIOGRAPHY

234

the post-infarct failing mouse heart by magnetic resonance imaging and conductance
catheter: a comparative analysis,” Acta Physiologica, vol. 194, no. 2, pp. 111–122, 2008.
[75] F. Franco, S. Dubois, R. Peshock, and R. Shohet, “Magnetic resonance imaging accurately estimates lv mass in a transgenic mouse model of cardiac hypertrophy,” American
Journal of Physiology-Heart and Circulatory Physiology, vol. 274, no. 2, pp. H679–
H683, 1998.
[76] G. Esposito, L. Santana, K. Dilly, J. Cruz, L. Mao, W. Lederer, and H. Rockman, “Cellular and functional defects in a mouse model of heart failure,” American Journal of
Physiology-Heart and Circulatory Physiology, vol. 279, no. 6, pp. H3101–H3112, 2000.
[77] J. Baan, T. Jong, P. Kerkhof, R. Moene, A. D Van Dijk, E. T Van Der Velde, and
J. Koops, “Continuous stroke volume and cardiac output from intra-ventricular dimensions obtained with impedance catheter,” Cardiovascular Research, vol. 15, no. 6, pp.
328–334, 1981.
[78] A. Kottam, J. Porterfield, K. Raghavan, D. Fernandez, M. Feldman, J. Valvano, and
J. Pearce, “Real time pressure-volume loops in mice using complex admittance: measurement and implications,” in Engineering in Medicine and Biology Society, 2006.
EMBS’06. 28th Annual International Conference of the IEEE. IEEE, 2006, pp. 4336–
4339.
[79] P. Cong, N. Chaimanonart, W. Ko, and D. Young, “A wireless and batteryless 10-bit
implantable blood pressure sensing microsystem with adaptive rf powering for real-time
laboratory mice monitoring,” Solid-State Circuits, IEEE Journal of, vol. 44, no. 12, pp.
3631–3644, 2009.
[80] A. Kottam, J. Dubois, A. McElligott, and K. K. Henderson, “Novel approach to admittance to volume conversion for ventricular volume measurement,” in Engineering

BIBLIOGRAPHY

235

in Medicine and Biology Society, EMBC, 2011 Annual International Conference of the
IEEE.

IEEE, 2011, pp. 2514–2517.

[81] Y. Gao, Y. Zheng, S. Diao, W. Toh, C. Ang, M. Je, and C. Heng, “Low-power ultrawideband wireless telemetry transceiver for medical sensor applications,” Biomedical
Engineering, IEEE Transactions on, vol. 58, no. 3, pp. 768–772, 2011.
[82] P. Dario, M. Carrozza, A. Benvenuto, and A. Menciassi, “Micro-systems in biomedical
applications,” Journal of Micromechanics and Microengineering, vol. 10, no. 2, p. 235,
2000.
[83] S. Lee, H. Lee, M. Kiani, U. Jow, and M. Ghovanloo, “An inductively powered scalable
32-channel wireless neural recording system-on-a-chip for neuroscience applications,”
Biomedical Circuits and Systems, IEEE Transactions on, vol. 4, no. 6, pp. 360–371,
2010.
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